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ABSTRACT 
Cardiovascular disease (CVD) is a complicated and multifarious disease, and is the number 
cause of mortality worldwide. The pathogenesis of CVD is attributed to the interaction between 
genetics and environment. There are numerous data that support the cardioprotective properties 
of omega (n)-3 polyunsaturated fatty acids (PUFA); however, there are also controversial 
reports. Considering the reported sex and age differences in the pathophysiology of CVD and the 
metabolism of n-3 PUFA, it is imperative to consider these factors in the cardioprotective effects 
of n-3 PUFA. The main objective of the current thesis was to investigate the effects of n-3 PUFA 
on the risk factors of CVD such as dyslipidaemia and obesity, with particular focus on how sex, 
age and dose of n-3 PUFA affect lipid and lipoprotein metabolism. The set of experiments 
presented in this thesis was investigated using the C57BL/6 mouse strain which has been 
established as a mouse model of choice for the study of diet-induced pathological conditions of 
lipid and lipoprotein metabolism. Plasma concentrations of lipids and lipoproteins of mice 
offspring at weaning and 16 weeks postweaning were chosen as study outcomes to assess the 
sex, age and dose-specific effects of n-3 PUFA on markers of dyslipidaemia, a well-known risk 
factor of CVD.  It was observed that a longer exposure to a postnatal diet high in n-3 PUFA 
increased plasma concentration of low-density lipoprotein cholesterol (LDL-c) in the offspring in 
a sex-specific manner; however, the profile of this increase was less atherogenic , as the high n-3 
PUFA group had a lower plasma concentration of very small LDL-particles in both males and 
females. There was no effect of high n-3 PUFA diet observed on plasma concentration of high-
density lipoprotein cholesterol (HDL-c); however, the high n-3 PUFA group had a higher 
cholesterol efflux in the male offspring but not in female offspring, further demonstrating the 
effect of sex on cholesterol metabolism. Lipidomic analyses revealed that high n-3 PUFA diet 
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led to higher hepatic and plasma concentrations of n-3 PUFA-containing bioactive lipids such a 
phosphatidylcholine, lysophosphatidylcholine and free fatty acids, which could positively 
influence pathways involved in cardioprotection.  The effects of dietary n-3 PUFA on obesity at 
the cellular level was also investigated, using adipocyte hypertrophy as the outcome measure of 
adipose tissue enlargement. A diet high in n-3 PUFA prevented adipocyte hypertrophy in males, 
with no effect in females. High n-3 PUFA diet also led to  the downregulation of the mRNA 
expression of acyl CoA:diacylglycerol acyltransferase 2 (DGAT2), fatty acid binding protein-4 
(FABP4), peroxisome proliferator-activated receptor protein γ (PPARγ), and leptin in males, 
which are key proteins involved in adipocyte hypertrophy; however no effect was observed in 
females. The last study assessed the effects of dose and duration of exposure to dietary n-3 
PUFA on DHA accretion in the brain, and the expression of neurotrophins known to have 
neuroprotective and cardioprotective benefits. A diet high in n-3 PUFA led to an accretion of 
DHA in the brain cortex of the male offspring. Furthermore, dietary n-3 PUFA led to an age-
dependent increase in the expression of brain-derived neurotrophic factor (BDNF), tropomyosin 
receptor kinase (TrKB), and phosphorylated cAMP response element binding protein (pCREB). 
Furthermore, there was a positive correlation between the cortical mRNA expression of BDNF 
and plasma concentrations of triglycerides and non-esterified fatty acids, suggesting a 
relationship between neurotrophins and regulation of lipid metabolism. 
In conclusion, the results from the current thesis demonstrate a sex, dose and age specific 
effect of n-3 PUFA on  risk factors of CVD, and on novel regulatory pathways by which n-3 
PUFA could reduce dyslipidaemia and obesity; the results also suggest that n-3 PUFA could be 
neuroprotective and cardioprotective through a common neurotrophin signalling pathway.  
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1.0 Introduction 
Cardiovascular disease (CVD) is a disorder of the cardiovascular system; it includes 
hypertension, coronary heart disease, stroke, cardiac arrhythmia, and heart failure. According to 
a World Health Organization (WHO) report,  30% of all deaths in 2008 were caused by CVD, 
and it was projected that more than 23 million people will die yearly from CVD by 2030 (WHO, 
2011).  Similarly, the Heart and Stroke Foundation of Canada has ascribed 29% of the total death 
in Canada in 2008 to CVD (Statistics Canada, 2008). It was formerly thought that CVD was a 
disease of affluence and only rampant in Western society. However, the prevalence of CVD is 
fast on the rise in developing countries as well (Reddy and Yusuf, 1998). CVD constitutes a huge 
socio-economic burden with an impact of $403.1 billion in the US, €169 billion in the European 
Union in 2006 (Leal et al., 2006), and $20.9 billion annually in Canada (Statistics Canada, 2008). 
The burden of CVD is further complicated by the reduced age of onset, with projected deaths of 
6.4 million people between the ages of 30 and 69 as a result of CVD by 2020 (Murray and 
Lopez, 1996). By the age of 60, 50% of the population will be diagnosed with some type of 
cardiovascular disorder including atherosclerosis (Holub, 2009). Studies have identified a 
number of risk factors associated with the morbidities of CVD; these factors are modifiable or 
non-modifiable.  
1.1 Non-modifiable risk factors of CVD 
These are factors that cannot be changed or modified by the external environment. Non-
modifiable risk factors of CVD include sex, age, and family history.   
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1.1.1 Sex/gender as a non-modifiable risk factor of CVD 
The most characterised risk factor affecting the development of CVD is sex; this has been 
ascribed to a clear distinction in hormonal regulation between males and females (McNamara et 
al., 2009). It has been reported that men and women differ significantly in their circulating blood 
lipids and predisposition to CVD (Johnson et al., 2004). Plasma total cholesterol (TC), a major 
risk factor of CVD has been shown to increase with age peaking at 50-59 years in men and at 60-
69 years in women (Carroll et al., 2005). Sex specific differences in blood lipid parameters have 
also been reported for plasma high-density lipoprotein cholesterol (HDL-c) and triglycerides 
(TG) (Carroll et al., 2005). Men are at a higher risk of developing CVD than premenopausal 
women (Finegold et al., 2013); however, after menopause, the risk is the same in both sexes. The 
female hormone, oestrogen, is involved in lipid metabolic pathways; it is responsible for the 
rapid transport and clearance of fat from the blood stream to the liver for excretion in women 
compared to men and this also partly accounts for the sex specific risk of CVD (Knopp et al., 
2005). Oestrogen has also been shown to improve glucose metabolism and endothelial function. 
After menopause, the concentration of oestrogen decreases, which consequently reduces the 
concentration of HDL-c and increases low density lipoprotein cholesterol (LDL-c) concentration, 
which explains the similar risk of CVD between postmenopausal women and men (Jousilahti et 
al., 1999). The effect of sex in the development of CVD cannot be overemphasized, however, 
beyond sex differences comes age. 
1.1.2 Age as a non-modifiable risk factor of CVD 
The risk of CVD increases as an individual ages, and the heart undergoes changes that 
contribute to this condition. Age remains one of the most prominent risk factors of CVD. The 
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majority of individuals reported to suffer from heart attack are 65 years or older. The risk of 
CVD triples with each decade (Finegold et al., 2013). The risk of age has been explained by the 
reduction of cholesterol catabolism with age (Jousilahti et al., 1999), and the loss of arterial 
elasticity which consequently leads to CVD (Jani and Rajkumar, 2006).  The plasma TC 
concentration increases with age (Corti et al., 1997) mainly because of the age dependent 
decrease in the catabolism of cholesterol (Corti et al., 1997). Furthermore, males and females 
have comparable plasma HDL-c concentration at puberty, after which the differences become 
apparent as they age (Abbey et al., 1999). There are also documented age effects on the plasma 
concentration of TG (Castelli, 1984). Although age is a non-modifiable risk factor, studies have 
shown that modifiable risk factors such as proper diet and physical activity also play important 
roles in the prevention of CVD in older individuals. 
1.1.3 Family history as a non-modifiable risk factor of CVD 
There is a genetic component to the development of CVD. Individuals with a family history 
of cardiovascular complications are at a higher risk of developing CVD. Some genetic 
aberrations known to promote the risk of CVD are heritable, and these include the mutation in 
the LDL receptor (LDL-r) gene which is the underlying cause of familial hypercholesterolemia a 
major risk factor of CVD. Mutation in the leptin or leptin-receptor gene can also be inherited 
which will cause a defect in leptin signalling and consequent obesity and associated 
complications.  
1.2 Modifiable risk factors of CVD 
Modifiable risk factors are risks associated with CVD that could be prevented or increased by 
altering environmental conditions. Hypertension, defined as the average blood pressure reading 
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greater than 140 mmHg for systolic pressure and greater than 90 mmHg for diastolic pressure is 
the principal cause of CVD. There are about 1 billion people worldwide diagnosed with 
hypertension. Hypertension is principally caused by narrowing of the blood vessels as result of 
plaque deposition, a process known as atherosclerosis. Another important modifiable risk factor 
of CVD is diabetes characterised by high circulating concentration of blood glucose as a result of 
defects in insulin production or regulation, with fasting blood glucose of 126 mg/dl (7 mmol/l) or 
higher (Abraham et al., 2014). A higher percentage of mortality in people with diabetes is 
accounted for by CVD. Tobacco smokers are also at a higher risk of developing CVD. Tobacco 
smoking is estimated to cause approximately 10% of all CVD, and the number of people 
smoking is fast on the rise with approximately 1.3 billion smokers globally (Thomas et al., 
2014). The best characterised modifiable risk factors of CVD are  obesity, dyslipidaemia, and 
nutrition.  
1.2.1 Obesity as a risk factor of CVD  
Obesity is the accumulation of excess fat in the body. Obesity has been identified as a risk 
factor of CVD and is one of the top ten global health problems (Madsen et al., 2005). 
Epidemiological studies have demonstrated a strong association between obesity and 
cardiovascular events (Wilson et al., 2002). Positive energy balance, which refers to when 
caloric intake is greater than energy expenditure, and physical inactivity, remain the major 
causes of obesity. However, some individuals living with obesity have been identified to have a 
genetic condition that predisposes them to the disease, such as a defect in any of the genes 
regulating appetite (Farooqi and O'Rahilly, 2004).    
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In addition to the total body fat, the location and distribution of body fat is also a well-known 
risk factor of CVD. Body fat is anatomically broadly classified as subcutaneous fat (SC) which 
are the lower and upper body fat, and the visceral or intra-abdominal fat (VF) and intrathoracic 
fat (IF) (Sironi et al., 2012). IF are found around the heart, SC fats occur under the skin, and VF 
occurs around organs in the abdominal region (Sironi et al., 2012). Fat that accumulates inside 
organs such as liver and heart causing metabolic dysfunction is termed ectopic fat (Gastaldelli 
and Basta, 2010). Studies have shown that the best predictor of CVD in relation to obesity is not 
the amount of fat but the location of fat, with VF showing a stronger risk of CVD (Fox et al., 
2007). Metabolic dysfunctions seen in obese individuals are linked to an increase in VF as a 
result of hypertrophy (Despres et al., 2008). Adipose tissue increases in size as a result of 
adipocyte hypertrophy and/or hyperplasia (Arner and Spalding, 2010). Adipocyte hypertrophy is 
regulated by the accumulation of TG (Klein et al., 1980). Obese individuals are known to have 
high TG storage rates (Arner et al., 2011). Adipocyte number is also known to contribute to 
adipocyte mass (Spalding et al., 2008). An estimated 10% of adipocytes are renewed yearly 
regardless of body weight in adults (Spalding et al., 2008); nonetheless, the total number of 
adipocytes is kept constant (Spalding et al., 2008), except in morbidly obese individuals where 
the number of adipocytes is seen to rise with BMI (Arner et al., 2011). Obese individuals have a 
larger number of adipocytes than lean individuals, however, these numbers are acquired before 
adulthood during which the number of adipocytes remain constant even after a weight loss 
procedure (Spalding et al., 2008).  
Adipose tissue inflammation is the major culprit of insulin resistance and type-2 diabetes 
(T2D) experienced by obese individuals (Lumeng and Saltiel, 2011). Adipose tissue contains a 
number of cells including adipocytes and macrophages. Obese individuals tend to have the 
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propensity of accumulating macrophages in the adipose tissue which leads to the secretion of 
inflammatory cytokines such as interleukin (IL)-6 and tumour necrosis factor (TNF)-α (Weisberg 
et al., 2003); this is an inflammatory environment that favours the development of pathological 
conditions associated with obesity. Studies have shown that an increase in adipose mass is 
accompanied by an increased recruitment of macrophages (Weisberg et al., 2003). Weight loss 
has been shown to reduce adipose tissue inflammation and improve insulin resistance by 
reducing macrophage infiltration in the adipose tissue (Cancello et al., 2005). In addition to the 
lipid storage function of the adipose tissue, the adipose tissue is also functionally an endocrine 
tissue capable of secreting adipokines that regulate body weight, appetite and insulin resistance. 
One such adipokine is adiponectin whose expression level decreases with an increase in adipose 
tissue mass and obesity (Turer et al., 2011). Increased secretion of adiponectin favours insulin 
sensitivity and reduces the risk of T2D (Li et al., 2009).  
The incidence of obesity and related complications are well established at the population 
level; however, there is still insufficient knowledge on the mechanistic insights at the cellular 
level. The accumulation of TG is the major cause of adipocyte hypertrophy; therefore, 
elucidating the molecular processes involved in the formation of TG in the adipose tissue is 
important in understanding the development of obesity. An excess of calories, especially from 
fat, are the primary cause of obesity as dietary fat contains more calories per gram compared to 
carbohydrate and protein.  The health effects of fats depend not only on the quantity of fats but 
also on the quality of fats. Saturated fatty acids (SFA), trans-fats, and cholesterol are the major 
culprits when it comes to increasing dyslipidaemia, obesity and CVD; however polyunsaturated 
fatty acids (PUFAs) have been shown to have beneficial effects (Hirafuji et al., 2003). The 
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mechanism/s by which the quality of fat affects adipose tissue metabolism and whether the 
effects are similar in both sexes are still not clear.  
1.2.2 Dyslipidaemia as a risk factor of CVD 
Dyslipidaemia is the abnormal circulating levels of plasma lipids and lipoproteins, which is a 
major risk factor of CVD. Dobsn et al. defined dyslipidaemia as the concentration of TC, LDL-c, 
apoplipoprotein (APO)-B and lipoprotein (a) (Lp(a)) above the 90th percentile, or circulating 
concentrations of HDL-c and APO-A1 below the 10th percentile (Dobson et al., 1996).  A 
number of key epidemiological studies have reported the link between dyslipidaemia and CVD. 
The Framingham Study (Dawber et al., 1951) and the Seven Country Study (Fidanza et al., 
1970) reported that dyslipidaemia, especially an increase in LDL-c concentration and a decrease 
in HDL-c concentration, is a major risk factor of CVD. Dyslipidaemia occurs in different forms 
ranging from hypercholesterolaemia, which is the elevated circulating concentration of 
cholesterol; hypertriglyceridaemia, which refers to an increase in circulating concentration of 
TG; and hyperlipoproteinaemia, an increase in lipoprotein concentration. Dyslipidaemia is 
caused by a number of factors which represent a blend of genetic and environmental factors. 
Dyslipidaemia and the homeostatic regulation of lipid and lipoprotein metabolism are central 
to the onset of CVD, where LDL-c remains the primary target for lowering blood lipid levels 
(Choi et al., 2014). However, cardiovascular events still occur despite maintaining optimal levels 
of LDL-c, indicating the need to consider other factors as well.  Therapies have also focussed on 
increasing the levels of HDL-c, the “good cholesterol”, and lowering blood TG levels.  Lifestyle 
modifications, especially dietary modifications, play an important role in dyslipidaemia and 
CVD.  Genetic composition also predisposes an individual to dyslipidaemia, obesity, and 
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diabetes mellitus; while nutrition, exercise, and smoking are the best studied environmental 
factors that contribute to the pathogenesis of CVD (Tymchuk et al., 2006). Dyslipidaemia such 
as hypercholesterolaemia creates an enabling platform for the development of atherosclerosis.  
1.2.3 Atherosclerosis and the risk of CVD 
Atherosclerosis has been identified as the major cause of CVD. Cholesterol plays an 
important role in atherosclerotic plaque formation resulting in cardiovascular complications. 
Cholesterol is important in mammalian cells, where it fulfils important roles in maintaining 
membrane fluidity, and as a precursor of steroid hormones and bile salts. Despite the functional 
roles of cholesterol, high circulating cholesterol concentration or a defect in cholesterol 
metabolism leads to atherosclerosis. Atherosclerosis is an inflammatory disease characterised by 
the deposition of LDL-c in the arterial wall. Atherosclerotic lesions are predominantly found in 
muscular and elastic arteries leading to cardiac or brain infarction. Deposition of atherosclerotic 
plaque in the wall of the arteries is a chronic process; fatty steak lesions have been observed in 
children (Napoli et al., 1997). Endothelial dysfunction is associated with atherosclerosis and this 
is caused by high, circulating LDL-c, free radicals from cigarette smoking, diabetes, and 
hypertension. Endothelial dysfunction leads to a compensatory physiological response aimed at 
maintaining normal endothelial function. This results in a pro-inflammatory endothelial state, 
and if persistent and not resolved, it will continue indefinitely with deleterious effects. Prolonged 
inflammation of the endothelium stimulates the recruitment, proliferation and migration of 
smooth muscle cells (SMC) leading to the formation of lesions (Glagov et al., 1987). If the 
inflammation continues, macrophages and lymphocytes are recruited from the blood to populate 
the lesion and further produce pro-inflammatory cytokines which further damages the artery. 
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Increased expression of adhesion molecules on the wall of the endothelium marks the onset 
of atherosclerosis permitting the penetration of monocytes and lymphocytes into the intima of 
the artery (Frostegard, 2013). Formerly considered a lipid storage disease, evidence of the role of 
inflammation in atherogenesis has been presented. The dysfunction of the arterial endothelium 
underlies the inflammation driven atherogenesis. In the intima of the artery, the monocytes 
differentiate into macrophages which pick up oxidized LDL, become lipid laden and form foam 
cells (Qiao et al., 1997), which stimulate an overall inflammatory state. Nutrition, especially the 
quantity and the quality of dietary fats, has been shown to be effective in atheroprotection by 
reducing obesity and alleviating the markers dyslipidaemia.  
1.3 Dietary fats and CVD 
The role of dietary fat in the development of CVD is well documented.  Dietary fats fall 
under the main categories of SFA, monounsaturated fatty acids (MUFA) and PUFA. High intake 
of SFA is generally considered to promote the development of CVD, while both MUFA and 
PUFA have been shown to be cardioprotective (Hansen and Harris, 2007, Gillingham et al., 
2011).  Dietary recommendations for fat are: 25-35% of total caloric intake; no more than 7-10% 
of caloric intake from SFA; less than 1% from trans fat; less than 300 mg/day of cholesterol; and 
the remainder should be made up of MUFA and PUFA (Perk et al., 2012). While the human 
body is capable of synthesizing SFA and MUFA, humans lack the enzymes required to 
synthesize PUFA (Engler and Engler, 2006); thus, PUFAs are essential fatty acids and must be 
consumed in the diet. Over the past years, there has been a drastic change in the Western diet; 
this change was promoted by the Industrial Revolution and modern food processing techniques 
(Grenon et al., 2012), and by the birth of modern day agriculture leading to the production of 
vegetable oils highly rich in n-6 PUFA (Simopoulos, 2002).  These changes led to an increased 
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intake of n-6 PUFA in the Western diet and an overall reduction in the dietary consumption of n-
3 PUFA (Simopoulos, 2002). It has been speculated that these changes in nutritional quality 
could be responsible for the majority of chronic diseases prevalent in the Western societies, 
including CVD (Eaton and Konner, 1985). 
1.3.1 Metabolism of essential PUFA 
The two major essential fatty acids are linoleic acid (LA) of the n-6 PUFA class and α-
linolenic acid (ALA) of the n-3 PUFA class (Seo et al., 2005).  LA is abundant in vegetable oils 
such as safflower and corn oils, while the essential n-3 PUFA, ALA, is rich in walnuts and 
flaxseed oils (Engler and Engler, 2006), all of which are plant-derived sources. The 
nomenclature of the essential fatty acids is based on the position of the first double bond from 
the methyl end of the fatty acid chain. N-3 PUFAs have their first double on carbon number 3 
while that of n-6 PUFA is on carbon number 6 (Engler and Engler, 2006).  The parent 18-carbon 
LA and ALA can undergo a series of enzyme-catalysed desaturation and elongation steps using 
desaturase enzymes to produce highly unsaturated longer-chain arachidonic acid (AA) in the n-6 
PUFA pathway, and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the n-3 
PUFA pathway (de Gomez Dumm and Brenner, 1975, Engler and Engler, 2006).  The 
conversion of ALA to EPA and DHA, the marine derived n-3 PUFA, is inefficient with the 
conversion rate in men estimated to be approximately 0-1% and ~ 9% in women (Brenna, 2002). 
Studies have shown that the desaturation and elongation processes favour the conversion of ALA 
to EPA and DHA over the conversion of LA to AA (Hagve and Christophersen, 1984). However, 
a high consumption of dietary LA could shift the pathway in favour of the production of longer 
chain n-6 PUFA (Figure. 1.1). The metabolism of n-3 and n-6 PUFA also involves the 
oxygenation of 20 carbon AA and EPA by cyclooxygenases (COX) and lipoxygenases (LOX) to 
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produce eicosanoids, which are signalling molecules of physiological and therapeutic 
importance; these include prostaglandins (PG), thromboxanes (TX), and leukotrienes (LT). 
Eicosanoids from AA are pro-inflammatory, pro-thrombotic, and generally promote 
atherosclerosis (Farooqui et al., 2007). On the other hand, eicosanoids derived from EPA have 
been shown to be anti-inflammatory, anti-thrombotic, and promote good health (Adkins and 
Kelley, 2010). It is therefore imperative to maintain an appropriate nutritional balance between 
n-6 and n-3 PUFA for optimal body function.  Over the years, there has been a decline in the 
consumption of n-3 PUFA in the Western diet forcing the ratio of n-6 to n-3 PUFA to 
approximately 20-30:1 which is relatively higher than the 1:1 ratio on which we evolved (Gomez 
Candela et al., 2011).  This decline has been suggested to be responsible for the recent higher 
prevalence of CVD.  
1.3.2 N-3 PUFA and CVD  
The scientific inquiry into the health benefits of n-3 PUFA originated from the Bang and 
Dyerberg’s observation of the Greenland Inuit (Bang et al., 1971). They observed that the 
Greenland Inuit had lower concentrations of plasma TG, LDL-c and TC as compared to a Danish 
cohort; these differences were ascribed to the high fish and marine mammal diet of the Inuit. N-3 
PUFA such as EPA and DHA occur predominantly in fish and fish oil. An inverse relationship 
between fish consumption and incidence of CVD has been reported in a meta-analysis of 
200,575 subjects (He et al., 2004).  Other clinical studies have also corroborated these findings 
(Burr et al., 1989, Hooper et al., 2006). Dietary supplementation of n-3 PUFA (>2g/day) has 
been shown to alleviate symptoms of dyslipidaemia, improve endothelial function, and resolve 
inflammation associated with the development of CVD (Balk et al., 2006, Harris, 1997,
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Figure 1.1 Pathways for the synthesis of long chain n-6 and n-3 PUFA . Leukotriene B (LTB); prostaglandin E (PGE); thromboxane A 
(TXA), prostacyclin (PGI)
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Linoleic acid (LA) 
(18:2 n-6) 
Gamma linoleic acid 
(18:3 n-6) 
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(20:3 n-6) 
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(18:3 n-3) 
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(18:4 n-3) 
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(20:4 n-3) 
Eicosapentaenoic acid (EPA) 
(20:5 n-3) 
Δ-6-desaturase 
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Lipoxygenase (LOX) 
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(PGE3,TXA3,PGI3,LTB5 ) 
Docosahexaenoic acid (DHA) 
(22:6 n-3) 
Δ-6-desaturase 
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Defilippis et al., 2010). There is also evidence supporting the anti-inflammatory, anti-thrombotic, 
anti-atherogenic and anti-arrhythmic properties of n-3 PUFA (Holub, 2002). The North 
American intake of n-3 PUFA is approximately 130-150 mg/day (Holub, 2002, Denomme et al., 
2005).  With the documented health benefits of n-3 PUFA, the consumption of two fatty fish 
servings per week for the prevention of CVD was recommended by the American Heart 
Association (Kris-Etherton et al., 2002); this is estimated to provide approximately 450-500 
mg/day of EPA and DHA (Kris-Etherton et al., 2002, Kris-Etherton et al., 2007). There is no 
universally recognized recommendation for the consumption of n-3 PUFA due to dietary 
variations in different countries.  However most countries and organisations have made different 
recommendations based on the recognized health benefits of n-3 PUFA and the consensus 
among the different recommendations is the n-6 to n-3 PUFA ratio of approximately 5:1 (Table. 
1.1). The health benefits of n-3 PUFA depends on its availability in the body and its accretion in 
body tissues; hence, the omega-3 index, which is the percentage of highly unsaturated n-3 PUFA 
(EPA+DHA) in the erythrocytes, can be considered as a marker for risk of cardiovascular 
irregularities (Harris, 2008). An omega-3 index of 4% represents low cardioprotective effects, 
while an index of 8% signifies relatively high cardioprotection (Jump et al., 2012). The premise 
for this marker was that the fatty acid composition of the blood can be used as a surrogate for the 
fatty acid composition of the cardiac muscle (Harris et al., 2004).  
1.4 Cardioprotective mechanisms of n-3 PUFA 
Several mechanisms have been proposed by which n-3 PUFA could prevent CVD; the three 
main mechanisms are: a) regulation of lipid and lipoprotein metabolism; b) alteration of 
membrane dynamics and production of bioactive lipids; and c) reduction of inflammation. The 
following sections focus on the involvement of n-3 PUFA in the regulation of these pathways.  
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1.4.1 Cardioprotective effects of n-3 PUFA by regulating lipid and lipoprotein metabolism 
Alterations in lipid metabolism underlie the pathology of CVD; thus the regulation of lipid 
metabolism is crucial for maintaining physiological functions. The following subsections 
highlight the importance of n-3 PUFA in regulating lipid and lipoprotein metabolism and the 
associated mechanisms.  
1.4.1.1 Metabolism of serum lipids and lipoproteins  
The liver plays a key role in the trafficking of cholesterol in the body. Three different routes 
of cholesterol movement have been identified in the body: 1) transport of cholesterol from the 
intestine to the liver; 2) transport of cholesterol from the liver to extrahepatic or peripheral 
tissues; and 3) reverse cholesterol transport from peripheral tissues to liver for further 
metabolism of cholesterol. Approximately half of the ingested cholesterol is absorbed in the 
small intestine. Subsequent to the uptake of cholesterol by the small intestine, cholesterol is 
esterified to produce a less polar cholesteryl ester (CE), a reaction catalysed by acyl-coenzyme 
A:cholesterol acyltransferase 2 (ACAT2). The CE formed is packaged into chylomicrons (CM) 
and travels through the lymph to the liver. CM are rich in TG and also contain free cholesterol, 
phospholipids and APO A-I, A-IV, and B-48. Upon reaching the circulation, CM acquires APO 
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Table 1.1: N-3 PUFA international intake recommendation  
A summary of the n-3 PUFA intake recommendation worldwide composed by the International 
Society for the Study of Fatty Acids and Lipids (ISSFAL)  
2010.http://www.issfal.org/statements/pufa-recommendations/recommendations-by-others. 
LCPUFA, long chain polyunsaturated fatty acids; CHD, coronary heart disease. 
Source  Date n-6:n-3 ratio 
Other specific recommendations (%en=% of daily 
energy intake)  
National Nutrition Council of Norway 1989 none 0.5% en n-3 LCPUFA (1-2 g/day) 
NATO Workshop on n-3/n-6 1989 none 0.8 g/day EPA/DHA (0.27%en) 
Scientific Review Committee  of Canada 1990 5:1-6:1 n-3 PUFA at least 0.5%en 
British Nutrition Foundation Task-force 1992 6:1 EPA 0.2-0.5%en:DHA 0.5%en 
FAO/WHO Expert Committee on Fats 
and Oils in Human Nutrition 1994 
5:1-
10:1 Consider pre-formed DHA in pregnancy 
UK Committee on Medical Aspects of 
Food Policy (COMA) 1994 none 
Fish twice/week, one of which should be oily, 
minimum intake EPA/DHA 200 mg/day 
Ad Hoc Expert Workshop 2000 none EPA+DHA 0.3%en:0.65 g/day minimum 
France: AFFSA, CNERNA & CNRS 2001 5:1 500 mg n-3 LCPUFA/day: DHA 120 mg minimum 
US National Academy of 
Science/Institute of Medicine 2002 none 130-260 mg EPA + DHA/day 
American Heart Association 2002 none 
If no CHD, eat (oily) fish twice/week; if CHD 
consume 1000mg n-3 LCPUFA/day; if high 
triglycerides, take 2-4g per day, under medical 
supervision. 
UK Scientific Advisory Committee on 
Nutrition (SACN) 2004 none 
Fish twice/week, one should be oily, min intake 
EPA/DHA 450 mg/day 
ISSFAL 2004 none 500 mg n-3 lcPUFA/day 
Australia and New Zealand Government 
Recommendations 2005 none  n-3 LCPUFA men 160 mg/day; women 90 mg/day 
Superior Health Council of Belgium 2006 none a minimum of 0.3en% EPA+DHA for adults 
Health Council of the Netherlands 2006 none 
to achieve the dietary reference intake of 450 mg of 
n-3 PUFA from fish a day, it is necessary to eat two 
portions of fish a week, at least one of them being 
oily fish (such as salmon, herring or mackerel). 
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C-1, C-II, C-III, and E, and the fatty acids of the TG are cleaved to produce free fatty acids 
(FFA). The transport of dietary fats from the intestine to the liver and movement of cholesterol to 
peripheral tissues in mammals is facilitated by lipoproteins (Genest, 2003). Lipoprotein particles 
are composed of lipids and APO responsible for their structural integrity (Ridker, 2014). 
Lipoproteins are categorized according to their particle density and size; the least dense 
lipoproteins are the CM, followed by very low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), LDL and HDL. (Ridker, 2014). The densities of these lipoproteins are affected 
by the relative concentration of lipids to proteins. The major types of lipoproteins and their 
properties are given in Table 1.2.  
During lipid metabolism, ingested dietary fats are transported from the intestine in the form 
of CM. The TG in the circulating CM is metabolised by lipoprotein lipase (LPL), transforming 
them into chylomicron remnants, which are cleared by the hepatic LDL-r and the LDL-r-related 
protein. The released fatty acids are transported to the adipose tissue and muscles where they 
form TG and are stored (Kwan et al., 2007). There is also an exchange of TG for CE between 
HDL and CM, and this is facilitated in humans by cholesterol ester transfer protein (CETP) 
(Barter et al., 2003). The liver synthesizes cholesterol and fatty acids which are packaged and 
transported in VLDL. Similar to CM metabolism, VLDL also undergoes hydrolysis by LPL to 
produce FFA, which is once again transported to the adipose tissue for storage as TG. VLDL 
loses its lipids and transforms to IDL which can be cleared by the liver or further metabolised by 
LPL resulting in a loss of APO-E to produce LDL. LDL contains APO B-100 and is the main 
transporter of plasma cholesterol. LDL can be cleared by LDL-r on the membrane of the liver. 
LDL has been said to carry the “bad cholesterol”, an excess of which could be highly 
atherogenic.
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Table 1.2: Properties and functions of lipoprotein classes 
 
 
 
 
 
 
 
 
 
 
 
VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL; low-density lipoprotein; HDL, high-density 
lipoprotein; TG, triglycerides; c, cholesterol; Phosp. Phospholipids. Adopted and modified from (Kwan et al., 2007)   
      Composition (%)     
Lipoproteins Density (g/ml) Apoproteins 
Protein TG c Phosp 
Lipid delivery method Function 
Chylomicron <0.95 B-48, C, E 2 90 5 3 Lipoprotein lipase hydrolysis 
Transport of dietary TG 
from intestine to hepatic 
and extrahepatic tissues 
VLDL 0.95-1.006 B-100, C, E 6 60 20 14 Lipoprotein lipase hydrolysis 
Transport of TG from liver 
to extrahepatic tissues and 
precursor of IDL 
IDL 1.006-1.019 B-100, E 18 20 40 22 
Receptor mediated hepatic 
endocytosis and conversion 
to LDL 
Precursor of LDL 
LDL 1.019-1.063 B-100 21 7 50 22 
Receptor mediated  
endocytosis by liver and 
extrahepatic tissues 
Primarily transports 
cholesterol from liver to 
extrahepatic tissues 
HDL 1.063-1.210 A 44 5 25 26 Transfers cholesterol to IDL and LDL 
Responsible for reverse 
cholesterol transport from 
extrahepatic tissues to the 
liver 
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Reverse cholesterol transport (RCT) involves the transport of cholesterol from peripheral 
tissues to the liver for further metabolism of cholesterol. RCT prevents atherosclerotic plaque 
formation by reducing the amount of cholesterol available for oxidation in the wall of the artery. 
Macrophage cholesterol efflux is an integral part of the overall RCT; it involves the regulated 
expulsion of cholesterol by HDL and APO-A1 from extrahepatic lipid laden macrophages, 
thereby preventing atherogenesis (Cuchel and Rader, 2006). APO-A1, a major apolipoprotein of 
HDL, is produced by the intestine and the liver. Lipid-poor APO-A1 acquires lipid by the action 
of ATP binding cassette transporter (ABCA1) to form nascent HDL particle (Parks et al., 2012).  
Lecithin:cholesterol acyl transferase (LCAT) esterifies cholesterol in the HDL thereby forming 
mature HDL (Rader and Hovingh, 2014). In rodents, the free and esterified cholesterol is taken 
up by the liver through scavenger receptor B1 (SR-B1) without the catabolism of the HDL 
particles (Acton et al., 1996). The involvement of HDL in RCT makes it functionally 
atheroprotective. Figure 1.2 shows a schematic representation of the lipoprotein metabolic 
pathway. 
 1.4.1.2 N-3 PUFA and serum lipoprotein metabolism 
Plasma TG is associated with atherogenic lipoproteins such as VLDL and LDL. N-3 PUFA 
reduces TG concentration chiefly by reducing hepatic VLDL production (Lu et al., 1999). This 
also leads to an increased conversion of VLDL to LDL (Chan et al., 2003), which explains the 
increase in large LDL cholesterol concentration upon supplementation with n-3 PUFA (Lu et al., 
1999). Individuals supplemented with n-3 PUFA have an increase in LDL cholesterol 
concentrations, which is a risk factor of CVD (Harris, 1997, Rivellese et al., 2003). The effects 
of n-3 PUFA on lipoprotein concentrations have been controversial. The current consensus is 
that n-3 PUFA improves the quality of lipoprotein profile to a less atherogenic subclass (large  
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Figure 1.2: Lipoprotein metabolic pathway. VLDL, very low-density lipoprotein; IDL, 
intermediate-density lipoprotein; LDL; low-density lipoprotein; HDL, high-density lipoprotein; 
LPL, lipoprotein lipase; Apo-A1, apolipoprotein A1; RCT, reverse cholesterol transport 
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buoyant LDL particles) without affecting its concentrations (Engler et al., 2005).  Studies have 
shown that small dense LDL is capable of infiltrating the arterial wall and prone to oxidation, 
making them more atherogenic compared to the large buoyant LDL particles (Tribble et al., 
1992). N-3 PUFA has been shown to increase the concentration of less atherogenic large LDL 
particles (Mori et al., 2000); this is facilitated by a decrease in TG concentration which causes an 
increase in LDL particle size as a result of an increase in hepatic VLDL clearance (Barter and 
Ginsberg, 2008).  With the documented effect of sex and age on LDL-c metabolism, no study 
has elucidated the effect of n-3 PUFA on the age-dependent changes in plasma LDL-c 
concentration and how this specifically affects the particle sizes of LDL in males and females.    
High circulating concentration of TC is also a risk factor for the development of CVD (Glass 
and Witztum, 2001).  N-3 PUFA regulates TC concentration by downregulating the expression 
of sterol regulatory element binding protein (SREBP) thereby supressing the expression of 3-
hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase, the key enzyme of cholesterol 
biosynthesis (Le Jossic-Corcos et al., 2005). Liver X receptor (LXR) also prevents cellular 
cholesterol accumulation by upregulating the expression of 7-α-hydroxylase, cytochrome P450 
[CYP7A], an enzyme involved in bile synthesis, thus converting excess cholesterol into bile 
(Davidson, 2006). There are also reports showing an increase in HDL cholesterol concentration 
upon supplementation with n-3 PUFA (Dunstan et al., 1997). The functionality of HDL depends 
on its ability to remove cholesterol, known as cholesterol efflux capacity (Khera et al., 2011). 
HDL is also a heterogeneous lipoprotein with different particle sizes each with different 
cholesterol efflux capability (von Eckardstein et al., 1994). HDL-2 and HDL-3 are the most 
studied classes of HDL; they differ by size and functionality with HDL-2 being larger and 
showing the most cholesterol-efflux potential (Ballantyne et al., 1982). N-3 PUFA has been 
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controversially reported to increase the concentration of larger and buoyant HDL-2 particles 
without affecting the total HDL cholesterol concentration (Chan et al., 2006), thereby increasing 
cholesterol efflux which has cardioprotective implication. Though there is plenty of evidence to 
show the effects of n-3 PUFA on lipid and lipoprotein metabolism, no study has accounted for 
the effects of sex and age on the regulation of lipid and lipoprotein metabolism by n-3 PUFA. 
Furthermore, the functionality of HDL, measured as a function of cholesterol efflux capacity, 
could be sex dependent, accounting for the reported differences between HDL cholesterol 
metabolism in females and males.   
1.4.1.3 Mechanisms by which N-3 PUFA regulate lipid metabolism 
Dyslipidaemia or abnormal concentration of lipids is a major independent risk factor of CVD 
(Ooi et al., 2013, Liberopoulos et al., 2005). Fish oil has been shown to be potent at treating 
hypertriglyceridaemia (Harris, 1999). It has been reported that 3-4 g/day EPA and DHA resulted 
in a 25% reduction of TG levels in normolipidaemic individuals and a 35% reduction in TG in 
individuals with hyperlipidaemia (Harris, 1997, Kris-Etherton et al., 2002). The mechanisms 
underlying the TG-lowering effects of n-3 PUFA have been explained by the involvement of n-3 
PUFA in the regulation of genes involved in lipid metabolism; such genes include SREBP, all 
forms of peroxisome proliferator-activated receptors (PPARs), retinoid X receptor-alpha (RXR-
α) and LXR-α. The retinoid X receptor (RXR) heterodimerises with LXR and regulates the gene 
expression of SREBP1-c by binding to the LXR response element in the SREBP1-c promoter 
region, thereby suppressing its expression (Yoshikawa et al., 2002). SREBP1-c is the key 
controller of lipogenesis; its inhibition has been shown to downregulate the expression of fatty 
acid synthase and acetyl-CoA carboxylase thereby, preventing fatty acid synthesis required for 
TG production (Strable and Ntambi, 2010). Another classic cardioprotective mechanism by 
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which n-3 PUFA reduce circulating levels of TG is by stimulating fatty acid β-oxidation. N-3 
PUFA reduces TG concentration by increasing the β-oxidation of non-esterified fatty acids 
(NEFA) a substrate for TG synthesis (Pegorier et al., 2004). N-3 PUFA also regulates the 
expression of PPAR-α which upregulates acyl coenzyme A oxidase, a rate limiting enzyme in 
fatty acid catabolism, which further stimulates β-oxidation (Jump and Clarke, 1999). There is an 
obvious difference in the prevalence of CVD between males and females (Castelli, 1984, Kuhn 
and Rackley, 1993, Njolstad et al., 1996), and the risk of CVD has also been shown to increase 
with age in both males and females (Castelli, 1984, Tunstall-Pedoe et al., 1994, Rich-Edwards et 
al., 1995). To date, the majority of studies have established the cardioprotective effects of n-3 
PUFA in adult life (Adkins and Kelley, 2010, Massaro et al., 2008), and only a handful of studies 
have reported the sex specific effects of n-3 PUFA (Phang et al., 2009, Phang et al., 2013). 
However, no study has comprehensively elucidated the possible interactions of sex, age, and n-3 
PUFA on lipid and lipoprotein metabolism. 
1.4.1.3.1  N-3 PUFA and adipocyte metabolism 
N-3 PUFA has also been shown to reduce obesity and the majority of the data in this regard 
have focused on the effect of n-3 PUFA on adipocyte differentiation (Okuno et al., 1997, 
Takahashi and Ide, 2000). Studies have shown that subjecting rodents to a high fat diet increases 
adipocyte differentiation and adipocyte hypertrophy (Ellis et al., 1990). This has been linked to 
the upregulation of the expression of CCAAT/enhancer binding protein and PPARγ by high fat 
diet, the key regulators of differentiation of adipocyte and the storage of lipids (Lopez et al., 
2003). The activation of PPARγ is at the heart of adipocyte differentiation and PPARγ deficient 
mice have been shown to lack adipose tissue (Barak et al., 1999). Mice heterozygous for the 
PPARγ gene had reduced adipose mass and smaller adipocytes (Yamauchi et al., 2001). Fatty 
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acids are well known activators of PPARs (Kliewer et al., 1997); however, PPARs respond 
differently to activation by different fatty acids. It has been reported that PUFAs are better 
activators of PPARs compared to both MUFA and SFA (Kliewer et al., 1997). A synthetic 
PPARγ agonist, pioglitazone, has been shown to facilitate an increase in fat mass in rodents by 
producing new, small fat cells (hyperplasia) (Hallakou et al., 1997). Whereas, activation of 
PPARγ by high fat diet induces both hypertrophy and hyperplasia; these effects  depend on the 
type, class, and degree of unsaturation of fat used. N-3 PUFA has been shown to reduce obesity 
and body weight (Nakatani et al., 2003).  
In-vitro studies using 3T3-L1 cells, a widely used model to study adipocyte differentiation, 
show that n-3 PUFA was less effective at stimulating adipocyte differentiation compared to SFA 
and MUFA (Madsen et al., 2005). The COX and LOX metabolic products of PUFA called 
eicosanoids are also known to activate PPARγ (Kliewer et al., 1997). While high n-3 PUFA has 
been shown to reduce obesity, high n-6 PUFA diet has the propensity to induce obesity 
(Massiera et al., 2003). In in-vitro studies, n-6 PUFA was reported to increase adipocyte 
differentiation and TG accumulation, whereas n-3 PUFA treatment caused less accumulation of 
TG compared to n-6 PUFA (Petersen et al., 2003). Eicosanoids produced by the metabolism of 
n-6 PUFA have been suggested to be responsible for n-6 PUFA-induced adipocyte 
differentiation (Catalioto et al., 1991); inhibiting the expressions of COX-1 and COX-2 has been 
suggested to rescue adipocyte differentiation induced by n-6 PUFA (Petersen et al., 2003). EPA 
is a poor substrate for COX relative to AA, and n-3 PUFAs are known to inhibit the expression 
of COX, further emphasizing the anti-obesity effects of n-3 PUFA (Ringbom et al., 2001).  
Adipocyte hypertrophy is the main cause of adipose tissue enlargement and obesity; 
however, most studies that sought to understand the cellular mechanism of obesity have focused 
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on adipocyte differentiation. Adipocyte hypertrophy is a consequence of excess accumulation of 
TG in the adipose tissue; therefore, elucidating the molecular processes involved in the formation 
of TG in the adipose tissue is important in understanding the development of obesity. Acyl 
CoA:diacylglycerol acyltransferase (DGAT) is responsible for the synthesis of TG (Bell and 
Coleman, 1980); it catalyses the covalent binding of acyl group to diacyglycerol (DG), which is 
the final step of TG synthesis (Chen et al., 2002). Furthermore, fatty acid binding protein-4 
(FABP4), also known as adipocyte fatty acid binding protein-2, has been shown to play a vital 
role in adipocyte hypertrophy (Uysal et al., 2000). Studies have shown that obese individuals 
have increased expression of FABP4 (Xu et al., 2006, Reinehr et al., 2007), and individuals who 
lost weight were reported to have a reduced expression of FABP4. However, there is still a 
paucity of knowledge on the mechanisms involved in adipocyte hypertrophy, and whether the 
anti-obesity effect of n-3 PUFA is elicited by regulating the key genes involved in adipocyte 
hypertrophy. Furthermore, obesity has been identified as an independent risk factor of CVD in 
both males and females (Willett et al., 1995, Manson et al., 1990); however, most researchers 
have excluded the effect of sex and an adequate amount of n-3 PUFA in the diet.    
1.4.2 Cardioprotective effects of n-3 PUFA by altering membrane dynamics and production of 
bioactive lipids 
 N-3 PUFA exists in nature as TG or PL. TG contains three fatty acids bound to a glycerol 
backbone, and PL contains two fatty acids bound to a glycerol backbone with phosphorus and a 
head group which could mainly be a choline, ethanolamine, serine, inositol or glycerol. There are 
three major classes of PLs: the glycerophospholipids, sphingolipids and etherglycerolipids (Burri 
et al., 2012). Because of their amphipathic nature, PLs are found primarily in plasma membranes 
where they influence membrane fluidity. The most common membrane PLs are the 
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glycerophospholipds, mainly phosphatidylcholine (PC), phosphatidylserine (PS) and 
phosphatidylethanolamine (PE).  
Membrane fluidity is influenced by the incorporation of long chain n-3 PUFA into membrane 
PL (Hulbert et al., 2005, Leaf et al., 2005), which could alter the functions of transmembrane 
proteins and their interaction with extracellular ligands (Ma et al., 2004).  These alterations 
indirectly affect signalling pathways and other physiological functions. Furthermore, the fatty 
acid on the sn-2 position of membrane PL could be cleaved by the action of phospholipase A2 
(PLA2) to produce FFA and lyosphosphatidylcholine (LPC) which are both bioactive molecules 
(Thies et al., 1992). The released twenty carbon AA and EPA from the membrane phospholipids 
undergo cyclooxygenases (COX-1 and COX-2) and lipoxygenases-(LOX-5, LOX-12, LOX-15) 
catalysed oxidation to produce bioactive lipid intermediates and eicosanoids (Jump et al., 2012). 
AA is a precursor to series-2 prostaglandins and series-4 leukotrienes; these are generally pro-
inflammatory, vasoconstrictive and pro-aggregatory, and generally promote CVD (Farooqui et 
al., 2007). On the other hand, series-3 prostaglandins and series-5 leukotrienes produced from 
EPA are anti-inflammatory and prevent the development CVD (Adkins and Kelley, 2010). AA-
derived eicosanoids include pro-inflammatory PGE2 (vasodilator), TXA2 (vasoconstrictor), PGI2 
(platelet aggregator), and LTB4 (chemotactic factor), while EPA-derived eicosanoids include 
anti-inflammatory PGE3 (vasodilator), PGI3 (inhibit platelet aggregator), and LTB5 and TXA3, 
which are less active than AA-derived eicosanoids (Simopoulos, 1999, Engler and Engler, 2006) 
(Figure. 1.1).  
The second product of hydrolysis of PC is LPC which has been generally considered 
atherogenic mainly because of its role in promoting arterial inflammation (Kabarowski, 2009). 
LPC has been shown to increase the expression of adhesion molecules such as vascular cell 
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adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), promote 
endothelial dysfunction and increase the expression of inflammatory cytokines and consequently 
atherogenic plaque formation (Zalewski and Macphee, 2005). It is important to acknowledge that 
the physiological properties of LPC are heavily dependent on its acyl chain moiety (Ojala et al., 
2007). The majority of data that have reported the pro-inflammatory and pro-atherogenic 
potential of LPC have used SFA or MUFA-containing LPC (Bach et al., 2010). There is, 
however, new evidence that supports the anti-inflammatory effects of DHA-containing LPC 
species (Huang et al., 2010).  DHA containing LPC has been shown to exhibit its anti-
inflammatory property by blocking the activity of 5-LOX responsible for the generation of pro-
inflammatory metabolites including LTB4 (Huang et al., 2008). DHA-LPC is more potent at 
stimulating the anti-inflammatory process compared to AA-LPC. DHA containing LPC also 
reduced the concentration of pro-inflammatory cytokines when compared with other LPC-
containing fatty acids (Huang et al., 2010). DHA-LPC could be metabolised to release free DHA 
which could stimulate anti-inflammatory pathways, or the DHA-LPC can be oxygenated by 15-
LOX to produce 17S-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (17-HPDHA-
LPC) which is further metabolised to generate protectin D, a strong anti-inflammatory metabolite 
(Serhan et al., 2002). In addition to its anti-inflammatory effects, DHA-LPC has been shown to 
be the preferred carrier of DHA to the brain where it is required for neuronal functions (Bernoud 
et al., 1999, Thies et al., 1994).  Furthermore, LPC has been shown to promote cholesterol efflux 
from macrophages (Hara et al., 1997). Although the mechanism involved is unclear, it has been 
suggested that LPC promotes cholesterol efflux through its association with HDL-associated 
paraoxonase 1(PON1) (Rosenblat et al., 2006). An increase in HDL LPC production increases 
the binding of HDL to macrophages thereby stimulating increased cholesterol efflux.  
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The type of fatty acid released from the membrane phospholipids depends on the dietary fatty 
acid composition. Given the information on the health benefits of bioactive compounds derived 
from the metabolism of n-3 PUFA, including n-3 PUFA containing LPC, it will be important to 
investigate the effect of high n-3 PUFA diet on the different classes of bioactive lipids generated 
from the metabolism of n-3 PUFA, and the functional role of these bioactive lipids.  
1.4.3. Cardioprotective effects of n-3 PUFA by reducing inflammation 
The development of atherosclerosis encompasses a cycle of inflammatory processes, and is 
now recognised as an inflammatory disease (Hansson, 2005).  Studies have reported the ability 
of n-3 PUFA to reduce the expression of adhesion molecules on macrophages (Hughes et al., 
1996) and endothelial cells (Weber et al., 1995), thereby preventing the atherosclerotic plaque 
progression. N-3 PUFA also prevents CVD by maintaining vascular endothelial function. The 
adhesion molecules secreted by endothelial cells are actively involved in platelet adhesion and 
leukocyte recruitment during inflammation, which are major players in atherogenesis (Adkins 
and Kelley, 2010). These adhesion molecules are activated by pro-inflammatory cytokines such 
as TNF-α, IL-6 and IL-8; n-3 PUFA has been shown to decrease the expression of these 
cytokines.  
The expression of adhesion molecules on the endothelium is also promoted by nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB), a pro-inflammatory transcription factor 
(Kumar et al., 2004, Sigal, 2006). NF-kB is involved in a number of cellular responses including 
inflammation and the immune response to infection. Activation of NF-kB leads to a sequence of 
reactions that promote inflammation, and consequently atherogenesis. The activated form of NF-
kB has been found in atherosclerotic vessel walls and promotes the formation of atherosclerotic 
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lesions (Brand et al., 1996). N-3 PUFA downregulates the expression of NF-kB to suppress 
inflammation (Chen et al., 2005); this reduces the markers of atherosclerosis, and enhances 
vascular function (Gupta et al., 2008). N-3 PUFA has also been found to impede the translation 
of genes involved in inflammation by inhibiting NF-kB. Furthermore, EPA was found to inhibit 
the expression of TNF-α, a classic pro-inflammatory cytokine by preventing the movement of 
NF-kB into the nucleus (Zhao et al., 2004). NF-kB upregulates the expression of inflammatory 
cytokines such as IL-6, IL-2, and TNF-α; n-3 PUFA has been shown to reduce these cytokines. 
The expression of PPARs, an important class of nuclear receptor proteins involved in the 
regulation of inflammation and lipid metabolism has also been shown to be directly regulated by 
n-3 PUFA (Marx et al., 1998). PPARα and γ inhibit NF-kB thereby blocking the production of 
potent inflammatory cytokines. PPARα has also been shown to exhibit its cardioprotective effect 
by blocking the production of cellular adhesion molecules, leading to a significant reduction of 
inflammation (Marx et al., 1998). Moreover, as mentioned previously, n-3 PUFA can also 
alleviate inflammation resulting from atherogenesis by producing anti-inflammatory eicosanoids 
and docosanoids from EPA and DHA, respectively (Wanten and Calder, 2007).  
1.5 N-3 PUFA and the brain 
Recent evidence suggests a relationship between cardiometabolic irregularities and 
neurocognitive decline (O'Brien et al., 2003); this proposition is further strengthened by the 
similarities in the events and timeline leading to the pathological decline of the brain and cardiac 
functions (Picano et al., 2014). Individuals with neurological abnormalities often have vascular 
impairment (Snowdon et al., 1997).  Emerging evidence reveals that certain trophic factors 
known as neurotrophins thought to be classically neurotrophic in function also possess 
metabotropic properties (Chaldakov et al., 2009). The brain’s structural component is 50-60% 
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lipids by dry weight, and 30-35% of brain’s total lipids are n-3 and n-6 PUFA (Youdim et al., 
2000). The maintenance of a unique fatty acid profile is very important for brain function and is 
characterized by  a high accretion of SFA, MUFA, DHA, AA, and less of EPA, LA and ALA 
(Youdim et al., 2000). The brain depends on dietary and hepatic supplies of PUFA to maintain 
its level (Demar et al., 2005). Although neuronal lipid composition is tightly regulated, dietary 
supplementation can go a long way in altering neuronal membrane lipid composition. Studies 
have shown that 6-8 weeks of supplementation with EPA significantly increased the accretion of 
EPA and its longer chain metabolite, docosapentaenoic acid (DPA), in mouse brain (Luchtman et 
al., 2012, Meng et al., 2010). Furthermore, a higher intake of DHA increased the accretion of 
DHA in the brain with a consequent decrease in longer chain n-6 PUFA (Bousquet et al., 2008), 
and a reciprocal effect is observed during DHA deprivation, thereby maintaining the overall level 
of unsaturation in the brain. However, DHA and AA are functionally different. A high intake of 
n-6 PUFA promotes cognitive impairment (Fedorova and Salem, 2006).  The lipid component of 
the brain is primarily PL, with high enrichment of DHA and AA (Sastry, 1985). DHA is 
preferentially incorporated into the PE and PS fractions of the brain’s membrane PLs (Rapoport, 
2001); however, the most abundant PLs in the brain are PE and PC (Rapoport, 2001). PUFAs are 
released from neuronal membrane PLs by the action of PLA2. There are three isoforms of PLA2; 
1) the calcium dependent PLA2 (cPLA2; 2) secretory PLA2 (sPLA2); 3) calcium independent 
PLA2 (iPLA2) (Rapoport, 2013).       
DHA is preferentially acylated to the sn-2 position of PE and PS (Lee and Hajra, 1991), and 
is mobilized by the action of iPLA2; while cPLA2 mobilizes AA (Farooqui and Horrocks, 2004). 
The released DHA is physiologically important in the regulation of signalling cascades 
(McNamara et al., 2006), production of anti-inflammatory metabolites (Hong et al., 2003), use 
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for β-oxidation (Yavin et al., 2002) or re-incorporation into membrane PLs. The increased 
accretion of DHA during foetal development corresponds to the period of neurogenesis, neuronal 
differentiation and myelination, further emphasizing the importance of DHA during these critical 
periods (Green et al., 1999). DHA is accumulated in the brain during the third trimester of 
pregnancy to two years after birth in humans and gestation day 7 to 21 day after birth in rodents 
(Green et al., 1999, Martinez, 1992). During this period in humans, there is rapid increase in 
weight of the human brain from approximately 20-1200 g (Carlson et al., 2013). This represents 
the period of rapid neuronal myelination and maturation of synapses (Dobbing and Sands, 1973). 
Clandinin et al reported that there is a rapid accretion of DHA and AA in the brain during the 
third trimester of pregnancy and a decrease in the concentration of LA and ALA (Clandinin et 
al., 1980).  Martinez found that the brain accretion of DHA and AA increases 30-fold from the 
third trimester until about two years after birth (Martinez, 1992).  
During pregnancy, the foetus depends on the mother for an adequate supply of DHA, and this 
is made available through placental transfer (Innis, 2005). DHA is transferred through the 
placenta in non-esterified form (Dutta-Roy, 2000), which comes from the lipoprotein lipase-
catalysed hydrolysis of maternal lipoprotein. Studies have shown that DHA is preferentially 
transferred across the placental to foetal circulation compared to ALA, LA, AA, oleic and 
palmitic acid (Larque et al., 2003, Haggarty et al., 1997). The developing foetus has a reduced 
ability to convert ALA to DHA because of a reduced hepatic expression of the enzymes involved 
during gestation; therefore the foetus relies on the mother for an optimal supply of the preformed 
DHA required for brain development (Uauy et al., 2000).     
DHA deficiency in the brain during development can be normalized by DHA 
supplementation; however, relative to other tissues such as the liver and red blood cells, recovery 
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from DHA deficiency is slow (Moriguchi et al., 2001, Xiao et al., 2005). DHA composition in 
adult brain is resistant to dietary n-3 PUFA deficiency (Bourre et al., 1992), as shown by an 
increase in the half-life of DHA as a result of a deficiency in n-3 PUFA (DeMar et al., 2004).  
Ageing is a natural process accompanied by a number of physiological changes. During ageing, 
there is a decrease in DHA concentration in the brain which coincides with the alteration in 
neurotransmission and other vital functions of the brain (Favrelere et al., 2000), including the 
development of neurological disorders such as Alzheimer’s disease (Soderberg et al., 1991).  
The protective role of n-3 PUFA in mental health is well documented. N-3 PUFA 
supplementation has been shown to reduce the symptoms of attention deficit hyperactivity 
disorder (ADHD) by 25% in patients supplemented with 174 mg DHA and 558 mg EPA for 3 
months (Johnson et al., 2009). The efficacy of n-3 PUFA in treating autism has also been 
reported. Autistic children supplemented with 700 mg DHA and 840 mg EPA for four weeks 
saw significant improvement of their symptoms compared to the control (Amminger et al., 
2007). The protective effects of n-3 PUFA in some neurological diseases such as Alzheimer’s 
disease (Morris et al., 2003) and multiple sclerosis (Mehta et al., 2009) have also been reported 
The beneficial effect of n-3 PUFA is essential in developing brain as well as in mature brain 
(Kitajka et al., 2004). Studies have also documented that mothers that consumed high amount of 
n-3 PUFA during pregnancy had children with better cognitive abilities than non-n-3 PUFA 
consuming mothers (Daniels et al., 2004), suggesting n-3 PUFA is vital for brain function. 
However, the exact mechanisms by which n-3 PUFA regulate the function of the developing 
brain as well as the mature brain are still not clear. The function of the brain is regulated by 
specific neurotrophins, and it has been suggested that n-3 PUFA likely alter the expression of 
neurotrophins.  
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 1.5.1 Neurotrophins and the brain 
The term neurotrophins refers to a group of trophic factors required for neuronal 
differentiation and survival (Huang and Reichardt, 2001). The major classes of neurotrophins are 
the nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-
3), and neurotrophin 4/5 (NT 4/5). The activities of neurotrophins are turned on during the 
embryonic stage, and may be restricted to a particular developmental period (Birling and Price, 
1995). There is high heterogeneity in the expression of neurotrophins in the nervous system, and 
they generally decrease with age (Zermeno et al., 2009). Neurotrophins are vital to the proper 
functioning of the central nervous system where they play an important role in neuronal survival, 
cell differentiation, synaptogenesis, and synaptic plasticity (Lu et al., 2008, Reichardt, 2006). 
Among the neurotrophins, the activity of BDNF is the best characterised, and an alteration in the 
expression of BDNF has been shown to have a significant impact on neuronal activities and 
predisposition to cognitive decline, and neuropsychiatric disorders in both humans and rodents 
(Castren and Rantamaki, 2008, Chen et al., 2006). The expression of BDNF is regulated both at 
the mRNA and protein levels (Greenberg et al., 2009). The endoplasmic reticulum synthesizes 
BDNF as a precursor protein preproBDNF which is then converted to proBDNF and transported 
to the Golgi, where it is converted to mature BDNF (mBDNF) by the action of furin and 
endoprotease, or in the secretory granules by convertases (Mowla et al., 1999).  
Neurotrophins are released as their precursor proneurotrophins approximately 30kDa in size, 
and are cleaved to form the mature neurotrophins of approximately 13kDa in size. All 
neurotrophins bind with low affinity to P75 NTR receptor (Rodriguez-Tebar et al., 1990), while 
neurotrophins binds specifically with high affinity to TrK receptors. NGF binds to TrKA (Klein 
et al., 1991a); the ligands for TrKB are BDNF (Klein et al., 1991b) and NT-4/5 (Klein et al., 
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1992) while TrKC is the receptor for NT-3 (Lamballe et al., 1991). Binding of neurotrophins to 
TrK receptors initiates a series of downstream phosphorylation of proteins including PI3K/AKT 
pathway, Ras kinase pathway (Kaplan and Miller, 2000), and the phosphorylation of cAMP 
response element binding protein (CREB), which consequently leads to the activation of genes 
involved in neuronal survival. Signalling activities of neurotrophins elicited through TrK 
receptors promote neuronal survival; on the contrary, signalling through the p75NTR promotes 
neuronal apoptosis (Bibel and Barde, 2000).  
1.5.1.1. Neurotrophins and n-3 PUFA: brain and heart connection 
The secretion of neurotrophins is not limited to the central nervous system as they are 
released in the peripheral system as well, where they have been shown to play a role in 
atherosclerosis and lipoprotein metabolism among others (Tasci et al., 2012).  Interestingly, 
neurotrophins and n-3 PUFA share some functional similarities; in addition to their effects on 
neural and cardiovascular functions, with age, there is a significant decrease in tissue accretion of 
n-3 PUFA (Lommatzsch et al., 2005), as well as neurotrophins (Golden et al., 2010), and a 
consequent increase in the risk of cardiovascular and neuropsychiatric disorders. Approximately 
80% of the secreted BDNF comes from the brain; however, there is evidence of secretion in 
peripheral tissues (Suliman et al., 2013). There are reports of the effects of BDNF in both 
neuropsychiatric and metabolic disorders suggesting a brain-body regulatory role of BDNF 
(Yoshida et al., 2012). There is also evidence of the involvement of BDNF in inflammation 
which is a major player in CVD (Cai et al., 2006); low circulating BDNF concentration has been 
reported in patients with CVD and metabolic syndrome (Golden et al., 2010). Mice expressing 
aberrant BDNF receptor TrKB have been shown to develop cardiovascular abnormalities (Palko 
et al., 1999). Heterozygous knockout mice for BDNF are hyperphagic, with the propensity to 
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become obese and insulin resistant (Kernie et al., 2000). Laboratory findings have shown that the 
administration of BDNF improves glucose metabolism in diabetic mice models (Tonra et al., 
1999), and the circulating BDNF concentration is age and sex-specific (Golden et al., 2010). 
Studies have also shown inverse correlation between plasma BDNF and circulating blood lipid 
concentrations including TG, cholesterol and LDL-c (Golden et al., 2010, Jung et al., 2011, Jiang 
et al., 2011).  BDNF has been shown to lower plasma NEFA, TC and blood glucose in mice 
(Tsuchida et al., 2002). Similar to neurotrophins, n-3 PUFA is well established to be both 
neuroprotective (Georgieff, 2007) and cardioprotective (Saravanan et al., 2010); however, the 
effects of n-3 PUFA on the causal relationship between these two conditions have not been 
elucidated. In addition to the neuroprotective effects of n-3 PUFA, neurotrophins have also been 
shown to be important in neuronal development. With the reported cardioprotective and 
neuroprotective properties of BDNF and n-3 PUFA, it will be important to investigate whether 
they both share a regulatory relationship. No study has investigated the age-dependent role of n-3 
PUFA in regulating neurotrophin signalling in the brain as all evidence points towards the 
speculation that the cardioprotective and neuroprotective effects of n-3 PUFA are centrally 
mediated by neurotrophin signalling. 
1.6 Controversies in the cardioprotective effects of n-3 PUFA  
There are numerous reports on the beneficial health effects of n-3 PUFA, however there are 
also controversial reports on the cardioprotective efficacy of n-3 PUFA. A recent systematic 
review and meta-analysis on the association between n-3 PUFA supplementation and risk of 
CVD revealed that n-3 PUFA was not associated with lower mortality from cardiovascular 
events (Rizos et al., 2012).  Furthermore, a recent study reported no significant effect on markers 
of CVD after a 6 year supplementation with n-3 PUFA (Investigators et al., 2012).  These 
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controversies could be due to differential effects of n-3 PUFA based on sex, dose, duration of 
exposure and the type of n-3 PUFA used.  
1.6.1  Sex, age and the cardioprotective effects of n-3 PUFA  
 There are sex-specific differences in the regulation of n-3 PUFA metabolism.  Studies have 
reported a higher tissue accretion of DHA in females compared to males (Decsi and Kennedy, 
2011, Extier et al., 2010), which is due to a higher conversion rate of ALA to longer chain EPA 
and DHA in women (Decsi and Kennedy, 2011).  This is explained mechanistically by the sex-
specific effect of the liver desaturase enzyme responsible for the conversion of ALA to EPA and 
DHA, with female rats showing a higher hepatic expression of δ-5 and δ-6 desaturases compared 
to males (Extier et al., 2010). Interestingly, oestrogen has been shown to affect tissue distribution 
of n-3 PUFA with females showing a higher concentration in plasma and tissues, further 
explaining sex specific differences (Childs et al., 2008). Although controversial, the role of 
oestrogen in LDL metabolism has been reported; oestrogen decreased the circulating 
concentration of atherogenic LDL (Campos et al., 1997).  There are also sex differences in the 
concentration of HDL particles between men and women (Knopp et al., 2005). The mechanism 
underlying the sex-specific difference in lipid metabolism has been explained by the interaction 
between PPAR-α and the oestrogen receptor. Studies have shown that a signal cross talk exists 
between PPAR-α and oestrogen receptor (Souidi et al., 1999, Wang and Kilgore, 2002). There is 
also evidence of the sex specific effect of PPAR-α on the regulation of cholesterol metabolism 
(Costet et al., 1998).  
The effect of sex in the development of CVD cannot be overemphasized; however, age may 
be equally important.  The prevalence of CVD is different between male and female, and this has 
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also been shown to be affected by age (Castelli, 1984); these differences have been linked to the 
age-dependent variation in cholesterol concentration between males and females (Rossouw, 
2002). The plasma TC concentration increases with age (Corti et al., 1997) mainly because of the 
age-dependent decrease in the catabolism of cholesterol (Corti et al., 1997). Furthermore, males 
and females have similar plasma HDL cholesterol concentration at puberty after which 
differences develop with age (Abbey et al., 1999). There are also documented age effects on 
plasma concentration of TG concentration (Castelli, 1984). Given the sex-specific effects on the 
distribution and accretion of n-3 PUFA, and the clear distinction in lipid and lipoprotein 
metabolism between males and females, it is important to elucidate the sex specific effects on n-
3 PUFA on markers of CVD before a solid recommendation of n-3 PUFA can be made. 
Furthermore, it will also be important to consider the effect of age on the sex specific effect of n-
3 PUFA as this clearly will provide information on how these factors will affect the 
cardioprotective effects of n-3 PUFA.    
1.6.2 Dose and the cardioprotective effects of n-3 PUFA  
It is imperative to administer an appropriate dose of n-3 PUFA to get the desired 
cardioprotective benefits. The recent systematic review and meta-analyses that discredited the 
cardioprotective effects of n-3 PUFA (Rizos et al., 2012) considered studies that used a lower 
than the recommended dosage of n-3 PUFA; the mean intake of EPA and DHA in their study 
was approximately half the recommended dosage of 3 g/day to treat cardiovascular 
complications. The beneficial effects of n-3 PUFA on cardiovascular events have been shown to 
be dose dependent.  Moertl et al found a 2.5% improvement in left ventricular ejection fraction 
in patients with coronary heart failure after administering 1g/day of n-3 PUFA for 3 months; 
however, a 5.5% improvement was recorded with a higher dose of 4g/day of n-3 PUFA (Moertl 
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et al., 2011). In the same cohort, only higher doses were effective at resolving inflammation and 
alleviating endothelial dysfunction, further emphasizing the importance of dose in the health 
benefits of n-3 PUFA (Moertl et al., 2011). Furthermore, studies have also reported the beneficial 
effect of n-3 PUFA dosage greater than 1g/day at treating endothelial dysfunction (Wright et al., 
2008). To obtain a full cardioprotective effect of n-3 PUFA, a dosage in excess of the currently 
recommended 1g/day will be required (Calder, 2009). The immunomodulatory effects of n-3 
PUFA has also been shown to be dose dependent, with observable benefits within the range of 
1.65 and 3.3 g/day (Calder, 2009). The importance of dosage in the health benefits of n-3 PUFA 
has also been corroborated by animal studies with significant improvement from cardiovascular 
events observed at a higher dosage of about 7%  of energy intake from EPA + DHA (Duda et al., 
2009). Several clinical trials have reported the beneficial effects of consuming fish and n-3 
PUFA supplements at different dosages. Subjects who were asked to consume 200-400 g oily 
fish per week or the equivalent of fish oil capsules (EPA; 180 mg and DHA; 120 mg) saw 
significant cardioprotective effects (Burr et al., 1989). In another study, individuals who received 
approximately 882 mg of EPA and DHA (1:2) had up to 20% reduction in the risk of CVD 
(Marchioli et al., 2002) compared to those without n-3 PUFA supplements (1999). Analyses of 
prospective cohort studies have shown that the consumption of 250-500 mg/day EPA and DHA 
is sufficient to prevent the risk of CVD (Harris et al., 2009).  Another study reported that the 
upper limit of 500 mg/day provided the most beneficial effect (Harris et al., 2008), and that even 
greater intake will confer additional protection (Makhoul et al., 2010). It was also reported that 4 
g/day of n-3 PUFA reduced TG concentration by 25-30 %, and a dose response relationship was 
also observed (Harris, 1997). Another study of 42 participants revealed a 45% decrease in TG 
after supplementing patients with 4 g/day n-3 PUFA (Harris et al., 1997). The cardioprotective 
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benefits of n-3 PUFA have been well documented; however, the optimal dose remains to be 
established. There is no firm recommended dietary intake for n-3 PUFA; however, different 
international organisations have made dietary recommendations with a common theme of n-6 to 
n-3 PUFA ratio of approximately 5:1 as shown in Table 1.1.   The n-6 to n-3 PUFA ratio of 5:1 
has been suggested as an optimal ratio for whole body homeostasis, which is different from the 
30:1 ratio which approximately represents the current n-6: n-3 PUFA ratio in a typical Western 
diet. No study has comprehensively assessed the effect of n-3 PUFA dosage with reference to the 
n-6: n-3 PUFA ratio on the markers of CVD.   
1.7 Mouse as an animal model 
Mouse genetics are the most characterised among mammals (Paigen et al., 1990). The mouse 
has also been favoured as a model of animal experimentation because of its small size and short 
reproduction time (Fazio and Linton, 2001), which would allow for studies involving the 
monitoring of transfer of genetic information through generations. We chose the C57BL/6 mouse 
for our study because it has been established as a model for the study of diet-induced 
atherosclerosis (Paigen et al., 1990, Paigen et al., 1987), diabetes and obesity (Surwit et al., 1988, 
Surwit et al., 1991). This model is susceptible to high-fat diet-induced hyperlipidaemia, 
atherosclerosis, and obesity, making it suitable for the study of lipid and lipoprotein metabolism. 
C57BL/6 is also a strain of choice used to generate numerous transgenic models to study 
pathological conditions related to lipid and lipoprotein metabolism (Getz and Reardon, 2006), 
thus leaving the option of extending our study with different transgenic models in the future. We 
acknowledge the difference in the regulation of lipid and lipoprotein metabolism between mice 
and humans. In contrast to humans, mice do not have CETP; therefore, 70% of TC occurs in 
HDL in mice, while the major carrier of cholesterol in human is LDL (Kako et al., 2002). 
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However, easily obtainable information from mice would provide a greater understanding of the 
regulation of the lipid and lipoprotein metabolism in humans. 
1.8 Rationale and hypotheses 
There are numerous reports supporting the cardioprotective effects of n-3 PUFA; however, 
there are also inconsistent reports. Given the complexity and physiological variation of the 
human population, it is pertinent to consider the various factors that could potentially affect the 
metabolism and hence the health benefits of n-3 PUFA before a strong recommendation can be 
made. The studies outlined in this thesis were carried out to better understand the effects of n-3 
PUFA on the risk factors of CVD such as dyslipidaemia and obesity, with particular emphasis on 
the regulation of lipid and lipoprotein metabolism, and factors such as age, sex, and dose that 
could potentially affect the health benefits of n-3 PUFA. These studies also sought to identify 
novel mechanisms by which n-3 PUFA could reduce the risk of CVD using C57BL/6 mouse 
model. The specific aims and the underlying hypotheses of the study were: 
Aim 1: To investigate dose-, age- and sex-specific effects of dietary n-3 PUFA on the regulation 
of plasma lipids and lipoprotein concentrations (Chapter 2) 
Hypothesis: There is an obvious difference in the prevalence of CVD between males and 
females, and the risk of CVD has also been shown to increase with age in both male and female. 
However, no study has comprehensively elucidated the possible interactions of sex, age, and n-3 
PUFA on lipid and lipoprotein metabolism. It was hypothesized that the effects of n-3 PUFA on 
lipid and lipoprotein concentrations will be dose-dependent, and longer exposure to n-3 PUFA 
diet will significantly enhance the effects of n-3 PUFA. It was further hypothesized that the 
effects of n-3 PUFA on lipids and lipoproteins will be higher in females compared to males. 
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Aim 2: To investigate the effects of dietary n-3 PUFA on the lipidomic profile of plasma and 
liver (Chapter 3) 
Hypothesis: Cells, tissues and biological fluids consist of numerous bioactive lipid mediators 
involved in cellular processes, which are likely altered by dietary n-3 PUFA. It was hypothesized 
that a diet high in n-3 PUFA will increase the proportion of longer chain n-3 PUFA in bioactive 
lipids.  
Aim 3: To investigate the sex-specific effects of dietary n-3 PUFA on adipocyte metabolism 
(Chapter 4) 
Hypothesis: Adipocyte hypertrophy is a consequence of excess accumulation of TG in the 
adipose tissue, therefore, elucidating the molecular process involved in the formation of TG in 
the adipose tissue is important in understanding the development of obesity. It was hypothesized 
that high dietary n-3 PUFA will prevent adipocyte hypertrophy by downregulating the mRNA 
expression of key proteins involved in adipocyte hypertrophy in a sex-dependent fashion. 
Aim 4: To investigate whether dose and duration of exposure to dietary n-3 PUFA will cause 
alterations in DHA accretion in the brain and the expression of neurotrophins (Chapter 5) 
Hypothesis: N-3 PUFA and neurotrophins are important to the proper functioning of the central 
nervous system.  However the mechanism/s by which n-3 PUFA regulate neurotrophin signalling 
are still not clear. It was hypothesized that perinatal and sustained post-weaning diet high in n-3 
PUFA will cause an accretion of DHA in the brain of the offspring, and consequently increase 
the mRNA expressions of BDNF, NGF, TrKB, and CREB in an age dependent fashion. 
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Dose, age, and sex-specific effects of dietary n-3 PUFA on the regulation of 
plasma lipids and lipoproteins metabolism  
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2.1 Abstract 
There is clear evidence of the effects of sex and age on the prevalence of cardiovascular 
disease. We investigated the interactions of dietary n-3 PUFA, sex, and age on plasma lipids and 
lipoproteins in the offspring of C57BL/6 mice exposed to varying amounts of n-3 PUFA at 
weaning and 16 weeks postweaning. There was an increase in plasma TG from weaning to 16 
weeks in both male and female offspring; however, the high n-3 PUFA group showed a 
reduction in TG in both sexes at 16 weeks. High n-3 PUFA caused an increase in plasma LDL-c 
from weaning to 16 weeks in male offspring; however, the LDL particle size was significantly 
larger in the high n-3 PUFA group. Plasma from male mice showed higher cholesterol efflux 
compared to females; high n-3 PUFA increased cholesterol efflux. Thus the effects of n-3 PUFA 
are age and sex dependent.  
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2.2 Introduction 
CVD is a complicated and multifarious disease, and is the number one cause of mortality 
worldwide. A report from WHO has shown that 30% of the global deaths in 2008 were caused 
by CVD, and by 2030, more than 23 million people will die annually from CVD (WHO, 2011). 
Even though CVD is the leading cause of death between men and women, there is a clear 
evidence of the influence of sex in the prevalence of CVD (Mosca et al., 2011). Several 
independent factors are associated with the morbidities of CVD, such as high circulating TG and 
LDL-c (Carmena et al., 2004, St-Pierre et al., 2005), hyperglycaemia (Eguchi et al., 2007, 
Wahab et al., 2002), hyperinsulinaemia (Ingelsson et al., 2005), and elevated makers of 
inflammation (Engler et al., 2003). In addition to the aforementioned risk factors, age and sex 
also play an important role in the development of CVD (Castelli, 1984).   
Growing evidence suggests that the predisposition to CVD begins in utero and progresses 
through adulthood (Barker, 1995, Barker, 1997, Barker, 2004a, Barker, 2004b). Research 
findings have also shown that a mother’s nutritional status during pregnancy may affect the 
future predisposition of the offspring to the onset of diseases in later years (de Boo and Harding, 
2006). Moreover, the hallmarks of metabolic and cardiovascular diseases such as dyslipidaemia, 
obesity, and diabetes have been linked to poor maternal diet and placental dysfunction (Hales 
and Barker, 2001). Previous studies from our laboratory demonstrated that a maternal diet high 
in SFA caused an increase in offspring plasma lipid and lipoprotein levels, and induced 
endothelial dysfunction (Chechi and Cheema, 2006, Chechi et al., 2009). SFA are known to 
increase the risk of CVD (Keys, 1997), while PUFAs are considered beneficial (Kushi et al., 
1995). There is an increased intake of PUFA, mainly n-6 PUFA, in the typical North American 
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diet (Simopoulos, 2002). On the other hand, the intake of highly unsaturated long chain n-3 
PUFA has declined in the recent years (Simopoulos, 2002). 
N-3 PUFA such as EPA, and n-6 PUFA such as AA, are primary substrates for eicosanoid 
production. Eicosanoids derived from AA are considered pro-inflammatory, pro-thrombotic, and 
generally promote atherosclerosis (Simopoulos, 2002).  On the contrary, diets rich in n-3 PUFA 
have been shown to be anti-inflammatory, anti-thrombotic, and prevent CVD (Simopoulos, 
2002).  Furthermore, n-3 PUFA has been reported to alleviate markers of CVD such as high TG, 
endothelial dysfunction, cardiac arrhythmia, and inflammation (Calder, 2006, Harris, 1997, Leaf 
et al., 2003, Goodfellow et al., 2000, Hirafuji et al., 2003). The cardiovascular benefits of n-3 
PUFA are mediated through modifications of lipoprotein profile, and by increasing LDL particle 
size (Sanders et al., 1997, Kelley et al., 2007). The metabolism of n-3 PUFA has been shown to 
be sex-specific, with sex hormones influencing the desaturation and elongation enzymes 
involved in the synthesis of long chain n-3 PUFA (Burdge and Wootton, 2002, Pawlosky et al., 
2001). However, it is not known whether the effect of n-3 PUFA on the regulation of lipid and 
lipoprotein profiles is sex and age specific. 
There is an obvious difference in the prevalence of CVD between males and females 
(Castelli, 1984, Kuhn and Rackley, 1993, Njolstad et al., 1996), and the risk of CVD has also 
been shown to increase with age in both males and females (Castelli, 1984, Tunstall-Pedoe et al., 
1994, Rich-Edwards et al., 1995). To date, the majority of studies have established the 
cardioprotective effects of n-3 PUFA in adult life (Adkins and Kelley, 2010, Massaro et al., 
2008), and a handful of studies have also reported the sex-specific effects of n-3 PUFA (Phang et 
al., 2009, Phang et al., 2013). However, no study has comprehensively elucidated the possible 
interactions of sex, age, and n-3 PUFA on lipid and lipoprotein metabolism. In the present study, 
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we hypothesized that the effects of n-3 PUFA on lipid and lipoprotein concentrations will be 
dose-dependent, and longer exposure to n-3 PUFA diet will significantly enhance the effects of 
n-3 PUFA. We further hypothesized that the effects of n-3 PUFA on lipids and lipoproteins will 
differ between males and females. We therefore investigated the effect of varying the quantity of 
dietary exposure to n-3 PUFA during gestation and lactation on lipid and lipoprotein 
concentrations of the male and female offspring of C57BL/6 mice at weaning. We further 
evaluated whether longer exposure to postweaning diet high in n-3 PUFA will cause further 
alterations in the concentrations of plasma lipids and lipoproteins, and whether the effect is sex-
specific. Our findings revealed that longer exposure to high dietary n-3 PUFA during perinatal 
and postweaning periods reduced plasma circulating concentrations of lipids, and atherogenic 
very small low density lipoprotein particles in the offspring. We further report for the first time 
that a diet high in n-3 PUFA increased cholesterol efflux ex-vivo. Our results also suggest sex- 
and age-specific effects of n-3 PUFA on the regulation of lipid and lipoprotein concentrations.  
2.3 Materials and methods 
2.3.1 Diets 
The experimental diets were prepared from a base semi-synthetic diet with the fat sources 
omitted and designed to allow the control of fat at 20% w/w (MP Biomedicals, USA). 
Information on the macronutrient composition of the semi-synthetic diet and oil mixtures are 
presented in Table 2.1. Fish oil (Menhaden), safflower oil, extra-virgin olive oil, and lard were 
used as sources of n-3 PUFA, n-6 PUFA, MUFA and SFA respectively. The oils were used to 
make three different mixtures containing approximately 10% (High n-3), 4% (Medium n-3), and 
2% (Low n-3) n-3 PUFA of the total dietary fat. Total SFA, MUFA, and PUFA were kept 
constant in the experimental diet.  The medium and low n-3 PUFA diets were designed to 
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contain an n-6:n-3 PUFA ratio of 15:1 and 30:1 respectively which approximately represent the 
current n-6:n-3 PUFA ratios in a typical Western diet; while the high n-3 PUFA diet contains an 
n-6:n-3 PUFA ratio of 5:1, which is suggested to be an optimal ratio for whole body homeostasis 
(Gomez Candela et al., 2011). The diets were isocaloric and contained the same amount of 
protein, carbohydrate and fat; the only difference was the ratio of n-6 to n-3 PUFA. The diets 
were designed to test the quality of dietary fat consumed in regards to the ratio of n-6:n-3 PUFA 
composition. Gas-liquid chromatography (GLC) was used to determine the fatty acid 
composition of the experimental diets (Table 2.2). Fresh diets were prepared by mixing the 
semi-synthetic powder with the oil mixture at 20% w/w as the only source of fat and treated with 
nitrogen gas to prevent oxidation, then stored frozen at -20C.  
2.3.2 Animals and experimental design 
All experimental procedures involving animals were carried out in accordance with the 
principles and guidelines of the Canadian Council on Animal Care and were approved by 
Memorial University’s Animal Care Committee. Male and female C57BL/6 mice (seven weeks 
old) were purchased from Charles Rivers Laboratories (MA, USA), and were housed in separate 
cages (2 mice/cage) under controlled temperature (21± 1°C) and humidity (35 ± 5%) conditions 
with a 12-hour light/12-hour dark period cycle. Mice were kept on standard rodent chow pellets 
(Prolab RMH 3000) (PMI nutrition, MO, USA) for a one week acclimatization period. After this 
period, female mice were randomly divided into three groups. Each group was fed one of the 
three experimental diets that differed only in their n-3 PUFA composition, and designated as 
“high n-3”, “medium n-3”, or “low n-3” diets for two weeks before mating, after which one male 
mouse was introduced into a cage with two female mice for a one week period. Vaginal plug 
formation was used to confirm pregnancy, and pregnant mice were moved to a clean cage 
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throughout gestation and until weaning. Mothers were fed experimental diets throughout 
gestation, lactation, and until weaning. Pups were counted on the first day of delivery as 
postnatal day one, after which pups and mothers were not disturbed to prevent cannibalism. 
Fresh food and water were provided ad-libitum every day, and body weight was recorded every 
week. At weaning, pups were sexed, culled, and housed separately according to sex (2 
mice/cage).  Half of the offspring (male, n=10 and female, n=10) were studied at weaning, while 
therest of the offspring (male, n=8 and female, n=8) were continued on their mothers’ designated 
diet for 16 weeks (healthy young adult mice).  Mice were sacrificed after an overnight fast either 
at weaning or after 16 weeks on specified diets using isoflurane. Blood was collected by cardiac 
puncture in tubes containing EDTA (4.5 mM, pH 7.4), and plasma was separated immediately. 
Tissues were removed and weighed at the time of sacrifice, snap frozen in liquid nitrogen and 
stored at -80ºC until further analyses.  
At weaning, dams were milked after anesthetizing with pentobarbital (35mg/kg/ 
intraperitoneal (IP) / (0.1ml/100g) and milk secretion was stimulated using oxytocin (4 IU/kg 
IP). Throughout the experimental period, animals were provided with water and fresh food ad-
libitum, every other day. Body weights were recorded once a week and food intake was recorded 
every other day. No significant differences were observed in both body weight and food intake 
amongst the groups (Appendix II).  
2.3.3 Analyses of biochemical parameters 
Plasma lipid and lipoprotein concentrations were quantified using commercially available 
kits according to the manufacturers’ instructions: plasma TG kit #236-17 (Genzyme Diagnostics, 
PEI, Canada); TC kit #234-60 (Genzyme Diagnostics, PEI, Canada); NEFA kit # 999-34691  
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(Wako Chemicals, VA, USA). HDL-c was precipitated from plasma using kit #200-26A 
(Diagnostic Chemicals Ltd, Canada) and the HDL-c concentration was determined using TC 
assay kit #234-60 (Genzyme Diagnostics, PEI, Canada). Plasma LDL-c concentration was 
calculated according to the method of Friedewald et al. (Friedewald et al., 1972, Fraulob et al., 
2010). Plasma LDL particle size was analyzed by LipoScience Inc. (NC, USA) using NMR 
techniques. LDL particle size was reported in particle concentration unit (nanomoles of particles 
per liter) (Jeyarajah et al., 2006).  
2.3.4 Fatty acid analyses of breast milk by gas liquid chromatography  
Lipids were extracted from breast milk using the method of Folch et al (1957). Fatty acid 
methyl esters were prepared by heating lipid extracts with 2 ml of trans-methylation reagent (6% 
concentrated sulfuric acid and 94% methanol + few crystals of hydroquinone added as an anti-
oxidant) for 2 h at 65C. Extraction of methyl esters was performed using hexane and water at -
20C overnight. The hexane layer of the sample was dried the following morning under gentle 
stream of nitrogen gas and the residue was dissolved in carbon disulfide prior to GLC analysis. 
Samples were run on an Omegawax X 320 (30 m x 0.32 mm) column from Supelco (Sigma-
Aldrich, Canada) using a flame ionization detector for 60 minutes. The GLC parameters were set 
as: oven, 200C; injector, 240C; detector 260C; helium was used as the carrier gas. PUFA 
standards -2 and -3 (Sigma-Aldrich, Canada) were used as standards for identification of fatty 
acids by retention time.  
2.3.5 Macrophage cholesterol efflux assay 
Macrophage cholesterol efflux assay was performed according to previously published 
methods with minor modifications (Adorni et al., 2007, Boone et al., 2011). Briefly, J774 cells 
85 
 
were seeded in 12 well plates at a density of 2 x 105 cells/well in RPMI medium supplemented 
with 10% foetal bovine serum (FBS) and 1 X antibiotic/antimycotic. The following day, 
labelling was performed in RPMI supplemented with 1% FBS, 1 µCi/ml 3(H)-cholesterol (Perkin 
Elmer, MA, USA), 2 µg/ml ACAT (acyl-CoA: cholesterol acyl transferase) inhibitor 58-035 
(Sandoz, QC, CA), and 1X antibiotic/antimycotic for 24 hours. Cells were equilibrated for 18 
hours in RPMI medium in the presence of LXR agonist and ABCA1 agonist, T0901317 (1µM) 
(Sigma, MO, USA), and Retinoic X receptor (RXR) agonist, retinoic acid (1µM) (Sigma, MO, 
USA). Cholesterol efflux was initiated by treating cells with RPMI containing 2% plasma 
samples from either the high (n=6) or low (n=6) n-3 PUFA group as the efflux acceptor; or 0.2% 
bovine serum albumin (BSA) as the control, for 5 hours. At the end of the 5 hour efflux interval, 
the medium was collected and centrifuged at 2000 rpm for 5 minutes. Supernatants were 
removed for liquid scintillation counting. Wells were washed twice with 1X PBS, and residual 
radioactivity in the cells was determined after scraping the cells in 1X PBS. Cholesterol efflux 
was calculated as [3H]-cholesterol in medium/([3H]-cholesterol in medium + [3H]-cholesterol in 
cells) x 100. All efflux values were corrected by subtracting the % efflux at time zero (before 
active/passive efflux).  
2.3.6 Statistical analysis  
Data were analyzed using IBM SPSS Statistics (Version 20.0).  Differences between means 
were compared using three way analysis of variance (ANOVA) to determine the main effects 
and interactions of diets, age, and sex. Two way ANOVA was used to analyze the very small 
LDL particle size and cholesterol efflux data with diet and sex as factors. Pairwise comparison 
using Bonferroni correction was used to determine differences when an interaction was 
observed.  Breast milk fatty acid composition was expressed as weight percentage of the total  
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Table 2.1. Composition of the semi-purified diet with 20% (w/w) fat level 
                      
Ingredients High n-3 diet Medium n-3 diet Low n-3 diet
      g/kg 
Casein 200 200 200 
DL-methionine 3 3 3 
Sucrose 305.8 305.8 305.8 
Corn starch 200 200 200 
Alphacel non-nutritive bulk 50 50 50 
DLA tocopherol powder 1.2 1.2 1.2 
Mineral mix* 40 40 40 
Fat 200 200 200 
Menhaden oil 42.3 10.7 2.1 
Safflower oil 131.9 135.55 136.55 
Olive oil 11.75 8.2 7.2 
Lard 14.05 45.55 54.15 
                      
Supplied in quantities adequate to meet NRC requirements (National Research Council, 1995). 
Vitamin Mix (1 kg): Thiamine hydrochloride, 0.6 g; riboflavin, 0.6 g; pyridoxine 
hydrochloride, 0.7 g; nicotinic acid, 3.0 g; d-calcium pantothenate, 1.6 g; folic acid, 0.2 g; d-
biotin, 0.02 g; cyanocobalamin (vitamin B12), 0.001 g; retinyl palmitate (vitamin A) pre-mix 
(250,000 IU/g), 1.6 g; DL-α-tocopherol acetate (250 IU/g), 20 g; cholecalciferol (vitamin D3, 
400,000 IU/g), 0.25 g; menaquinone (vitamin K2), 0.005 g; sucrose, finely powdered, 972.9 g 
*Mineral Mix: Calcium phosphate dibasic, 500.0 g/kg; sodium chloride, 74.0 g/kg; potassium 
citrate monohydrate, 220.0 g/kg; potassium sulfate, 52.0 g/kg; magnesium oxide, 24.0 g/kg; 
manganese carbonate (43-48% Mn), 3.50 g/kg; ferric citrate (16-17% Fe), 6.0 g/kg; zinc 
carbonate (70% ZnO), 1.6 g/kg; cupric carbonate (53-55% Cu), 0.30 g/kg; potassium iodate, 
0.01 g/kg; sodium selenite, 0.01 g/kg; chromium potassium sulfate, 0.55 g/kg; sucrose, finely 
powdered, 118.0 g/kg 
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Table 2.2  Fatty acid composition of the experimental diets* 
Fatty Acids Low n-3 Medium n-3 High n-3 
  
14:0 0.11 0.39 1.26 
16:0 6.32 7.43 8.71 
18:0 5.35 4.53 2.67 
∑ SFA 11.77 12.35 12.64 
  
16:1n-7 0.36 0.09 2.41 
18:1n-9 + C18:1n-7 27.82 25.81 25.14 
20:1n-9 ND 0.54 0.61 
∑ MUFA 28.18 26.43 28.16 
  
18:2n-6 57.73 57.03 47.86 
20:4n-6 0.11 0.14 0.23 
18:3n-6 0.04 0.04 0.10 
22:4n-6 0.09 ND 0.54 
∑ Omega-6 57.92 57.18 48.90 
  
18:3n-3 0.55 0.64 0.78 
20:5n-3 0.31 1.37 3.64 
22:6n-3 0.39 1.16 3.19 
18:4n-3 0.15 0.20 0.87 
22:5n-3 0.46 0.32 0.63 
20:4n-3 0.08 0.12 0.66 
∑Omega-3 1.93 3.81 9.76 
    
 
*Data are expressed as weight percentage of the total extracted fatty acids. Σ SFA= sum of 
saturated fatty acids, Σ MUFA= sum of monounsaturated fatty acids, Σ PUFA= sum of 
polyunsaturated fatty acids, Σ Omega-6= sum of omega-6 fatty acids, Σ Omega-3= sum of 
omega-3 fatty acids, ND= Not detected.  
 
88 
 
extracted fatty acids; fatty acid composition data were then arcsine transformed before subjecting 
to one way ANOVA and Newman-Keuls post hoc statistical tests. Values were expressed as 
mean ± SD. Differences were considered to be statistically significant if the associated P value 
was < 0.05.  
2.4 Results 
2.4.1 Effect of perinatal exposure to diets varying in n-3 PUFA on breast milk fatty acid 
composition 
Breast milk fatty acid composition of female mice fed high, medium, or low n-3 PUFA diet 
during gestation and lactation is given in Table 2.3. There was no significant difference in total 
and individual SFA and MUFA among the three dietary groups.  Furthermore, there was no 
significant difference in the total composition of n-6 PUFA between the three dietary groups. 
However, the high n-3 PUFA group showed a significantly lower concentration of AA compared 
to both medium and low n-3 PUFA groups (P<0.01). There was a significant difference in total 
n-3 PUFA and DHA among the three dietary groups (P<0.01), with the high n-3 PUFA group 
showing the highest concentration, followed by the medium and low n-3 PUFA groups. There 
was a significant increase in breast milk concentrations of EPA and docosapentaenoic acid 
(22:5n3; DPA) in the high n-3 PUFA group compared to the medium n-3 PUFA group (P<0.01). 
Red blood cells phospholipids fatty acid composition was measured at weaning and 16 weeks, 
which also confirmed dietary incorporation of essential fatty acids. 
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Table 2.3 Total breast milk fatty acid composition of mothers fed experimental diets during 
pregnancy and lactation* 
Fatty Acids Low n-3 Medium n-3 High n-3 
C14:0 2.52 ± 1.28 3.41 ± 2.06 2.85 ± 1.64 
C16:0 15.53 ± 1.99 14.95 ± 2.75 14.13 ± 2.50 
C18:0 5.28 ± 0.48 5.84 ± 0.89 6.92 ± 4.53 
∑ SFA 23.32 ± 2.83 24.19 ± 5.05 23.91 ± 3.84 
C16:1n7 1.05 ± 0.71 1.57 ± 0.83 1.90 ± 1.23 
C18:1n9 26.47 ± 2.05 29.51 ± 1.57 21.84 ± 6.65 
C20:1n9 0.87 ± 0.24 0.82 ± 0.09 0.59 ± 0.05 
∑ MUFA 34.13 ± 3.02 32.78 ± 4.96 27.34 ± 9.14 
C18:2n6 39.63 ± 4.37 36.92 ± 1.51 39.60 ± 5.67 
C18:3n6 0.45 ± 0.19 0.40 ± 0.11 0.50 ± 0.18 
C20:4n6 2.02 ± 0.05a 1.89 ± 0.12a 1.44 ± 0.13b 
∑ Omega-6 42.18 ± 4.46 39.97 ± 1.90 41.76 ± 5.79 
C18:3n3 0.23 ± 0.20 0.32 ± 0.01 0.36 ± 0.16 
C20:5n3 ND 0.42 ± 0.10b 1.68 ± 0.56a 
C22:5n3 ND 0.66 ± 0.11b 1.30 ± 0.26a 
C22:6n3 0.12 ± 0.21c 1.22 ± 0.37b 2.69 ± 0.61a 
∑ Omega-3 0.36 ± 0.37c 2.80 ± 0.56b 6.46 ± 1.73a 
*Data are expressed as weight percentage of the total extracted fatty acids. Values are expressed 
as mean  SD, n = 3. Data were assessed using one-way ANOVA after arcsine transformation. 
Significant effects were further analysed using Newman-Keuls post hoc test. Mean values within 
a row with unlike superscript letters were significantly different (P < 0.05).  Σ SFA= sum of 
saturated fatty acids, Σ MUFA= sum of monounsaturated fatty acids, Σ PUFA= sum of 
polyunsaturated fatty acids, Σ Omega-6= sum of omega-6 fatty acids, Σ Omega-3= sum of 
omega-3 fatty acids, ND= Not detected.  
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2.4.2 Effect of diets varying in n-3 PUFA on the concentrations of plasma lipids of male and 
female offspring at weaning and 16 weeks postweaning 
There was an independent effect of age on plasma concentration of TG (P < 0.0001; Figure 
2.1A), with plasma TG increasing significantly from weaning to 16 weeks in both male and 
female offspring. There was also a significant independent effect of diet on plasma TG 
concentration (P < 0.0001; Figure 2.1A). The male offspring showed no significant difference in 
plasma TG among the three experimental groups at weaning (Figure 2.1A); however, at 16 
weeks, there was a significant decrease in plasma TG in the high n-3 PUFA group compared to 
medium and low n-3 PUFA groups (P<0.001: Figure 2.1A). The female offspring on the other 
hand showed significantly lower plasma TG in the high n-3 PUFA groups at both weaning and 
16 weeks compared to the low n-3 PUFA group (P<0.01; Figure 2.1). No significant interaction 
of age and diet, age and sex, and diet and sex were observed in the plasma TG concentration 
(Figure 2.1A). Furthermore, it was interesting to note that there was no significant difference in 
plasma TG concentration between low and medium n-3 PUFA diet groups in male and female 
offspring at 16 weeks (Figure 2.1A).    
A significant interaction of diet and sex was observed in plasma TC cholesterol concentration 
(P = 0.015; Figure 2.1B). There was a significant diet dependent increase in plasma TC in the 
low n-3 PUFA group compared to the medium and high n-3 PUFA group in the male offspring at 
weaning and 16 weeks (P < 0.05; Figure 2.1B). At weaning, the female offspring in the low n-3 
PUFA group showed a significantly higher plasma TC concentration (P < 0.05; Figure 2.1B) 
compared to the medium and high n-3 PUFA groups, while no significant effect of diet was 
observed at 16 weeks. Furthermore, a significant interaction of age and sex was observed in 
plasma TC concentration (P < 0.0001; Figure 2.1B).  There was an age-dependent increase in the 
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concentration of plasma TC concentration in male offspring; interestingly, this effect was not 
observed in female offspring (Figure, 2.1B).  
There was a significant interaction of age and diet in plasma concentration of NEFA (P < 
0.0001; Figure 2.1C). A significant effect of age and sex was also observed in plasma 
concentration of NEFA (P < 0.003; Figure 2.1C). Perinatal exposure to diet high in n-3 PUFA 
had no effect on plasma circulating NEFA at weaning both in male and female offspring (Figure 
2.1C). However, there was a significant decrease in plasma NEFA concentration after sustained 
exposure to high n-3 PUFA diet for 16 weeks in both male (P<0.0001; Figure 2.1C) and female 
(P<0.0001; Figure 2.1C) mice compared to both medium and low n-3 PUFA diets. Interestingly, 
there was no difference in NEFA concentrations in medium and low n-3 PUFA groups at 16 
weeks.  
2.4.3 Effect of diets varying in n-3 PUFA on the concentrations of plasma lipoproteins of male 
and female offspring at weaning and 16 weeks post-weaning 
Plasma HDL-c revealed a significant interaction between age and sex (P < 0.01; Figure 
2.2A). Perinatal and postweaning diets high in n-3 PUFA had no effect on HDL-c concentrations 
among the three dietary groups both at weaning and 16 weeks in male and female offspring 
(Figure 2.2A). Cholesterol efflux showed significant interaction of diet and sex (P = 0.006; 
Figure 2.2B). The female offspring had lower cholesterol efflux with respect to diet as compared 
to the male offspring (P = 0.006; Figure 2.2B). The high n-3 PUFA group had higher cholesterol 
efflux compared to the low n-3 PUFA group in male offspring at 16 weeks (P<0.05; Figure 
2.2B). However, there was no effect of diet on cholesterol efflux in female offspring at 16 weeks 
(Figure 2.2B).  
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Figure 2.1. Effects of diets varying in the quantity of n-3 PUFA on plasma lipids of offspring at 
weaning and 16 weeks: Plasma triglycerides (A), total cholesterol  (B), and non-esterified fatty acids, 
NEFA (C) concentrations of male and female offspring were measured at weaning and 16 weeks as 
explained under methods section. Values are expressed as means  SD, n =10 (weaning) and n=8 (16 
weeks). Data were assessed using three way ANOVA to determine the main effects and interactions of 
diets, age and sex; pairwise comparison using Bonferroni correction was used to determine differences 
when there was an observed interaction. Letters (a,b) were used to denote significant differences between 
various dietary groups at weaning, and letters (x,y) represent significant differences between various 
dietary groups at 16 weeks.  P < 0.05 was considered significant. 
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Plasma LDL-c concentration showed significant interactions of age and diet (P = 0.002; 
Figure 2.3A); age and sex (P = 0.012; Figure 2.3A); and diet and sex (P = 0.004; Figure 2.3A).  
There was a marked reduction of LDL-c concentration in the high and medium n-3 PUFA groups 
compared to the low n-3 PUFA group at weaning in male offspring (P < 0.001; Figure 2.3A). 
These differences in LDL-c concentration however, disappeared at 16 weeks, with the three 
dietary groups showing no statistically significant differences (Figure 2.3A). There was however 
an increase in LDL-c concentration at 16 weeks compared to weaning in male offspring. 
Interestingly, the female mice showed a somewhat distinct LDL-c profile. At weaning the female 
offspring showed no difference in LDL-c concentration between the high and low n-3 PUFA 
groups (Figure 2.3A); however, the medium n-3 PUFA group was significantly lower than the 
low n-3 PUFA group (P<0.01; Figure 2.3A). At 16 weeks, the female offspring in the high n-3 
group showed an increase in LDL-c compared to both the medium and low n-3 PUFA groups 
(P<0.01; Figure 2.3A), the medium n-3 PUFA group had the lowest LDL-c concentration groups 
(P<0.01; Figure 2.3A). 
Since the high n-3 PUFA group showed higher LDL-c concentrations at 16 weeks, the LDL 
particle size of the high and low n-3 PUFA groups was measured. Although there was no 
difference in plasma LDL-c concentration in the male offspring at 16 weeks between the high 
and low n-3 PUFA groups, the high n-3 PUFA group showed a significantly lower concentration 
of very small LDL particles compared to the low n-3 PUFA group (P<0.05; Figure 2.3B). The 
female offspring in the high n-3 PUFA group also showed a significantly lower concentration of 
very small LDL particles compared to the high n-3 PUFA group at 16 weeks (P<0.05; Figure 
2.3B). There was also an effect of sex on the plasma concentration of very small LDL particles,  
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Figure 2.2. Effects of diets varying in the quantity of n-3 PUFA on plasma HDL-cholesterol 
(HDL-c) concentration and cholesterol efflux. 
 Plasma HDL-c concentration (A) of male and female offspring were measured at weaning and 
16 weeks as explained in the methods section.  Values are expressed as means  SD, n =10 
(weaning) and n = 8 (16 weeks). Data were assessed using three way ANOVA to determine the 
main effects and interactions of diets, age and sex for plasma HDL-cholesterol; pairwise 
comparison using Bonferroni correction was used to determine differences when there was an 
observed interaction. Cholesterol efflux (B) was measured from plasma from male and female 
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mice as explained in the methods section. Cholesterol efflux was calculated as ([3H]-cholesterol 
in medium/[3H]-cholesterol in medium + [3H]-cholesterol in cells) x 100. All efflux values were 
corrected by subtracting the % efflux at time zero (before active/passive efflux).  Values are 
expressed as % cholesterol efflux mean  SD, n = 5. Data were assessed using two way ANOVA 
to determine the main effects and interactions of diets and sex; pairwise comparison using 
Bonferroni correction was used to determine differences when there was an observed 
interaction. Letters (a,b,c) represent significant differences where P < 0.05 was considered 
significant. 
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Figure 2.3 Effects of diets varying in the quantity of n-3 PUFA on plasma LDL-cholesterol 
(LDL-c) and very small LDL particle size concentrations  
Plasma LDL-c concentration (A) of male and female offspring was measured at weaning and 16 
weeks as explained in the methods section.  Values are expressed as means  SD, n =10 
(weaning) and n = 8 (16 weeks). Data were assessed using three way ANOVA to determine the 
main effects and interactions of diets, age and sex; pairwise comparison using Bonferroni 
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correction was used to determine differences when there was an observed interaction. Letters 
(a,b,c) were used to denote significant differences between various dietary groups at weaning, 
and letters (x,y,z) represent significant differences between various dietary groups at 16 weeks.  
P < 0.05 was considered significant. Plasma concentration of very small LDL particle size (B) of 
male and female offspring was measured at 16 weeks as explained in the methods section. LDL 
particle size was reported in particle concentration units (nanomoles of particles per litre) and 
values are expressed as means  SD. Data were assessed using two way ANOVA to determine 
the main effects and interactions of diets and sex; pairwise comparison using Bonferroni 
correction was used to determine differences when there was an observed interaction. Letters 
(a,b,c) represent significant differences between various dietary groups where P<0.05 was 
considered significant. 
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with the female offspring showing a lower concentration of very small LDL particles compared 
to male offspring (P = 0.013; Figure 2.3B). 
2.5 Discussion 
The predisposition to CVD has been shown to be affected by age and sex, and the difference 
in sex predisposition to CVD has been linked to disparities in age-dependent fluctuation of 
cholesterol concentration in males and females (Rossouw, 2002). The cardiovascular benefits of 
n-3 PUFA are mediated by the modification of lipid and lipoprotein profiles; however, there is a 
paucity of information on sex- and age-specific effects of n-3 PUFA (Kelley et al., 2007, Sanders 
et al., 1997). In the current study, the effect of sustained exposure to perinatal and postweaning 
diets high in n-3 PUFA on plasma lipid and lipoprotein concentrations was investigated in the 
male and female offspring of C57BL/6 mice at weaning and 16 weeks postweaning. Our findings 
reveal for the first time, that a perinatal diet high in n-3 PUFA reduced the markers of 
dyslipidaemia in the offspring, and that the effects of n-3 PUFA on lipids and lipoproteins are 
augmented by sustained exposure to a postweaning diet rich in n-3 PUFA. Our findings also 
established that the effect of n-3 PUFA on the concentration of plasma lipids and lipoproteins is 
age- and sex-dependent. 
 Breast milk fatty acids, especially long chain PUFA are required for optimal development of 
the offspring (Novak and Innis, 2011). The breast milk fatty acid composition was therefore 
measured to confirm that the essential fatty acids in the perinatal diet fed to the mothers are 
incorporated in their breast milk. There was a positive correlation between diet and breast milk 
fatty acid composition (Appendix III), confirming that maternal dietary n-3 PUFA supplemented 
during pregnancy and lactation is reflected in the breast milk. The breast milk samples from the 
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high n-3 PUFA group were highly enriched with DHA, followed by the medium n-3 PUFA 
group, and the low n-3 PUFA group showed the least breast milk concentrations of DHA. Others 
have also shown that supplementing maternal diet with n-3 PUFA during lactation led to an 
increase in breast milk EPA and DHA composition (Novak and Innis, 2011, Arterburn et al., 
2006, Brenna et al., 2007, Jen et al., 2009). EPA and DPA were not detected in the low n-3 
PUFA which could be as a result of the low concentration of fish oil in the low n-3 PUFA diet. 
Others have reported a low concentration of EPA and no detection of DPA in breast milk of rats 
fed low n-3 PUFA diet (Novak and Innis, 2011).  
Elevated plasma TG is an independent risk factor of CVD, and a long standing association 
exists between TG and coronary heart diseases (Austin et al., 1998, Sarwar et al., 2007). Both 
epidemiological and animal studies support the TG-reducing effect of n-3 PUFA (Imaichi et al., 
1963, von Lossonczy et al., 1978, Mori and Woodman, 2006, Kelley et al., 2007, Zampolli et al., 
2006, Niot et al., 1994). However, the majority of studies that assessed the effects of n-3 PUFA 
on plasma TG used adults. We report an independent effect of age and diet on the plasma 
concentration of TG. There was an age-dependent increase in the concentration of TG in both 
male and female offspring. This is not surprising as TG concentration increases with age as a 
result of increase in body weight and accumulation of fat from weaning to adulthood (Castelli, 
1984). No significant difference in plasma TG concentration was found in the male offspring at 
weaning. This is consistent with the findings of Korotkova et al (Korotkova et al., 2005, 
Korotkova et al., 2004), who reported that the offspring of mothers fed a high n-3 PUFA diet 
showed no change in plasma TG at three weeks. However, our findings showed that after 16 
weeks of sustained exposure to the experimental diets, the male offspring on high n-3 PUFA diet 
showed a significant reduction in plasma TG concentrations compared to both medium and low 
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n-3 PUFA groups. On the other hand, female offspring in the high n-3 PUFA group showed a 
significant reduction in plasma TG concentration both at weaning and 16 weeks compared to the 
low n-3 PUFA group. Joshi et al reported a lower TG level at 6 months in male offspring of 
dams fed an n-3 PUFA rich diet (Joshi et al., 2003). Other studies also support our findings that 
longer exposure to n-3 PUFA has TG lowering effects in adult rats (Niot et al., 1994, Froyland et 
al., 1997). It was interesting to note that plasma TG concentration was not different between low 
and medium n-3 PUFA groups in both male and female offspring at 16 weeks. Thus, our data 
strongly suggests that a longer exposure to n-3 PUFA and a higher dose of n-3 PUFA is 
necessary to elicit its TG reducing effects. 
Several mechanisms have been proposed by which TG levels are reduced by n-3 PUFA 
(Kawakami et al., 2006).  TG is synthesized in the liver in response to the circulating 
concentrations of NEFA (Kersten et al., 1999, Pegorier et al., 2004), and it has been suggested 
that the TG lowering effect of n-3 PUFA could be due to an increased stimulation of β-oxidation, 
which leads to a decrease in available NEFA for TG formation (Mizushima et al., 1997). We 
found a significantly lower plasma NEFA concentration in both male and female offspring fed a 
high n-3 PUFA diet at 16 weeks, which could be responsible for the lower TG concentration in 
this group. N-3 PUFA is well known to increase the gene expression of PPARα (Wahli et al., 
1995), which upregulates acyl coenzyme A oxidase to increase β-oxidation (Jump and Clarke, 
1999). Furthermore, TG synthesis is controlled by the transcription factor sterol regulatory 
element binding protein-1c (SREBP-1c), the key gene in lipogenesis. PPARα has been shown to 
regulate the expression of SREBP-1c (Fernandez-Alvarez et al., 2011, Knight et al., 2005), thus, 
n-3 PUFA controls TG concentration by downregulating the gene expression of SREBP-1c 
(Pegorier et al., 2004), which in turn inhibits lipogenesis, and by stimulating β-oxidation. 
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There was an age dependent increase in plasma concentration of TC in male offspring from 
weaning to 16 weeks, however, this was not observed in female offspring. An increase in plasma 
TC with age is well documented (Richter et al., 2004, Corti et al., 1997, Shepherd, 2001), which 
results from an age-dependent decrease in catabolism of cholesterol (Corti et al., 1997). 
Furthermore, there was a significant interaction of diet and sex on the concentration of plasma 
TC; the high and medium n-3 PUFA groups showed lower plasma TC concentration compared to 
the low n-3 PUFA group in both male and female offspring at weaning. The novel interactive 
effect of n-3 PUFA and sex on the concentration of TC could be attributed to hormonal 
influence. It has been suggested that the regulation of lipid metabolism by n-3 PUFA is affected 
by oestrogen. Clinical and laboratory findings have shown that there is a regulatory relationship 
between PPARα and oestrogen receptor, and this relationship is influenced by n-3 PUFA and 
oestrogen (Souidi et al., 1999, Wang and Kilgore, 2002). The sex specific effects of PPARα have 
been demonstrated in mice where cholesterol concentration was shown to be greater in male 
mice compared to female mice (Costet et al., 1998, Linden et al., 2001); interestingly, this was 
also observed in our results.  Reports from studies that measured plasma TC in offspring of 
mothers fed n-3 PUFA diet are controversial. Yessoufou et al observed a low TC concentration 
in male rats offspring fed high n-3 PUFA diet for 90 days postweaning (Yessoufou et al., 2006); 
however, other studies reported no change in total TC in offspring after feeding n-3 PUFA rich 
diet for 3 weeks (Korotkova et al., 2002, Korotkova et al., 2005). As stated before, n-3 PUFA is 
well known to downregulate the gene expression of SREBP (Fernandez-Alvarez et al., 2011, 
Knight et al., 2005), thereby inhibiting the expression of  hydroxylmethylglutaryl-coenzyme A 
(HMG-CoA) reductase, the rate limiting enzyme in cholesterol synthesis (Le Jossic-Corcos et al., 
2005, Li et al., 2006).  Our findings suggest that the time of exposure is critical in determining an 
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effect of dietary n-3 PUFA on plasma TC levels, and that the effect is sex specific, where only 
male offspring on high n-3 PUFA showed reduction in TC. Thus, future studies will focus on the 
sex and age dependent effects of n-3 PUFA on the regulation of SREBP and HMG-CoA 
reductase. Furthermore, we suspect a cross-talk between n-3 PUFA and estrogen signalling that 
needs to be investigated. 
There was no effect of diet on plasma HDL-c in male and female offspring both at weaning 
and 16 weeks. Studies in adult mice have also reported no change in plasma HDL-c after 
supplementing with n-3 PUFA for 4 weeks (Zampolli et al., 2006), 20 weeks (Magdeldin et al., 
2009), and for 32 weeks (Wang et al., 2009). Interestingly, there was an age dependent 
difference in the concentration of HDL-c between the male and female offspring, where females 
showed lower levels. Studies have shown that men and women have a similar concentration of 
HDL-c concentration at puberty, after which hormonal influences result in a marked difference 
of HDL-c concentration between males and females (Abbey et al., 1999, Kirkland et al., 1987, 
Matthews et al., 1989). Furthermore, the effects of n-3 PUFA on HDL-c has been shown to be 
more pronounced in men compared to women (Okuda et al., 2005). Thus, it will be important to 
investigate the effect of n-3 PUFA and sex hormones on HDL-c concentration.  
HDL elicits its atheroprotective effect mainly through reverse cholesterol transport (RCT), a 
process involving the transportation of excess cholesterol from peripheral tissue to the liver for 
further metabolism of cholesterol. Studies have reported that the cardioprotective effect of HDL-
c depends on its efflux capacity (Morgan et al., 2004, Khera et al., 2011).  Although we did not 
observe a significant effect of diet on HDL-c, we investigated the cholesterol efflux capacity of 
plasma obtained from mice fed high and low n-3 PUFA diets and report for the first time an 
interaction of n-3 PUFA and sex with cholesterol efflux. Plasma from the male offspring showed 
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a significantly higher cholesterol efflux capacity compared to the female offspring.  Furthermore, 
plasma samples from the high n-3 PUFA male offspring caused an increase in cholesterol efflux 
compared to the low n-3 PUFA group. However, there was no difference in cholesterol efflux in 
the female offspring between the two dietary groups. To our knowledge, there are only two other 
studies that evaluated the effect of n-3 PUFA on cholesterol efflux in adult hamster (Kasbi 
Chadli et al., 2013), and rat (Marmillot et al., 2000). However, these studies did not elucidate the 
sex specificity of n-3 PUFA on cholesterol efflux. It is well established that there are different 
subclasses of HDL with different capabilities to mediate cholesterol efflux (von Eckardstein et 
al., 1994). HDL-2 and HDL-3 are the most characterised HDL subclasses, and HDL-2 has been 
shown to be involved in scavenging more cholesterol from the peripheral tissues compared to 
HDL-3 (Ballantyne et al., 1982, Asayama et al., 1990). N-3 PUFA has been shown to increase 
the concentration of HDL-2 particles (Chan et al., 2006, Wilkinson et al., 2005), even without 
obvious change in total HDL concentration (Agren et al., 1996).  It is likely that n-3 PUFA 
caused an increase in cholesterol efflux by increasing the concentration of HDL-2 subclass, 
which needs to be further investigated.  
We observed a significant interaction between: age and diet; age and sex; and diet and sex on 
plasma concentration of LDL-c. The plasma concentration of LDL-c increased with age in the 
male offspring. Furthermore, there was a significant increase in plasma LDL-c concentration in 
the high n-3 PUFA group from weaning to 16 weeks in both male and female offspring. The 
increase in LDL-c with age has been well documented (Heiss et al., 1980, Moulopoulos et al., 
1987, Schaefer et al., 1994), which is due to reduced catabolism of LDL with ageing (Grundy et 
al., 1985). N-3 PUFA may potentially increase LDL-c concentration by promoting the 
conversion of VLDL to LDL through rapid TG clearance by lipoprotein lipase (Park and Harris, 
104 
 
2003). The female offspring, showed a very interesting LDL-c profile. Diet high in n-3 PUFA 
increased the concentration of LDL-c in female offspring compared to the other groups at 16 
weeks. This is an exciting observation, opening a new frontier of research on the sex specificity 
of n-3 PUFA in regulating lipid metabolism. (Rossouw et al., 2012, Kavanagh et al., 2009). 
Reports on the effect of n-3 PUFA on LDL-c have been contradictory; some have proposed a 
reducing effect (Yamashita et al., 2005, Vasandani et al., 2002, Magdeldin et al., 2009), some 
assert there is no effect (Mori et al., 2000, Conquer and Holub, 1996), while others believe n-3 
PUFA increase LDL-c concentration (Theobald et al., 2004, Sanders et al., 2006). There are also 
noteworthy studies that linked oestrogen receptor to LDL-c and the risk of CVD, thus, sex 
specific regulation of LDL-c needs to be investigated in future studies.  
Since we observed an increase in plasma LDL-c concentration, we measured LDL particle 
size which is used as a predictor of LDL related risk of CVD (Sanders et al., 2006, Griffin, 
1999). Individuals with a high concentration of small LDL particles are more at risk of 
developing CVD compared to those with equal concentration of large LDL particle size 
(Rosenson et al., 2002, Berneis and Krauss, 2002, Sacks and Campos, 2003). Small LDL particle 
penetrate the arterial wall easily, and are more prone to oxidation (Rajman et al., 1999, Hurt-
Camejo et al., 2000). Oxidative modification of LDL could eventually lead to the formation of 
foam cells, recruitment of adhesion molecules, stimulation of inflammation, and a consequent 
atherosclerotic plaque formation (Yui et al., 1993, Toshima et al., 2000, Lusis, 2000). Our NMR 
data show that n-3 PUFA supplementation led to a reduction in the concentration of the more 
atherogenic small LDL particle. Others have also indicated that n-3 PUFA increase LDL particle 
size (Suzukawa et al., 1995, Lee et al., 2013).   
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     In conclusion, our findings demonstrate that sustained exposure of the offspring to perinatal 
diet high in n-3 PUFA reduces the concentration of atherogenic lipoproteins, and increases 
cholesterol efflux. In addition, our findings indicate that the effect of perinatal exposure to diet 
high in n-3 PUFA could be augmented if the offspring is exposed for a longer time period to a 
postweaning diet high in n-3 PUFA. This would consequently lead to a less atherogenic lipid 
profile to reduce the risk of CVD. We also report novel sex specific effects of n-3 PUFA on the 
concentration of plasma lipids and lipoproteins. As summarized in figure 2.4, there are different 
effects of n-3 PUFA on plasma lipids and lipoproteins of males and females; these sex specific 
effects are very important in the recommendation of n-3 PUFA for treating dyslipidaemia.   
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CHAPTER THREE 
 
The effects of dietary n-3 PUFA on the fatty acid composition of hepatic and 
plasma bioactive lipids  
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3.1 Abstract 
N-3 PUFAs are converted to bioactive lipid components that are important mediators in 
metabolic and physiological pathways; however, which bioactive compounds are metabolically 
active, and their mechanisms of action are still not clear.  We investigated using lipidomic 
techniques, the effects of diets high in n-3 PUFA on the fatty acid composition of various 
bioactive lipids in plasma and liver. Female C57BL/6 mice were fed semi-purified diets (20% 
w/w fat) containing varying amounts of n-3 PUFA before mating, during gestation and lactation, 
and until weaning. Male offspring were continued on their mothers’ diets for 16 weeks 
postweaning. Hepatic and plasma lipids were extracted in the presence of non-naturally 
occurring internal standards, and tandem electrospray ionization mass spectrometry methods 
were used to measure the fatty acyl compositions.  There was no significant difference in total 
concentrations of phospholipids in both groups. However, there was a significantly higher 
concentration of EPA-containing PC, LPC, and CE (p < 0.01) in the high n-3 PUFA group 
compared to the low n-3 PUFA group in both liver and plasma. Plasma and liver from the high n-
3 PUFA group also had a higher concentration of free n-3 PUFA (p < 0.05).  There were no 
significant differences in plasma concentrations of different fatty acyl species of PE, TG, 
sphingomyelin and ceramide. Our findings reveal for the first time that a diet high in n-3 PUFA 
caused enrichment of n-3 PUFA in PC, LPC, CE and free fatty acids in the plasma and liver of 
C57BL/6 mice. PC, LPC, and nonesterified free n-3 PUFA are important bioactive lipids, thus 
altering their fatty acyl composition may have important metabolic and physiological roles.   
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3.2 Introduction 
Essential PUFAs of the n-3 and n-6 classes are important in the regulation of metabolic 
processes.  N-3 PUFAs such as DHA and EPA have attracted a lot of attention in the past years 
as a result of their potential health benefits (Calder, 2004, Schmidt et al., 2005, Belluzzi et al., 
2000).  N-3 PUFA has been shown to prevent atherosclerosis (Wassall and Stillwell, 2009, 
Riediger et al., 2009), regulate nuclear transcription factors involved in gene expression of 
inflammatory markers, and stimulate cognitive development (Cottin et al., 2011, Banni and Di 
Marzo, 2010).  Markers of cardiovascular disease such as high TG, endothelial dysfunction, 
cardiac arrhythmia, and inflammation are also reduced by the administration of n-3 PUFA 
(Calder, 2004, Harris, 1997, Leaf et al., 2003, Goodfellow et al., 2000, Hirafuji et al., 2003).     
In vivo¸ n-3 PUFA can either exist as free products of enzyme hydrolysis or bound to PL or 
TG. Reports have shown that dietary n-3 PUFA are preferentially incorporated into PL compared 
to TG (Holub, 1978).  PLs are important constituents of the cellular membrane bilayers, with PC 
and PE being the most abundant (Gundermann et al., 2011). Membrane fluidity can be 
influenced by the incorporation of dietary long chain n-3 PUFA into membrane PL, which 
enhances the functions of transmembrane proteins and their interactions with extracellular 
ligands (Hulbert et al., 2005, Leaf et al., 2005, Stillwell and Wassall, 2003).  This indirectly 
affects signalling pathways and other physiological functions of the membrane.  PC has been 
implicated in an array of physiological functions, and their functional properties depend on their 
fatty acyl chains.  
The liver is principally involved in the metabolism and release of PC into circulation. PC is 
metabolised by the enzyme PLA2, releasing the fatty acid at the sn-2 position, and LPC into the 
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plasma pool for distribution to extrahepatic tissues (Thies et al., 1992, Huwiler and Pfeilschifter, 
2009).  Upon hydrolysis of the sn-2 fatty acid of PC, the released FFA is further metabolised to 
form bioactive compounds with either pro-inflammatory or anti-inflammatory properties 
(Huwiler and Pfeilschifter, 2009).  AA, a long chain n-6 PUFA released from the metabolism of 
PC, is further metabolised by the COX or LOX enzyme pathways to produce the inflammatory 
series-2 prostaglandins or series-4 leukotrienes, respectively (Farooqui et al., 2007).  On the 
contrary, the COX and LOX metabolic products of EPA, an n-3 PUFA, are generally anti-
inflammatory (Adkins and Kelley, 2010). Furthermore, protectins and resolvins, the products of 
oxygenation of DHA and EPA, have been reported to exhibit anti-inflammatory properties (Ariel 
and Serhan, 2007, Bannenberg and Serhan, 2010, Kohli and Levy, 2009).  
LPC, the other product of enzyme hydrolysis of PC, is an important lipid mediator involved 
in cellular metabolism.  Direct hepatic secretion is an important source of the abundant 
unsaturated LPC found in the plasma (Croset et al., 2000).  LPC has been controversially linked 
with the development of atherosclerosis (Wu et al., 2005, Lucas et al., 2008, Schmitz and 
Ruebsaamen, 2010).  However, there is evidence suggesting that the biological properties of LPC 
depend on the acyl chain of the molecule (Hayashi et al., 2001, Yoshida et al., 2003).  Studies 
have reported an increase in plasma concentration of saturated LPC in diseases conditions such 
as obesity, diabetes and rheumatoid arthritis (Fuchs et al., 2005).  In another line of evidence, 
polyunsaturated LPC significantly reversed saturated LPC-induced inflammation (Hung et al., 
2012).  However, the importance of specific LPC fatty acyl chains in metabolic regulation is still 
not clear. 
Most studies to date have explored the health benefits of n-3 PUFA esterified to ethyl esters 
or TG (Schuchardt et al., 2011, Galli et al., 2012, Tang et al., 2012).  Moreover, the majority of 
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the reported findings that support the pro-inflammatory and the atherogenic actions of LPC were 
established using saturated or monounsaturated LPC (Wu et al., 2005, Lucas et al., 2008, 
Portman and Alexander, 1969, Thukkani et al., 2003, Aiyar et al., 2007).  Cells, tissues, and 
biological fluids contain numerous bioactive lipid mediators involved in cellular processes, 
which are likely altered by dietary n-3 PUFA.  The aim of this study was to employ high 
throughput lipidomic techniques to evaluate the effect of diets high or low in n-3 PUFA content 
on the fatty acid composition of various lipids in the plasma and liver of C57BL/6 mice.  Our 
findings reveal for the first time that diets high in n-3 PUFA caused enrichment of n-3 PUFA in 
PC, LPC, CE and FFA in the plasma and liver of C57BL/6 mice, which will likely have 
important physiological roles.   
3.3 Materials and Methods 
3.3.1 Ethics Statement 
All experimental procedures were approved by Memorial University Animal Care 
Committee in accordance with the principles and guidelines of Canadian Council on Animal 
Care (approval no: 10-09-SK). 
3.3.2 Animals and diets  
Animals were treated, housed and acclimated as described in section 2.3.2. After the period 
of acclimatization, female mice were randomly divided into two groups.  Each group was fed 
either of the two experimental diets that differed only in their n-3 PUFA composition, and 
designated as “high n-3” and “low n-3” diets for two weeks before mating.  The experimental 
diets were made as described in section 2.3.1 and the fatty acid composition of the experimental 
diet is given in Table 2.2. Females were continued on the experimental diets throughout 
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gestation, lactation, and until weaning. Just before weaning, breast milk samples were collected 
from the mothers, to ascertain that the dietary essential fatty acid is reflected in the breast milk. 
There was a positive correlation between dietary and breast milk fatty acids composition 
(Appendix III).  At weaning, male offspring (n=6) were continued on their mothers’ designated 
diet for 16 weeks (i.e. offspring obtained from mother’s fed a high n-3 PUFA diet continued on 
high n-3 PUFA diet). Animals were provided with water and fresh food ad libitum, every other 
day.  Body weights were recorded once a week, and food intake was recorded every other day.  
No significant differences were observed in both body weight and food intake (Appendix II).  At 
16 weeks, male offspring were fasted overnight and sacrificed using isoflurane.  Blood was 
collected by cardiac puncture in tubes containing EDTA (4.5 mM, pH 7.4), and plasma was 
separated immediately.  Tissues were removed and weighed at the time of sacrifice, snap frozen 
in liquid nitrogen and stored at -80ºC until further analyses. 
3.3.3 Lipidomic analysis 
3.3.3.1 Lipid extraction, standards, and solvents 
Plasma or liver samples were flash frozen at the temperature of liquid nitrogen at collection.  
10µl plasma was directly extracted into organic solvent, while 100 mg liver tissue was pulverised 
and homogenised and then immediately lipids were extracted into organic solvent.  Lipid 
extraction into organic solvent was performed using the Bligh-Dyer method (Bligh and Dyer, 
1959) with high performance liquid chromatography-mass spectrometry grade solvents in the 
presence of non-naturally occurring internal lipid standards.  The standards used were 9-trans-
triheptadecenoin (tri-17:1 TG), 1, 2-diarachidoyl-sn-glycero-3-phosphocholine (di-20:0 PC), N-
heptadecanoyl-D-erythro-sphingosylphosphorylcholine (17:0 sphingomyelin), 1-heptadecanoyl-
2-hydroxy-sn-glycero-3-phosphocholine (17:0 LPC), 1, 2-dimyristoyl-sn-glycero-3-
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phosphoethanolamine (di-14:0 PE), cholesteryl heptadecanoate (17:0 CE), and N-heptadecanoyl-
D-erythro-sphingosine (17:0 ceramide).  The extracted lipids in the chloroform phase were dried 
down under a gentle stream of N2 gas, and were re-suspended in 500 µl of chloroform. 50 µl 
aliquot of the suspension was then mixed with 200µl methanol and 2µl of 10 mM methanolic 
NaOH and injected into a Thermo Fisher TSQ Quantum Ultra tandem electrospray ionization 
mass spectrometry (ESI-MS) system for lipid analyses.  High pressure liquid chromatography-
mass spectrometry grade methanol and chloroform were used for all extractions; these solvents 
were purchased from Burdick and Jackson (NJ, USA). 
3.3.3.2 Electrospray ionization-mass spectrometry (ESI-MS) 
Samples were analysed using direct-infusion ESI-MS in positive or negative ion mode using 
a Thermo Fisher TSQ Quantum Ultra system with XCalibur data acquisition software (Han and 
Gross, 2005). The tune parameters for sample analyses were optimized and set as follows: spray 
voltage = 3500 V, flow rate = 3 µl/min, ion sweep gas pressure = 0.2 (arbitrary units), sheath gas 
= 12 (arbitrary units), auxiliary gas pressure = 6 (arbitrary units), and capillary temperature = 
270oC.  The collision energies for the analyses of PC, LPC, and sphingomyelins (SM) were set at 
28 eV. The collision energies for analyses of CE was set at 25 eV, and for ceramide (CER) was 
set at 32 eV.  CEs were detected in positive ion mode by scanning for neutral loss (NL) of 
cholestadiene (m/z 368.5).  Sodiated species of SM, PC, and LPC were detected in positive ion 
mode by scanning for the NL of choline (m/z 59.1). FFA and PE were identified in negative ion 
mode by survey scan for [M-H] - between m/z 200 and 900. Sodiated species of TG were 
identified in positive ion mode by survey scan for [M+Na]+ between m/z 800 and 1000.  All data 
analyzed were corrected for 13C isotope effects as described by Han et al. (Han and Gross, 2005). 
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3.3.4 Statistical Analysis 
Data were analysed using GraphPad Prism software (version 5.0).  Statistical significance 
for differences between groups was determined by unpaired t-test.  Results are expressed as 
mean ± standard deviation (SD). Differences were considered to be statistically significant if the 
associated P value was < 0.05.   
3.4 Results 
3.4.1 PC fatty acyl composition of mice fed high and low n-3 PUFA 
There were no significant differences in the total concentrations of PL in both plasma and 
liver between high and low n-3 PUFA fed mice (Appendix IV). However, there was a 
significantly higher concentration of 16:0-20:5 PC in the plasma (P < 0.01; Figure 3.1A) and 
liver (P < 0.05; Figure 3.1B) of the high n-3 PUFA group compared to the low n-3 PUFA group. 
Interestingly, 20:4 containing PC (16:0-20:4 and 18:0-20:4) increased significantly in the plasma 
of the low n-3 PUFA group compared to the high n-3 PUFA group (P < 0.05; Figure 3.1A).  A 
similar effect was observed in the liver, with 16:0-20:4 and 18:0-20:4 showing a significant 
increase in the low n-3 PUFA group (P < 0.001; Figure 3.1B).  This signifies a higher 
incorporation of EPA and a lower incorporation of AA into plasma PC in the high n-3 PUFA 
group. The high n-3 PUFA group also showed higher incorporation of DHA into hepatic PC 
compared to the low n-3 PUFA group (P < 0.05; Figure 3.1B); however, there were no 
differences in plasma DHA-containing PC in both groups (Figure 3.1A).  
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Figure 3.1. Phosphatidylcholine (PC) fatty acyl composition of mice fed high and low n-3 
PUFA enriched diets. Plasma (A) and liver (B) PC species were quantified by measuring the 
sodiated adducts of PC using ESI-MS in positive ion mode by NL scanning for m/z 59.1, as 
described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented as 
mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 
0.001. 
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3.4.2 FFA of mice fed high and low n-3 PUFA   
There was a significant accretion of AA in the plasma of the low n-3 PUFA group compared 
to the high n-3 PUFA group (P < 0.05; Figure 3.2A).  The plasma concentration of EPA was 
considerably higher in the high n-3 PUFA group compared to the low n-3 PUFA group (P < 
0.05; Figure 3.2A).  However, no significant difference was observed in the plasma 
concentration of DHA between groups.  Livers of the mice fed a low n-3 PUFA diet were 
significantly enriched with 18:1 and 20:4 FFA (P < 0.01; Figure 3.2B) compared to the high n-3 
PUFA group.  Similarly, the liver concentrations of EPA (P < 0.01; Figure 3.2B) and DHA (P < 
0.05; Figure 3.2B) were significantly higher in the high n-3 PUFA group compared to the low n-
3 PUFA group. 
3.4.3 LPC fatty acyl composition of mice fed high and low n-3 PUFA 
Similar to the PC data, the concentration of 20:5 LPC was significantly higher in the high n-
3 PUFA group compared to the low n-3 PUFA group, in both plasma (P < 0.01; Figure 3.3A) 
and liver (P < 0.01; Figure 3.3B).  However, there was a significant accretion of 20:4 LPC in the 
plasma (P < 0.01; Figure 3.3A) and liver (P < 0.05; Figure 3.3B) of the low n-3 PUFA group 
compared to the high n-3 PUFA group.  Irrespective of the differences observed in LPC, there 
was no significant difference in the total concentration of LPC in both groups (Appendix III). 
3.4.4 PE fatty acyl composition of mice fed high and low n-3 PUFA 
No significant differences were observed in the fatty acyl species of PE in the plasma (Figure 
3.4A) of the high n-3 PUFA and low n-3 PUFA groups.  The liver showed no differences 
amongst PE species containing EPA; however, there was a significant increase of hepatic 18:0- 
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Figure 3.2. Free fatty acid (FFA) composition of mice fed high and low n-3 PUFA enriched 
diets. Plasma (A) and liver (B) FFA composition was quantified by measuring [M-H]- using ESI-
MS in negative ion mode between m/z 200 and 900. Data were corrected for 13C isotopic effects. 
Data are presented as mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 
0.05; **P < 0.01; ***P < 0.001. 
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Figure 3.3. Lysophosphatidylcholine (LPC) fatty acyl composition of mice fed high and low n-
3 PUFA enriched diets. Plasma (A) and liver (B) LPC species were quantified by measuring the 
sodiated adducts of PC using ESI-MS in positive ion mode by NL scanning for m/z 59.1, as 
described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented as 
mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 
0.001. 
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Figure 3.4. Phosphatidylethanolamine (PE) fatty acyl composition of mice fed high and low n-
3 PUFA enriched diets. Plasma (A) and liver (B) levels of PE species were quantified by 
measuring [M-H]- using ESI-MS in negative ion mode between m/z 200 and 900. Data were 
corrected for 13C isotopic effects. Data are presented as mean (n=6) ± SD and P-values 
calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001. 
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22:6 PE in the high n-3 PUFA group compared to the low n-3 PUFA group (P < 0.05; Figure 
3.4B). 
3.4.5 Sphingolipid and ceramide fatty acyl composition of mice fed high and low n-3 PUFA  
Treatment with high n-3 PUFA did not significantly modify the fatty acyl species of SM in 
the plasma (Figure 3.5A) and liver (Figure 3.5B) of mice fed diet high in n-3 PUFA.  Plasma of 
mice from high n-3 PUFA group showed an increase in 16:0 CER compared to the low n-3 
PUFA group (P < 0.05 Figure 3.6A); however, there was no effect of diet on different fatty acyl 
species of CER in the liver (Figure 3.6B).  
3.4.6 CE and TG fatty acyl composition of mice fed high and low n-3 PUFA 
The high n-3 PUFA group showed a significant increase in plasma 20:5 CE compared to the 
low n-3 PUFA group (P < 0.05; Figure 3.7A).  Conversely, there was a high accumulation of 
plasma 20:4 CE in the low n-3 PUFA group compared to the high n-3 PUFA group (P < 0.05; 
Figure 3.7A). The liver of the high n-3 PUFA group was enriched in 20:5 CE (P < 0.001; Figure 
3.7B) and 22:6 CE (P < 0.01; Figure 3.7B) compared to the low n-3 PUFA group. The liver 
concentration of 20:4 CE was significantly higher in the low n-3 PUFA group (P < 0.01; Figure 
3.7B) compared to the high n-3 PUFA group. 
No differences were observed in the concentrations of the different fatty acyl species of TG 
found in the plasma between experimental groups (Figure 3.8A).  Nevertheless, the liver showed 
a distinctive difference in the concentration of fatty acyl species profile for TG. The          
concentrations of 54:6, 56:7, and 58:8 TGs were significantly greater in the high n-3 PUFA 
group compared to the low n-3 PUFA group (P < 0.01; Figure 3.8B).  The low n-3 PUFA group  
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Figure 3.5. Sphingomyelin (SM) fatty acyl composition of mice fed high and low n-3 PUFA 
enriched diets. Plasma (A) and liver (B) levels of SM species were quantified by measuring the 
sodiated adducts of PC using ESI-MS in positive ion mode by NL scanning for m/z 59.1, as 
described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented as 
mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 
0.001. 
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Figure 3.6. Ceramide (CER) fatty acyl composition of mice fed high and low n-3 PUFA 
enriched diets.  Plasma (A) and liver (B) CER species were quantified using ESI-MS in negative 
ion mode by NL scanning for m/z 256.2. Data were corrected for 13C isotope effects. Data are 
presented as mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 
0.01; ***P < 0.001. 
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Figure 3.7. Cholesteryl ester (CE) fatty acyl composition of mice fed high and low n-3 PUFA 
enriched diets. Plasma (A) and liver (B) CE species were quantified using ESI-MS in positive ion 
mode by NL scanning of m/z 368.5 as described in the “Methods”. Data were corrected for 13C 
isotope effects. Data are presented as mean (n=6) ± SD and P-values calculated using unpaired 
t-test. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Figure 3.8. Triglyceride (TG) fatty acyl composition of mice fed high and low n-3 PUFA 
enriched diets. Plasma (A) and liver (B) TG species were quantified by measuring [M+Na]+ 
using ESI-MS in positive ion mode between m/z 800 and 1000 described in the “Methods”. Data 
were corrected for 13C isotope effects. Data are presented as mean (n=6) ± SD and P-values 
calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001. 
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showed a significantly higher 54:3 and 56:5 TG species compared to the high n-3 PUFA group 
(P < 0.05; Figure 3.8B).  
3.5 Discussion 
N-3 PUFA has been shown to reduce plasma TG (Hartweg et al., 2008, Harris, 1997), 
prevent atherosclerosis (von Schacky, 2003), and alleviate inflammation (Calder, 2006).  It has 
been proposed that the beneficial effects of n-3 PUFA are mediated through the actions of 
bioactive lipid components; however, which bioactive lipids are metabolically active, and their 
mechanisms of action are still not clear.  We performed lipidomic analyses on plasma and liver 
samples of high and low n-3 PUFA fed male C57BL/6 mice.  There was an evident distinction in 
the fatty acid profiles of different lipids present in the plasma and liver of the two dietary groups.  
Feeding a high n-3 PUFA diet led to a marked reduction of AA-containing PC, with a 
concomitant increase of EPA-containing PC.  Although plasma samples from mice fed a high or 
low n-3 PUFA diet showed no difference in DHA-containing PC, there was a trend towards an 
increase in the high n-3 PUFA group.  Browning et al. reported that habitual supplementation of 
fish oil led to an increased incorporation of EPA in plasma PC (Browning et al., 2012); however, 
they did observe a significant incorporation of DHA into PC after dietary supplements of DHA 
(Browning et al., 2012).  A plausible explanation for the disparity in our findings is that DHA-
containing PC is rapidly converted to LPC for delivery to extrahepatic tissues.  The liver PC fatty 
acyl composition is consistent with changes in plasma PC, where high dietary n-3 PUFA 
increased the concentrations of hepatic EPA and DHA species of PC.  On the contrary, there was 
a significant reduction of hepatic AA-containing PC in mice fed high n-3 PUFA diet.  PC is an 
important phospholipid involved in lipid metabolism.  PC has been shown to play a major role in 
cellular proliferation, degeneration, and membrane fluidity and functions (Gundermann et al., 
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2011).  The physiological properties of PC are heavily dependent on their fatty acid composition 
and n-3 PUFA has been shown to be preferentially incorporated into PC (Browning et al., 2012).  
PC from marine sources are rich in n-3 PUFA and have been shown to significantly reduce 
markers of inflammation (Deutsch, 2007), by the inhibition of TNF-α induced activity of NF-B 
(Treede et al., 2007).  In addition to their anti-inflammatory effects, n-3 PUFA rich PC are also 
known to possess lipid lowering effects (Klimov et al., 1995, Bunea et al., 2004, Taylor et al., 
2010).   
Plasma PC is rapidly metabolised by PLA2 to produce FFA and LPC.  These bioactive 
metabolites of PC can also elicit beneficial effects depending on the type, chain length, and 
degree of unsaturation of their fatty acids.  Feeding diets enriched in n-3 PUFA caused an 
increase in the plasma concentration of EPA and a decrease in plasma concentration of AA.  PC 
is an important source of FFA in plasma (Browning et al., 2012).  We found a high concentration 
of EPA-containing PC in the high n-3 PUFA group; it is thus reasonable to assume that the high 
plasma concentration of EPA found in the high n-3 PUFA fed mice is partly a product of enzyme 
hydrolysis of EPA rich PC.  This is in line with previous findings that support the incorporation 
of n-3 PUFA into the plasma pool when given as dietary supplements (Browning et al., 2012, 
Hodson et al., 2008).  We observed that the dietary supplementation with high n-3 PUFA caused 
an increase in the concentrations of hepatic EPA and DHA, and a decline in the hepatic 
concentration of AA.  Our observation is in line with the study of Lamaziere et al., who reported 
an increase in hepatic EPA and DHA after rats were administered fish oil for 30 days (Lamaziere 
et al., 2013).  In addition to the aforementioned health benefits of n-3 PUFA, high levels of 
hepatic n-3 PUFA are also involved in inhibiting lipogenesis, thereby preventing the 
development of non-alcoholic fatty liver disease (NAFLD) (Lamaziere et al., 2013).  
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Mechanistically, n-3 PUFA has been shown to regulate lipogenesis by inhibiting LXR and 
SREPB-1c (Xu et al., 1999, Yoshikawa et al., 2002).  Chronic low-grade inflammation underlies 
the pathology of most metabolic disorders, and free n-3 PUFA has been shown to possess potent 
anti-inflammatory properties (Massaro et al., 2008).  N-3 PUFA alleviates inflammation by 
directly regulating transcription factors involved in inflammation (Jump et al., 1994, Pawar and 
Jump, 2003, Pawar et al., 2003) and indirectly by producing series-3 and series-5 eicosanoids 
(von Schacky et al., 1985, Wanten and Calder, 2007). In addition to their inflammation-resolving 
properties, free unesterified n-3 PUFA have also been shown to improve symptoms of 
dyslipidaemia (Hirafuji et al., 2003, Goodfellow et al., 2000, Leaf et al., 2003).  
Another important bioactive product of enzyme hydrolysis of PC is LPC.  We found that    
feeding a diet high in n-3 PUFA considerably increased plasma circulating levels of 20:5 LPC, 
and drastically reduced plasma concentration of 20:4 LPC.  Similar to our plasma data, we found 
a higher concentration of hepatic 20:5 LPC and a low concentration of hepatic 20:4 LPC in the 
high n-3 group.  Interestingly, there was no significant difference in hepatic 22:6 LPC, although 
there was a trend towards an increase in the high n-3 PUFA group.  Ottestad et al. recently 
reported a similar finding where fish oil supplementation to healthy humans significantly 
increased plasma 20:5 LPC and 22:6 LPC (Ottestad et al., 2012).  Another study by Block et al. 
also found that fish oil supplementation increased EPA and DHA-containing LPC (Block et al., 
2010).   However, we only found a change in plasma EPA containing LPC, while there was no 
difference in DHA containing LPC between the two groups. LPC has been suggested as the 
major carrier of DHA to the brain tissues (Lagarde et al., 2001). Tracer studies revealed that 
labelled LPC-DHA and unesterified DHA injected into the blood of rat disappeared within 20 s 
and labelled LPC-DHA was recovered in different organs including the brain (Thies et al., 1992).  
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It would thus be logical to believe that the DHA-containing LPC was rapidly cleared from 
circulation.  
Studies have linked LPC with the development of atherosclerosis (Wu et al., 2005, Lucas et 
al., 2008, Schmitz and Ruebsaamen, 2010).  This is possibly due to their association with 
oxidized LDL, and promotion of inflammation (Fuentes et al., 2002, Eguchi et al., 2007) by 
generating reactive oxygen species and nitric oxides in different types of cells (Park et al., 2009, 
Colles and Chisolm, 2000).  However, the studies that linked LPC with the pathogenesis of 
obesity, diabetes, and rheumatoid arthritis have reported an increase in saturated LPC (Fuchs et 
al., 2005).  Of paramount importance to the biological functions of LPC are acyl length and 
degree of saturation of their fatty acids (Block et al., 2010).  LPC rich in n-3 PUFA have been 
shown to possess beneficial properties.  N-3 PUFA species of LPC were found to reduce 
inflammation (Chen et al., 2005, Yan et al., 2004), and LPC containing DHA at sn-1 position 
exhibits significantly higher anti-inflammatory properties compared to LPC with either LA or 
AA (Hung et al., 2011b, Hung et al., 2011a, Hung et al., 2012).  It has been proposed that LPC 
containing n-3 PUFA exhibit their anti-inflammatory properties through hydrolytic cleavage of 
the n-3 PUFA moiety, or oxygenation by 15-lipooxygenase (15-LOX) to produce inflammation 
resolving lipids such as 1-(15-hydroperoxyeicosatetraenoyl)-LPC and 1-(17- 
hydroperoxydocosahexaenoyl)-LPC (Hung et al., 2011a).  Most of the available data on the 
health benefits of n-3 PUFA rich LPC were shown using LPC containing n-3 PUFA at sn-1 
position.  We have not investigated the position of the acyl group of our LPC; however, it is 
known that there is rapid isomerization of acyl group from sn-2 to a more stable sn-1 position in 
LPC (Pluckthun and Dennis, 1982).  It has been reported that after separation of blood from 
plasma, 90% of the unsaturated fatty acids were found at sn-1 position in LPC (Croset et al., 
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2000).  We can therefore speculate that a significant percentage of the plasma 20:5 LPC contain 
EPA at sn-1 position.  
Also noteworthy is the fact that, despite the changes in fatty acyl species of PC and LPC in 
response to diet, there was no difference in the total concentrations of PC and LPC between the 
two experimental groups.  A similar observation was reported by Ottestad et al., who found no 
difference in total concentrations of PC and LPC despite the apparent changes in   individual 
fatty acyl species in response to fish oil supplementation (Ottestad et al., 2012).  This interesting 
observation suggests that the functional properties of n-3 PUFA involve remodelling and   
improving the quality of bioactive lipid mediators without affecting their concentrations. 
A diet rich in n-3 PUFA had no effect on different fatty acyl species of plasma TG,            
confirming preferential incorporation of n-3 PUFA into PC.  However, the high n-3 PUFA diet 
led to an increase in plasma and liver concentrations of n-3 PUFA CE, and a decrease in 20:4 
CE. CE is less polar than free cholesterol and it functions as an inert storage molecule. The high 
incorporation of n-3 PUFA in CE could be explained as a response to the high n-3 PUFA in the 
diet. This would simply indicate that n-3 PUFA are stored and will be later released for other 
physiological functions. A cross sectional study has reported a positive correlation between 
dietary PUFA and CE (Ma et al., 1997) 
Although we have shown that there is high incorporation of n-3 PUFA in the liver and 
plasma PC and LPC of mice fed high n-3 diet, it was also imperative to ascertain the effect of 
high n-3 PUFA diet on PE, which is also abundant in the membranes. There was no difference in 
plasma PE between the two dietary groups; the only difference detected in the liver was an 
increase in 18:0-22:6 PE in the high n-3 group.  Our findings confirm that fish oil 
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supplementation leads to a preferential incorporation of n-3 PUFA into PC and LPC compared to 
other phospholipids (Ottestad et al., 2012).   
Sphingolipids, such as CER and SM, are important signalling molecules.  CER is a 
sphingolipid linked with inflammation and the pathogenesis of CVD (Pfeiffer et al., 2001, de 
Mello et al., 2009).  There are also speculations on the involvement of CER in insulin signalling, 
although available information is scanty (Wymann and Schneiter, 2008, Turpin et al., 2006).  We 
found no difference in total concentration of CER in plasma and liver.  Our findings are similar 
to Ottestad et al., who found that fish oil supplement had no effect on plasma concentration of 
CER.  Interestingly, we found an increase in 16:0 CER in the high n-3 PUFA group.  The 
functional roles of this CER species are currently unknown and need to be explored.  There was 
no difference in plasma and liver SM concentrations between the two groups.  The physiological 
functions of SM have not been extensively studied. However, it is known that SM is involved in 
the formation of specialized membrane microdomains known as lipid rafts involved in 
signalling.  
In conclusion, our findings have shown that diets high in n-3 PUFA alter plasma and liver 
lipidomic profile of the offspring.  We found that n-3 PUFA is preferentially incorporated into 
PC and LPC, and despite the changes in lipidomic profile, the total concentrations of these lipids 
were not altered.  Additionally, we found that dietary n-3 PUFA is capable of remodelling the 
fatty acyl moieties of PC, LPC, and CE, which may have important physiological   implications, 
and needs to be further investigated.  Future studies will be undertaken to investigate the 
mechanism(s) by which n-3 PUFA remodelled bioactive lipids regulate metabolic pathways.  
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4.1 Abstract 
Obesity is characterised by an increase in fat mass primarily as a result of adipocyte 
hypertrophy. Diets enriched in n-3 PUFA are suggested to reduce obesity; however, the 
mechanisms are not well understood. We investigated the effect of n-3 PUFA on adipocyte 
hypertrophy and the key genes involved in adipocyte hypertrophy. Female C57BL/6 mice were 
fed semi-purified diets (20% w/w fat) containing high n-3 PUFA before mating, during 
pregnancy, and until weaning. Male and female offspring were continued on high n-3 PUFA 
(10% w/w), medium n-3 PUFA (4% w/w), or low n-3 PUFA (2% w/w) diet for 16 weeks 
postweaning. Adipocyte area was quantified using microscopy, and gonadal mRNA expression 
of DGAT2, FABP4 and leptin were measured. The high n-3 PUFA group showed higher levels 
of total n-3 PUFA in gonadal TG compared to the medium and low n-3 PUFA groups (P<0.001). 
The high n-3 PUFA male group had a lower adipocyte size compared to the medium and low n-3 
PUFA group (P<0.001); however, no difference was observed in females. The high n-3 PUFA 
male group showed lower mRNA expression of FABP4, DGAT2 and leptin compared to the low 
n-3 PUFA group, with no difference in females. Plasma lipid levels were lower in the high n-3 
PUFA group compared to the other groups. Our findings show for the first time that n-3 PUFA 
prevents adipocyte hypertrophy by downregulating FABP4, DGAT2 and leptin; the effects are 
however sex specific.     
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4.2 Introduction 
The incidence of obesity is on the rise in both developed and developing countries (Dunstan 
et al., 2002, Flegal et al., 1998). Obesity is defined as the accumulation of excess fat, and is 
associated with pathophysiological conditions such as T2D, CVD, and dyslipidaemia (Grundy, 
2004, Zou and Shao, 2008). The phenotype of obesity is characterised at the cellular level by an 
increase in adipose tissue mass, mainly as a result of the enlargement of adipocytes 
(hypertrophy) (van Harmelen et al., 2003). Adipocyte hypertrophy is accompanied by changes in 
metabolic activities such as lipid metabolism, which could exacerbate the development of 
obesity (Engfeldt and Arner, 1988). Larger adipocytes are known to both release more fatty acids 
and produce more TG relative to smaller adipocytes (Jamdar, 1978). The size of an adipocyte is a 
great predictor of a healthy metabolic profile (Grundy, 2004, Zou and Shao, 2008). Studies have 
linked adipocyte hypertrophy to dyslipidaemia and T2D (Bernstein et al., 1975, Haller et al., 
1979).  
Adipocyte hypertrophy is a consequence of excess accumulation of TG in the adipose tissue, 
and it is highly dependent on the nuclear receptor protein, PPARγ (Lopez et al., 2003). 
Therefore, elucidating the molecular process involved in the formation of TG in the adipose 
tissue is important in understanding the development of obesity. DGAT is responsible for the 
synthesis of TG (Bell and Coleman, 1980); it catalyses the covalent binding of acyl CoA to 
diacyglycerol (DG), which is the final step of TG synthesis (Chen et al., 2002). DGAT2, one of 
the two isoforms of the enzyme has been shown to be the main DGAT isoform involved in TG 
synthesis (Stone et al., 2004). Furthermore, the size of an adipocyte affects its endocrine 
functions (Kubota et al., 1999). Larger adipocytes secrete more inflammatory cytokines and 
NEFA, and increase lipolysis, which could lead to the development of metabolic syndrome 
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(Kubota et al., 1999). FABP4, also known as adipocyte fatty acid binding protein 2 (aP2), and 
accounts for around 6% of cellular protein (Xu et al., 2006) and has also been implicated in the 
regulation of glucose and lipid metabolism (Xu et al., 2006). Mice lacking the FABP4 gene are 
genetically protected from developing obesity and its complications (Uysal et al., 2000). Adipose 
tissue also secretes adipokines such as leptin. Leptin is a hormone produced primarily by 
adipocytes and it plays a vital role in food intake and metabolism (Ahima et al., 1996). Both 
human and rodent studies have reported a positive correlation between plasma leptin 
concentration and body fat (Frederich et al., 1995). The secretion of leptin has been positively 
correlated with the size of adipocytes (Guo et al., 2004), and clinical studies have also shown a 
positive correlation between the size of adipocyte and circulating leptin concentration (Couillard 
et al., 2000).   
The aetiology of obesity remains elusive; however obesity has been suggested to arise as a 
result of the interplay between genetic and environmental factors (Orio et al., 2007). The 
development of obesity is closely linked with nutrition; hence, nutritional intervention is a viable 
option of tackling the obesity epidemic. High dietary fat consumption has been suggested to be a 
major risk factor of obesity (Astrup et al., 2008). Due to the high caloric content of fat, it has 
been proposed that a reduction in the consumption of dietary fat could be a viable option of 
alleviating the obesity epidemic; however, this has not been successful, and obesity continues to 
be on the rise (Connor and Connor, 1997, Weinberg, 2004). Besides the quantity of dietary fat, 
the quality of fat has also been suggested to play an important role in the development of obesity. 
Studies using rodents have shown that a high fat diet promotes adipose tissue differentiation and 
hypertrophy (Ellis et al., 1990, Shillabeer and Lau, 1994). N-3 PUFA has been shown to elicit 
several health benefits, including but not limited to the prevention of T2D, CVD, and alleviation 
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of inflammation (Connor, 2000). The Western diet has witnessed a transition to lower 
consumption of n-3 PUFA (Gomez Candela et al., 2011), which may be part of the reason for the 
rise in the prevalence of obesity. There is burgeoning evidence of the anti-obesity effects of n-3 
PUFA. Rodent studies have shown that n-3 PUFA can prevent the development of insulin 
resistance and obesity (Ruzickova et al., 2004, Kuda et al., 2009). Studies in rats have also 
shown that n-3 PUFA could reduce obesity by reducing the size of an adipocyte without 
affecting the adipocyte number and the body weight (Parrish et al., 1990).  
The incidence of obesity and related complications are well established at the population 
level, however, there is still a lack of information on the mechanism at the cellular level. 
Furthermore, obesity has been identified as an independent risk factor of CVD in both males and 
females (Willett et al., 1995, Manson et al., 1990); however, most researchers have excluded the 
effect of sex and an adequate amount of n-3 PUFA in the diet.  In the present study, we 
hypothesized that high dietary n-3 PUFA will prevent adipocyte hypertrophy by downregulating 
the mRNA expression of DGAT2 and FABP4 in a sex dependent fashion in C57BL/6 mice. The 
specific objectives were to investigate the sex specific effects of diets varying in the quantity of 
n-3 PUFA on: adipocyte TG fatty acid composition; on adipocyte size; 3) on the mRNA 
expression of adipocyte DGAT2, FABP4, leptin, PPARγ; and on plasma lipids and lipoproteins 
of C57BL/6 mice. Our findings show for the first time that n-3 PUFA prevents adipocyte 
hypertrophy by downregulating the mRNA expression of DGAT2, FABP4, and leptin; however 
the effects were sex dependent.    
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4.3 Materials and Methods 
4.3.1 Experimental Diets 
The experimental diets were prepared as previously described in section 2.3.1. The 
composition of the semi-synthetic diet is provided in Table 2.1. The fatty acid composition of 
the experimental diet was analysed by GLC and is given in Table 2.2.   
4.3.2 Animals and experimental design 
All the experimental procedures were done in accordance with the principles and guidelines 
of the Canadian Council on Animal Care and were approved by Memorial University’s Animal 
Care Committee. Seven week old male and female C57BL/6 mice were obtained from Charles 
Rivers Laboratories (MA, USA) and were housed in separate cages under regulated temperature 
(21± 1°C) and humidity (35 ± 5%) conditions with a 12-hour light/12-hour dark period cycle. 
Mice were acclimatized on standard rodent chow pellets (Prolab RMH 3000) (PMI nutrition, 
MO, USA) for one week. After this period, female mice were fed the high n-3 PUFA diet for two 
weeks before mating. Female mice were continued on this diet throughout gestation, lactation, 
and until weaning to ensure an optimum level of n-3 PUFA for maintaining whole body 
homeostasis (Gomez Candela et al., 2011). At weaning, the offspring (male and female) were 
divided into three separate groups. Each group was fed one of the three experimental diets that 
differed in n-3 PUFA levels, and designated as “High n-3”, “Medium n-3”, and “Low n-3” diets, 
for 16 weeks postweaning. At the end of the experimental period, the animals were sacrificed 
after an overnight fast using isoflurane. Blood was collected by cardiac puncture in tubes 
containing EDTA (4.5 mM, pH 7.4), and plasma was separated immediately. Tissues were 
removed and weighed at the time of sacrifice, snap frozen in liquid nitrogen and stored at -80ºC 
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spots were scraped and the fatty acid composition was determined using GLC according to our 
previously published method (Chechi et al., 2010). 
4.3.4 Adipocyte histology and imaging 
Adipocyte area was measured using computer image analysis according to the method of 
Chen and Farese (Chen and Farese, 2002) with minor modifications. Briefly, gonadal fat was 
harvested from mice and fixed in 4% paraformaldehyde for 24 hours. Fixed tissues were 
transferred to phosphate-buffered saline (PBS) and stained using standard haematoxylin and 
eosin (H&E) staining procedure. The stained sections were visualized using the Epiflouresence 
microscope (E600) at 10X magnification. All the pictures were taken at the same time, using the 
same settings and magnification. The analyses of cell area were performed using the same scale 
bar (50μm) to ensure uniformity. Adipocytes areas were determined using Image J software. A 
total of 4 images per animals was obtained, and the sizes of 40 cells in two different microscopic 
fields were obtained per image giving a total of 800 cells per group.  
4.3.5 RNA extraction and real-time qPCR    
Total RNA was extracted from gonadal fat pads using Trizol method (Chomczynski and 
Sacchi, 1987) and contaminating genomic DNA was removed by treating with DNAse enzyme 
(Promega, USA). RNA concentration and purity were measured using NanoDrop 2000 (Thermo 
Scientific, USA). Primers for DGAT2, FABP4, leptin, and PPARγ used for qPCR were designed 
using NCBI primer blast (www.ncbi.nlm.nih.gov/tools/primer-blast/), and obtained from IDT 
technologies (IA, USA); primer sequences are given in Table 4.1.  Amplification was performed 
using iQ SYBER Green Supermix (Biorad, USA).  The reactions were run in a reaction volume 
of 20 µl and 100 ng cDNA per reaction.  The  Ct was recorded for each gene of interest, and 
167 
 
normalized with RPLPO (large ribosomal protein) as the housekeeping gene. The expression 
levels between the two groups were compared using the Pfaffl’s method (Pfaffl, 2001). The 
Pfaffl’s method is based on the relative quantification of mRNA expression level of the target 
gene relative to a reference gene. This method takes into account the difference in the efficiency 
between the target and reference genes. The Ct value of the target gene is normalized to that of 
the reference gene, and the change in Ct is normalized to a change in Ct of chosen calibrator 
sample; the expression ratio is calculated by the published Pfaffl’s equation (Pfaffl, 2001) 
4.3.6 Plasma biochemical parameters 
Plasma biochemical parameters were measured using commercially available kits according 
to the manufacturer’s instruction (kit #236-17 and 234-60 for plasma TG and TC respectively, 
Genzyme Diagnostics, PEI, Canada; and kit # 999-34691 for non-esterified fatty acids (NEFA), 
Wako Chemicals, VA, USA). HDL-c was precipitated from plasma using kit #200-26A 
(Diagnostic Chemicals Ltd, Canada) and the HDL-c concentration was determined using total 
cholesterol assay kit #234-60 (Genzyme Diagnostics, PEI, Canada). Plasma LDL-c concentration 
was calculated according to the method of Friedewald et al. (Friedewald et al., 1972, Fraulob et 
al., 2010). The current study on the effects of high n-3 PUFA on adipocytes was conducted at the 
same time as our previous study describing the sex-specific effects of perinatal and postnatal 
dietary n-3 PUFA on lipids and lipoproteins (Chapter 2), and therefore shares the same high n-3 
PUFA group for plasma biochemical parameters.  
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Table 4.1. Sequences of primers used for qPCR* 
Gene   Primers   
DGAT2 (S) ctgctgttggctggtttcac 
DGAT2 (AS) caggaggatatgcgccagag
FABP4 (S) cataaccctagatggcgggg 
FABP4 (AS) ccagcttgtcaccatctcgt 
Leptin (S) accaggcacccttggagggg
Leptin (AS) tgtggggccctcactccctg 
PPARγ (S)  tgttatgggtgaaactctggg  
PPARγ (AS)  agagctgattccgaagttgg  
    
RPLPO (S) tcactgtgccagctcagaac 
RPLPO (AS) aatttcaatggtgcctctgg 
        
 
*All primers were designed using NCBI primer blast, and obtained from IDT technologies. 
Abbreviation: S, sense primer; AS, anti-sense primer; DGAT2, acyl CoA:diacylglycerol 
acyltransferase 2; FABP4, fatty acid binding protein 4; PPARγ, peroxisome proliferator 
activator receptor protein gamma;  RPLPO, large ribosomal protein  (P0) 
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4.3.7 Statistical Analysis 
Data were analysed using IBM SPSS Statistics (version 20.0).  Sample means were 
compared using two way analysis of variance (ANOVA) to determine main effects of sex and 
diet, and the interactions between them. Pairwise comparison using Bonferrroni correction was 
used to determine differences among the groups when there was an observed statistical 
significant difference.  Results are expressed as mean ± standard deviation (SD).  Gonadal fat 
TG fatty acid compositions were expressed as weight percentage of the total extracted fatty 
acids. Fatty acid composition data were then arcsine transformed and real-time qPCR data were 
log10 transformed prior to statistical analyses. Differences were considered to be statistically 
significant if the associated P value was < 0.05.   
4.4  Results 
No significant differences were observed in body weight, fat pad weight, and food intake 
amongst various dietary groups, and between males and females (Appendix V). 
4.4.1 Fatty acid composition of gonadal TG of mice fed varying quantity of dietary n-3 PUFA 
The gonadal TG fatty acid composition of both male and female mice fed varying amounts of 
dietary n-3 PUFA is presented in Table 4.2. There was a concentration dependent significant 
increase in the gonadal levels of myristic acid (C14:0), with the high n-3 PUFA diet showing the 
highest amount (P<0.0001) in both male and female mice. There was however, no effect of sex 
on C14:0 or an interaction between sex and diet. The male mice showed a significant 
independent increase in the levels of palmitic acid (C16:0), stearic acid (C18:0), and total 
saturated fatty acids (SFA) compared to the female mice (P<0.001). The levels of C16:0 and 
total SFA were significantly higher in the high n-3 PUFA group compared to the low and 
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medium n-3 PUFA groups in male offspring (P<0.001).  The level of C18:0 was higher in the 
high n-3 PUFA group compared to the medium n-3 PUFA group, but was not different from the 
low n-3 PUFA group. On the other hand, females showed higher level of C18:0 on the high n-3 
PUFA diet compared to both the low and medium n-3 PUFA groups (P<0.001). Similar to the 
males, females also showed the highest total SFA level followed by the medium and the low n-3 
PUFA groups (P<0.001).  
Female mice showed a significantly higher level of palmitoleic acid (C16:1n7) compared to 
male mice (P<0.001); however, no effect of sex was observed in the TG fatty acid levels of 
C18:1n9/C18:1n7, C20:1n9, and total MUFA. High n-3 PUFA group showed the lowest level of 
C18:1n9/C18:1n7 compared to the medium and low n-3 PUFA groups in both male and female 
mice.  The medium n-3 PUFA group showed significantly lower level of C18:1n9/C18:1n7 than 
the low n-3 PUFA group (P<0.001). No difference was observed in the level of C20:1n9 among 
the three dietary groups in male mice. The female mice fed the high n-3 PUFA diet however 
showed significantly lower levels of C20:1n9 compared to the medium and low n-3 PUFA 
groups (P<0.01). A lower concentration of total MUFA was observed in the high n-3 PUFA 
mice compared to the low n-3 PUFA mice for both male and female mice (P<0.001). 
There was no effect of sex on individual and total gonadal n-6 PUFA levels, and no 
interaction between diet and sex was observed; however, there was a significant independent 
effect of diet in both male and female mice (P<0.01). Interestingly, there was a significantly 
higher amount of linoleic acid (LA; C18:2n6) and total n-6 PUFA in the high n-3 PUFA group 
compared to both medium and low n-3 PUFA groups in male mice (P<0.05).  A similar trend 
was also observed in female mice; however, there was no statistically significant difference in 
LA between high and medium n-3 PUFA groups. AA was significantly lower in the high and 
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medium n-3 PUFA groups compared to the low n-3 PUFA group in the male mice; however, no 
difference was observed in the female mice among the three dietary groups.  
There was a significant interaction of sex and diet in the levels of EPA (P<0001); however, 
no interaction was observed in DHA (C22:6n3) and total n-3 PUFA.  As expected, the high n-3 
PUFA fed male and female mice had a significantly higher accretion of EPA, DPA, DHA and 
total n-3 PUFA compared to the low n-3 PUFA group (P<0.001). There was however no 
difference in DHA and total n-3 PUFA between the medium and low n-3 PUFA group in the 
female mice. Interestingly, female mice had a significantly higher level of DHA and total n-3 
PUFA compared to male mice (P<0.01).   
 4.4.2 Adipocyte area of mice fed varying quantity of dietary n-3 PUFA 
H&E staining of the gonadal fat pads revealed smaller adipocytes in male mice fed the high 
n-3 PUFA diet compared to other groups (Fig. 4.1A, B and C); however, no noticeable 
difference was observed among the three dietary groups in the female mice (data not shown). 
Imaging and statistical analyses of the stained sections showed a significant interaction between 
sex and diet on adipocyte area (P<0.001; Fig. 4.1D). The female mice in the medium and low n-
3 PUFA groups had significantly smaller adipocytes (P<0.001; Fig. 4.1D) compared to their 
male counterparts. Male mice on the high n-3 PUFA diet had significantly smaller adipocytes 
compared to male mice on both medium and low n-3 PUFA diet (P<0.001; Fig. 4.1D); no 
difference was observed in the male mice between the medium and low n-3 PUFA groups. There 
was no difference in the size of adipocytes in female mice among the three dietary groups.     
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Table 4.2. Gonadal TG fatty acid composition of male and female mice fed diets varying in the quantity of n-3 polyunsaturated 
fatty acids  
Fatty Acids 
(%) 
Male    Female Main effect 
Low n-3 Medium n-3 High n-3    Low n-3 Medium n-3 High n-3 Diet Sex Diet*Sex 
C14:0 0.82 ± 0.04c 1.1 ± 0.07b 1.71 ± 0.25a 0.83 ± 0.13z 0.99 ± 0.08y 1.66 ± 0.19x P<0.0001 NS NS 
C16:0 13.8 ± 0.45b 14.2 ± 0.77b 15.7 ± 1.47a 11.22 ± 1.35y 12.76 ± 1.15xy 13.8 ± 1.5x 0.0002 P<0.0001 NS 
C18:0 2.78 ± 0.36ab 2.45 ± 0.36b 3.35 ± 0.84a 1.91 ± 0.26y 2.16 ± 0.18y 2.68 ± 0.46x 0.0007 0.0002 NS 
∑ SFA 17.4 ± 0.69b 17.7 ± 0.95b 20.8 ± 1.71a 14.0 ± 1.66z 15.8 ± 1.25y 18.15 ± 1.71x P<0.0001 P<0.0001 NS 
C16:1n7 4.03 ± 0.75 4.53 ±  0.57 4.56 ± 0.37 7.4 ± 1.28 6.25 ± 1.28 5.68 ± 0.64 
 
NS 
 
P<0.0001 
 
NS 
C18:1n9/18:1n7 50.26 ± 3.2c 45.87 ± 4.5b 35.18 ±  1.65a 49.7 ± 5.71z 44.0 ± 3.35y 34.8 ± 1.81x P<0.0001 NS NS 
C20:1n9 0.69 ± 0.08 0.56 ± 0.3 0.6 ± 0.04 0.95 ± 0.45y 0.67 ± 0.11y 0.41 ± 0.13x 0.008 NS 0.049 
∑ MUFA 55.0 ± 2.95b 51.0 ± 4.62b 40.3 ± 1.68a 58.0 ± 6.0z 51.0 ± 4.12y 40.9 ± 2.4x P<0.0001 NS NS 
C18:2n6 27.2 ± 3.23b 30.7 ± 4.5b 36.8 ± 2.18a 26.9 ± 7.25y 31.9 ± 3.22xy 38.0 ± 2.90x 
 
P<0.0001
 
NS 
 
NS 
C20:4n6 0.22± 0.03b 0.13 ± 0.04a 0.15 ± 0.02a 0.2 ± 0.07 0.16 ± 0.06 0.11 ± 0.06 0.009 NS NS 
∑ Omega-6 27.4 ± 3.26b 30.8 ± 4.52b 37.1 ± 2.21a 27.1 ± 7.24y 32.1 ± 3.27y 38.9 ± 2.15x P<0.0001 NS NS 
C18:3n3 0.17 ± 0.04 0.14 ± 0.1 0.19 ± 0.03 0.12  ± 0.1 0.19  ± 0.11 0.18  ± 0.11 
 
NS 
 
NS 
 
NS 
C18:4n3 0.06 ± 0.06 0.08 ± 0.05 0.14 ± 0.05 0.33  ± 0.33 0.15  ± 0.11 0.33  ± 0.33 NS NS NS 
C20:4n3 ND ND 0.1 ±0.03 0.17  ± 0.09 0.13  ± 0.09 0.08  ± 0.06 0.08 
C20:5n3 ND 0.18 ± 0.07b 0.48 ± 0.14a 0.29 ± 0.09y 0.24 ± 0.15y 0.5 ± 0.16x P<0.0001 0.001 P<0.0001 
C22:5n3 ND ND 0.3 ± 0.05 ND 0.11  ± 0.1y 0.28  ± 0.03x P<0.0001
C22:6n3 ND 0.12 ± 0.1b 0.58 ± 0.08a 0.11  ± 0.08y 0.18  ± 0.08y 0.49 ± 0.07x P<0.0001 0.004 NS 
∑ Omega-3 0.3 ± 0.18c 0.52 ± 0.2b 1.76 ± 0.28a 0.9  ± 0.4y 1  ± 0.19y 2.1  ± 0.79x P<0.0001 P<0.0001 NS 
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*Data are expressed as weight percentage of the total extracted fatty acids.  Values are 
expressed as mean  SD, n = 6.  Main effects and interactions were determined by two-way 
ANOVA after arcsine transformation.  Letters (a,b,c) were used to denote significant differences 
between dietary groups in males, and letters (x,y,z) represent significant differences between 
dietary groups in females. Σ SFA= sum of saturated fatty acids; Σ MUFA= sum of 
monounsaturated fatty acids; Σ PUFA= sum of polyunsaturated fatty acids; Σ Omega-6= sum of 
omega-6 polyunsaturated fatty acids; Σ Omega-3= sum of omega-3 polyunsaturated fatty acids, 
ND = Not detected; NS = Not significant 
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Figure 4.1. Effect of diets varying in the quantity of n-3 PUFA on gonadal adipocyte size: 
Haematoxylin and eosin stained histological sections of gonadal fat of male mice fed: (A) low n-
3 PUFA diet; (B), medium n-3 PUFA diet; and (C), high n-3 PUFA diet, at image capture of 10X 
magnification. Figure D represents the mean surface area of gonadal adipocytes in male and 
female mice; bar represents 50μm. Values are expressed as means  SD, n=5 per dietary group; 
800 cells were measured per group. Data were assessed using two way ANOVA to determine the 
main effects and interactions of diets and sex; pairwise comparison using Bonferroni correction 
was used to determine differences when there was an observed significant difference. Letters (a, 
b) represent significant differences between dietary groups in male mice where P<0.05 was 
considered significant. 
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4.4.3 Gonadal mRNA expressions of FABP4, DGAT2, leptin, and PPARγ of mice fed varying 
quantity of dietary n-3 PUFA 
The mRNA expressions of key genes involved in adipocyte hypertrophy were measured 
using real time qPCR.  No significant interaction was observed between sex and diet in the 
mRNA expression levels of FABP4 and leptin (Fig. 4.2A and B). Interestingly, similar to the 
adipocyte data, the female mice fed the low and medium n-3 PUFA diets showed  lower mRNA 
expression levels of FABP4 and leptin compared to the male counterparts (P<0.05; Fig.4.2A and 
B). An independent effect of diet was observed, where the high n-3 PUFA diet revealed 
significantly lower mRNA expression of FABP4 and leptin compared to low n-3 PUFA diet 
(P<0.05; Fig. 4.2A and B). There was an interaction between sex and diet on the mRNA 
expression of DGAT2 and PPARγ (P<0.05; Fig 4.2C and D), where female mice showed a lower 
expression. The high n-3 PUFA group had significantly lower mRNA expression of DGAT2 and 
PPARγ compared to the low n-3 PUFA groups in male mice (P<0.05; Fig. 4.2C and D); 
however, no significant differences were observed among the three dietary groups in female 
mice. 
4.4.4 Plasma biochemical parameters of mice fed varying quantity of dietary n-3 PUFA 
Obesity could result in dyslipidaemia, characterised by an increase in plasma concentration of 
lipids and lipoproteins; thus we measured these parameters in mice fed the high, medium and 
low levels of n-3 PUFA (Table 4.3). There was no independent effect of sex on plasma 
concentration of NEFA; there was also no interaction between sex and diet. However, both male 
and female mice fed the low n-3 PUFA diet had a significantly higher concentration of NEFA  
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Figure 4.2. Effect of diets varying in the quantity of n-3 PUFA on gonadal mRNA expression: 
The data represent male and female gonadal mRNA expression of: A) fatty acid binding protein-
4 (FABP4); B) leptin, C) Acyl CoA:diacylglycerol acyltranferase-2 (DGAT2), and D) 
peroxisome proliferator activator receptor protein-gamma (PPAR-γ) normalized with RPLPO as 
the house-keeping gene. Values are expressed as means  SD, n=6 per dietary group. Data were 
assessed using two way ANOVA to determine the main effects and interactions of diets and sex; 
pairwise comparison using Bonferroni correction was used to determine differences when there 
was an observed significant difference. Letters (a, b, c) represent significant differences between 
dietary groups in males, where P<0.05 was considered significant. NS, not significant 
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compared to the medium and high n-3 PUFA groups (P<0.01). However, there was no 
significant difference in plasma NEFA concentration between the high and medium n-3 PUFA 
groups in both males and females. Similar to the adipocyte area data, there was a sex-dependent 
effect of diet on plasma concentration of TG (P<0.001). The female mice in the low and medium 
n-3 PUFA groups had a significantly lower plasma TG concentration compared to their male 
counterparts (P<0.01). The concentration of TG was significantly lower in the high n-3 PUFA 
groups compared to the medium and low n-3 PUFA groups in male offspring (P<0.001); 
however, no difference was observed between the low and medium n-3 PUFA groups. 
Interestingly, female mice showed no significant effect of the diet in any of the dietary groups. 
Plasma TC concentration was lower in female mice compared to male mice (P<0.01). The high 
n-3 PUFA group had a significantly lower concentration of TC compared to the medium and low 
n-3 PUFA groups in both male and female mice (P<0.01). There was no effect of sex on plasma 
LDL-c levels; however, similar to TC data, LDL-c was lower in the high n-3 PUFA group 
compared to the medium and low n-3 PUFA groups in both male and female mice, and no 
difference was observed between medium and low n-3 PUFA groups (P<0.01). Diet and sex had 
no effect on the plasma concentration of HDL-c in both male and female mice. 
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Table 4.3  Plasma biochemical parameters of mice fed diets varying in the quantity of n-3 PUFA* 
 
*Values are expressed as means  SD, n =8. Data were assessed using two way ANOVA to determine the main effects and interactions 
of diets and sex; pairwise comparison using Bonferroni correction was used to determine differences when there was a significant 
difference. Letters (a,b) were used to denote significant differences between dietary groups in males, and letters (x,y) represent 
significant differences between dietary groups in females.  P < 0.05 was considered significant. Abbreviation: NEFA, non-esterified 
fatty acids; TG, triglycerides; TC, total cholesterol; LDL, low-density lipoprotein, HDL, high-density lipoprotein. NS, not significant 
 
 
 
Lipids  
(mmol/L) 
Male Female Main effect 
Low n-3 Medium n-3 High n-3 Low n-3 Medium n-3 High n-3 Diet Sex Diet*Sex 
NEFA 0.49 ± 0.19a 0.32 ± 0.07b 0.27 ± 0.08b 0.41 ± 0.12x 0.3 ± 0.08y 0.24 ± 0.1y P<0.0001 NS NS 
TG 0.41 ± 0.08a 0.46 ± 0.1a 0.23 ± 0.08b 0.28 ± 0.05 0.28 ± 0.08 0.28 ± 0.08 P<0.0001 P<0.0001 P<0.0001
TC 1.78 ± 0.23a 1.86 ± 0.16a 1.25 ± 0.15b 1.63 ± 0.15x 1.54 ± 0.24x 1.1 ± 0.18y P<0.0001 P<0.0001 NS 
LDL 1.22 ± 0.24a 1.34 ± 0.2a 0.77 ± 0.16b 1.15 ± 0.17x 1.13 ± 0.23x 0.71 ± 0.16y P<0.0001 NS NS 
HDL 0.38 ± 0.07 0.32 ± 0.1 0.41 ± 0.15 0.36 ± 0.13 0.28 ± 0.09 0.31 ± 0.08 NS NS NS 
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4.5 Discussion 
The underlying mechanism connecting obesity with the pathogenesis of T2D and CVD is 
poorly understood, however, the role of adipose tissue has been implicated (Ferroni et al., 2004). 
Obesity can be defined at the cellular level as the enlargement of adipose tissue mass as a result 
of hyperplasia and/or hypertrophy. In the current study, the sex dependent effect of diets varying 
in the quantity of n-3 PUFA was investigated on adipocyte hypertrophy, and the mRNA 
expression of key genes such as DGAT2, FABP4, leptin, and PPARγ involved in adipose tissue 
enlargement. We report a novel effect of n-3 PUFA on the cellular events that lead to obesity by 
preventing adipocyte hypertrophy through the downregulation of the mRNA expression of 
DGAT2 and FABP4.  Our findings also suggest a sex dependent anti-obesity effect of a diet high 
in n-3 PUFA.  
Adipose tissue composition of essential fatty acids is mainly determined by dietary intake 
(Hodson et al., 2008); however, factors such as sex also play a major role in tissue accretion of 
these fatty acids (Childs et al., 2008). It was thus imperative to assess the accretion of dietary n-3 
PUFA in adipose tissue TG. As expected, there was a dose-dependent accretion of EPA, DHA, 
and total n-3 PUFA in adipose tissue. The high n-3 PUFA group had the highest accretion of 
EPA, DHA, and total n-3 PUFA compared to the two other groups; these findings are in line 
with previously reported data (Hodson et al., 2008).  Interestingly, female mice had a higher 
accretion of gonadal fat TG DHA and total n-3 PUFA compared to the male mice. Clinical 
studies have indicated that females have a higher concentration of DHA than their male 
counterparts in the serum and plasma (Crowe et al., 2008, Garneau et al., 2012). This has been 
suggested to be due to higher and more efficient conversion of ALA to EPA and DHA 
(Pawlosky et al., 2001, Burdge and Wootton, 2002), and also a decreased retroconversion of 
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DHA to EPA and DPA in females (Brossard et al., 1996). This is evident in our data, with no 
difference in TG ALA composition between male and female mice; however, female mice had 
more accretion of EPA compared to male mice. Human studies have also reported a higher 
incorporation of DHA in female adipose tissue compared to male (Walker et al., 2014), further 
confirming our observations. Another interesting observation was the percentage of different 
fatty acids present in the gonadal TG; there was higher accretion of medium chain and saturated 
fatty acids compared to longer chain and highly unsaturated fatty acids in the high n-3 PUFA 
group. Studies have shown that the mobilization of fatty acids from adipose tissue is a function 
of their structure and not their composition in adipose tissue (Conner et al., 1996). SFA was 
reported to be mobilized the least, followed by MUFA, and PUFA was mobilized the most, 
especially the 20 carbon PUFAs such as EPA and AA because they serve as precursors to 
eicosanoids production (Conner et al., 1996).  Thus, lower levels of EPA and AA in our study 
could be due to rapid mobilization of these fatty acids for physiological functions. The high n-3 
PUFA group, however, showed a lower concentration of AA and higher concentration of EPA in 
the gonadal TG.  AA is metabolised to pro-inflammatory, pro-aggregatory, and vasoconstrictive 
eicosanoids, which support the development of CVD (Farooqui et al., 2007). Conversely, EPA 
derived eicosanoids are anti-inflammatory and prevent the development CVD (Adkins and 
Kelley, 2010). Higher amounts of n-3 PUFA in mice fed with a high n-3 PUFA diet suggests that 
these fatty acids and their bioactive metabolic products could be responsible for regulating key 
genes involved in adipocyte metabolism, thereby preventing obesity and associated 
complications. 
An increase in the mass of the adipose tissue is characterised by an increase in size and/or 
number of adipocytes (Hausman et al., 2001). Mature adipocytes are postmitotic and can only 
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undergo hypertrophy; as a result, new adipocytes arise from a population of preadipocytes (Gray 
and Vidal-Puig, 2007). The progression of obesity does not affect the death or production of 
adipocyte, however there is enlargement of adipose tissue mass primarily by adipocyte 
hypertrophy (Bjorntorp, 1974). Our data show a reduction of adipocyte hypertrophy in response 
to high dietary n-3 PUFA in male mice; however, this response was not observed in female mice. 
Furthermore, there was no effect of any of the diets on body weight of male or female mice. 
Only very few rodent studies have reported that n-3 PUFA could reduce obesity by reducing the 
size of an adipocyte without affecting the adipocyte number and the body weight (Parrish et al., 
1990). Given the gender disparity in the development of obesity and CVD, no study has 
investigated the sex-specific effect of n-3 PUFA on adipocyte hypertrophy. We are the first to 
report sex specific effects of diets varying in the amount of n-3 PUFA on adipocyte hypertrophy. 
The mechanism for the observed sex specific differences in adipocyte hypertrophy between male 
and female is unclear; our speculation is that the differences are mediated by sex hormones that 
needs to be investigated in the future. Body composition differs between male and females, and 
fat deposition is driven by testosterone and oestrogen differently in both genders (Guo et al., 
1998). The female sex hormone oestrogen has been shown to drive adipose tissue proliferation 
(Roncari and Van, 1978). Furthermore, the metabolism of n-3 PUFA is affected by oestrogen 
(Childs et al., 2008); thus there could be a possible interplay in the metabolism of n-3 PUFA, sex 
hormones, and adipose tissue hypertrophy.  
Adipocyte hypertrophy is mainly caused by excess storage of TG in the adipose tissue; 
therefore, regulating the storage of TG in adipose tissue could be a potentially viable mechanism 
for preventing obesity. DGAT catalyses the final step of TG synthesis (Chen et al., 2002), which 
makes it an important enzyme in TG accumulation in adipose tissue. Our study demonstrates that 
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high n-3 PUFA diet reduced the mRNA expression of DGAT2 in a sex-dependent fashion; with 
smaller adipocytes showing the lowest mRNA expression of DGAT2. Two isoforms of DGAT 
have been identified (Cases et al., 1998, Lardizabal et al., 2001); the genes that code for DGAT1 
and DGAT2 belong to different families, however, they have comparable substrate specificity 
(Cases et al., 2001). Increased expression of DGAT2 is associated with the formation of large 
lipid droplets, on the contrary overexpression of DGAT1 produces small lipid droplets (Stone et 
al., 2004), emphasizing the importance of DGAT2 in TG synthesis. Furthermore, DGAT2   can 
compensate for the function of DGAT1, however, DGAT1 cannot compensate for DGAT2. In-
vitro downregulation of DGAT2 results in reduction of TG synthesis, and inhibition of DGAT2 
alleviates markers of hyperlipidaemia, obesity and CVD by inhibiting the enzymes involved in 
lipogenesis (Yu et al., 2005). DGAT2 null mice are lipopenic with a 93% reduction in total 
carcass TG (Stone et al., 2004). Our finding showing inhibition of DGAT2 mRNA expression by 
a high n-3 PUFA diet is novel, and to the best of our knowledge, no study has linked adipocyte 
hypertrophy to the regulation of DGAT2 by n-3 PUFA.  There is a paucity of data on the anti-
obesity effect of DGAT2 in adults as DGAT2 knockout mice are lipopenic and die after birth 
(Stone et al., 2004). Dietary n-3 PUFA could serve as a promising therapy for downregulating 
the expression of DGAT2 and consequently  reducing obesity.  
DGAT2 requires the presence of free fatty acids to catalyse the covalent binding of acyl CoA 
to DG, and larger adipocytes are known to release more fatty acids into circulation compared to 
smaller adipocytes (Zimmermann et al., 2004, Holm et al., 1975).  FABP are proteins found in 
the cytoplasm that binds strongly with a variety of fatty acids, and are evolutionarily conserved 
between species and are involved in the transport of fatty acids for utilization by enzymes and 
tissues (Zimmerman and Veerkamp, 2002). Under normal conditions, FABP4 is responsible for 
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regulating the release and transport of fatty acids (Baar et al., 2005), and is largely expressed in 
adipocytes and macrophages (Boord et al., 2002, Pelton et al., 1999). It has been reported that the 
production and secretion of FABP4 in the adipose tissue result in lipogenesis and excess 
secretion of free fatty acids and TG, which could lead to ectopic lipid accumulation and 
consequent development of metabolic syndrome (Rasouli et al., 2007). We report for the first 
time, a reduction in the mRNA expression of FABP4 in response to high n-3 PUFA diet and 
adipocyte hypertrophy; however, this effect was sex-specific, where female mice showed a lower 
mRNA expression of FABP4 compared to male mice. The role of FABP4 in obesity is not well 
studied; however, it has been suggested that FABP4 could be a novel adipokine just like leptin 
and adiponectin whose expression levels correlate with the size of the adipocyte (Kralisch and 
Fasshauer, 2013). Obese individuals have been shown to have higher expression of FABP4 (Xu 
et al., 2006, Reinehr et al., 2007) and individuals who lost weight were reported to have a 
reduced expression of FABP4. FABP4 is transcriptionally regulated (Chmurzynska, 2006); it has 
been suggested that FABP4 has a peroxisome proliferator receptor element (PPRE) in its 
promoter region (Schachtrup et al., 2004). PPARγ is highly expressed in the adipose tissue and 
FABP4 may act closely with PPARγ to elicit its biological function (Tan et al., 2002). Upon 
interacting with PPARγ ligand, cytosolic FABP4 translocates to the nucleus where it interacts 
with PPARγ thereby stimulating its transcriptional activity (Tan et al., 2002).  Interestingly, 
similar to our findings with downregulation of FABP4 mRNA expression by a high n-3 PUFA 
diet, the mRNA expression of PPARγ was also significantly lower in the high n-3 PUFA group 
compared to the low n-3 PUFA group.  Furthermore, the effect was sex specific with female 
mice showing a lower expression of PPARγ compared to male mice.  Targeting the expression of 
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FABP4 by n-3 PUFA could be a potential mechanism to prevent adipocyte hypertrophy and diet 
induced obesity.  
The function of the adipose tissue is not only limited to the storage of TG, it also functions as 
an endocrine organ, and release a number of adipokines such as leptin into circulation (Kershaw 
and Flier, 2004).  The mRNA expression of leptin has been shown to be reduced by n-3 PUFA in 
both in-vitro and in-vivo studies (Reseland et al., 2001). We found a sex-dependent reduction in 
the mRNA expression of leptin in response to high n-3 PUFA diet, with the female mice 
showing a lower expression compared to male mice that correspond with the size of the 
adipocytes. Leptin is mostly expressed following the differentiation of pre-adipocytes to 
adipocytes which marks the onset of lipid accumulation in the cell (Mitchell et al., 1997), and the 
expression is increased postweaning in rodents (Rousseau et al., 1997). As the adipose tissue 
grows, the secretion of leptin also increases (Considine et al., 1996). A strong association has 
been reported between leptin secretion and adipocyte size (Zhang et al., 2002) which confirms 
our observations. We are however, reporting for the first time that the effect of n-3 PUFA on 
leptin mRNA expression is sex specific. There is a direct correlation between the mRNA 
expression of leptin and PPARγ; a reduction in leptin mRNA expression also leads to a reduction 
in the mRNA expression of PPARγ (Reseland et al., 2001). Our findings demonstrate a reduction 
in leptin and PPARγ mRNA expression on a high n-3 PUFA diet, further supporting the 
regulation of leptin by PPARγ. It has also been suggested that leptin controls circulating lipid 
concentration and regulates the size of an adipocyte by influencing the expression of DGAT 
through the central nervous system thereby controlling the level of TG synthesis (Suzuki et al., 
2005), supporting our observations on similar changes in leptin, DGAT and adipocyte 
hypertrophy.  
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Obesity is closely associated with dyslipidaemia which is a disorder of lipid and lipoprotein 
metabolism, involving hypercholesterolaemia, hypertriglyceridaemia, and elevated LDL-
cholesterol concentrations (Misra et al., 2005, Misra et al., 2006).  One of the major causes of 
dyslipidaemia is the alteration of fatty acid metabolism in the adipose tissue (Smith et al., 2006, 
Sniderman et al., 1998).  It has been reported that the production and secretion of FABP4 in the 
adipose tissue result in lipogenesis and excess secretion of free fatty acids and TG, which could 
lead to ectopic lipid accumulation and consequent development of metabolic syndrome (Rasouli 
et al., 2007). The plasma biochemical parameters in our study showed that the high n-3 PUFA 
diet had reduced plasma concentration of TG and NEFA in the male offspring; however, the 
female mice showed no difference in plasma TG concentration, which is similar to the trend we 
observed in the adipocyte cell size. Furthermore, n-3 PUFAs have been shown to reduce TG by 
stimulating β-oxidation of NEFA among other hypotriglyceridaemic effects of n-3 PUFA 
(Pegorier et al., 2004).  An increase in the release of NEFA from adipocytes leads to the 
accelerated uptake of these fatty acids by the liver and channelled towards the production of TG, 
cholesterol and LDL-c (Julius, 2003).  This was confirmed in our study, as the low n-3 PUFA 
group had higher plasma LDL-c and NEFA concentration compared to the low n-3 PUFA 
groups.  
A higher concentration of TC was also observed in low and medium n-3 PUFA groups 
compared to the high n-3 PUFA group in male mice. It has been reported that the higher 
concentration of cholesterol observed in obese individuals leads to the production of more LDL-
c resulting in the downregulation of the expression of LDL- r and reduced clearance of LDL-c 
(Cox et al., 1995, Katan and Beynen, 1987).  It was interesting however, to notice that the 
plasma NEFA and TC cholesterol concentrations were lower in the high n-3 PUFA group 
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compared to the low n-3 PUFA group in female mice, despite no significant difference in 
adipocyte size, suggesting a sex-specific effect on lipid and lipoprotein metabolism. The sex-
specific effects of high n-3 PUFA diet on plasma lipids and lipoprotein concentration (Balogun 
et al., 2014)  is likely due to  a clear distinction in hormonal regulation between male and female 
(McNamara et al., 2009).  
Taken together, my data suggest a novel mechanism by which  n-3 PUFA affects the cellular 
events that may lead to obesity, and I am the first to report a sex-specific effect of n-3 PUFA on 
adipocyte hypertrophy. I am proposing that the downregulation of DGAT2, FABP4 and leptin by 
n-3 PUFA is facilitated by PPARγ. Moreover, an association between leptin and DGAT2 has 
been previously reported (Suzuki et al., 2005) that supports our data.  My findings show that 
feeding high dietary n-3 PUFA could prevent obesity by reducing the mRNA expression of 
critical genes involved in adipose hypertrophy. My findings also demonstrate that although 
female mice had lower expression of the key genes involved in adipocyte hypertrophy, lower 
levels of lipids and lipoproteins, and smaller adipocytes compared to male mice, however males 
appeared to be more responsive to high n-3 PUFA diet. Thus, my findings emphasize that sex 
differences should be incorporated in the dietary recommendation of n-3 PUFA for the 
prevention of obesity and associated complications. 
 
 
 
 
187 
 
4.6 References 
ADKINS, Y. & KELLEY, D. S. 2010. Mechanisms underlying the cardioprotective effects of 
omega-3 polyunsaturated fatty acids. J Nutr Biochem, 21, 781-92. 
AHIMA, R. S., PRABAKARAN, D., MANTZOROS, C., QU, D., LOWELL, B., MARATOS-
FLIER, E. & FLIER, J. S. 1996. Role of leptin in the neuroendocrine response to fasting. 
Nature, 382, 250-2. 
ASTRUP, A., DYERBERG, J., SELLECK, M. & STENDER, S. 2008. Nutrition transition and 
its relationship to the development of obesity and related chronic diseases. Obes Rev, 9 
Suppl 1, 48-52. 
BAAR, R. A., DINGFELDER, C. S., SMITH, L. A., BERNLOHR, D. A., WU, C., LANGE, A. 
J. & PARKS, E. J. 2005. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-
) mice. Am J Physiol Endocrinol Metab, 288, E187-93. 
BELL, R. M. & COLEMAN, R. A. 1980. Enzymes of glycerolipid synthesis in eukaryotes. Annu 
Rev Biochem, 49, 459-87. 
BERNSTEIN, R. S., GRANT, N. & KIPNIS, D. M. 1975. Hyperinsulinemia and enlarged 
adipocytes in patients with endogenous hyperlipoproteinemia without obesity or diabetes 
mellitus. Diabetes, 24, 207-13. 
BJORNTORP, P. 1974. Effects of age, sex, and clinical conditions on adipose tissue cellularity 
in man. Metabolism, 23, 1091-102. 
BOORD, J. B., FAZIO, S. & LINTON, M. F. 2002. Cytoplasmic fatty acid-binding proteins: 
emerging roles in metabolism and atherosclerosis. Curr Opin Lipidol, 13, 141-7. 
188 
 
BROSSARD, N., CROSET, M., PACHIAUDI, C., RIOU, J. P., TAYOT, J. L. & LAGARDE, 
M. 1996. Retroconversion and metabolism of [13C]22:6n-3 in humans and rats after 
intake of a single dose of [13C]22:6n-3-triacylglycerols. Am J Clin Nutr, 64, 577-86. 
BURDGE, G. C. & WOOTTON, S. A. 2002. Conversion of alpha-linolenic acid to 
eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J 
Nutr, 88, 411-20. 
CASES, S., SMITH, S. J., ZHENG, Y. W., MYERS, H. M., LEAR, S. R., SANDE, E., NOVAK, 
S., COLLINS, C., WELCH, C. B., LUSIS, A. J., ERICKSON, S. K. & FARESE, R. V., 
JR. 1998. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a 
key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A, 95, 13018-23. 
CASES, S., STONE, S. J., ZHOU, P., YEN, E., TOW, B., LARDIZABAL, K. D., VOELKER, 
T. & FARESE, R. V., JR. 2001. Cloning of DGAT2, a second mammalian diacylglycerol 
acyltransferase, and related family members. J Biol Chem, 276, 38870-6. 
CHECHI, K., HERZBERG, G. R. & CHEEMA, S. K. 2010. Maternal dietary fat intake during 
gestation and lactation alters tissue fatty acid composition in the adult offspring of 
C57Bl/6 mice. Prostaglandins Leukot Essent Fatty Acids, 83, 97-104. 
CHEN, H. C. & FARESE, R. V., JR. 2002. Determination of adipocyte size by computer image 
analysis. J Lipid Res, 43, 986-9. 
CHEN, H. C., SMITH, S. J., TOW, B., ELIAS, P. M. & FARESE, R. V., JR. 2002. Leptin 
modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine 
fur and sebaceous glands. J Clin Invest, 109, 175-81. 
CHILDS, C. E., ROMEU-NADAL, M., BURDGE, G. C. & CALDER, P. C. 2008. Gender 
differences in the n-3 fatty acid content of tissues. Proc Nutr Soc, 67, 19-27. 
189 
 
CHMURZYNSKA, A. 2006. The multigene family of fatty acid-binding proteins (FABPs): 
function, structure and polymorphism. J Appl Genet, 47, 39-48. 
CHOMCZYNSKI, P. & SACCHI, N. 1987. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 162, 156-9. 
CONNER, W. E., LIN, D. S. & COLVIS, C. 1996. Differential mobilization of fatty acids from 
adipose tissue. J Lipid Res, 37, 290-8. 
CONNOR, W. E. 2000. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr, 71, 
171S-5S. 
CONNOR, W. E. & CONNOR, S. L. 1997. Should a low-fat, high-carbohydrate diet be 
recommended for everyone? The case for a low-fat, high-carbohydrate diet. N Engl J 
Med, 337, 562-3; discussion 566-7. 
CONSIDINE, R. V., SINHA, M. K., HEIMAN, M. L., KRIAUCIUNAS, A., STEPHENS, T. 
W., NYCE, M. R., OHANNESIAN, J. P., MARCO, C. C., MCKEE, L. J., BAUER, T. L. 
& ET AL. 1996. Serum immunoreactive-leptin concentrations in normal-weight and 
obese humans. N Engl J Med, 334, 292-5. 
COUILLARD, C., MAURIEGE, P., IMBEAULT, P., PRUD'HOMME, D., NADEAU, A., 
TREMBLAY, A., BOUCHARD, C. & DESPRES, J. P. 2000. Hyperleptinemia is more 
closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int 
J Obes Relat Metab Disord, 24, 782-8. 
COX, C., MANN, J., SUTHERLAND, W. & BALL, M. 1995. Individual variation in plasma 
cholesterol response to dietary saturated fat. BMJ, 311, 1260-4. 
190 
 
CROWE, F. L., SKEAFF, C. M., GREEN, T. J. & GRAY, A. R. 2008. Serum n-3 long-chain 
PUFA differ by sex and age in a population-based survey of New Zealand adolescents 
and adults. Br J Nutr, 99, 168-74. 
DUNSTAN, D. W., ZIMMET, P. Z., WELBORN, T. A., DE COURTEN, M. P., CAMERON, 
A. J., SICREE, R. A., DWYER, T., COLAGIURI, S., JOLLEY, D., KNUIMAN, M., 
ATKINS, R. & SHAW, J. E. 2002. The rising prevalence of diabetes and impaired 
glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care, 
25, 829-34. 
ELLIS, J. R., MCDONALD, R. B. & STERN, J. S. 1990. A diet high in fat stimulates adipocyte 
proliferation in older (22 month) rats. Exp Gerontol, 25, 141-8. 
ENGFELDT, P. & ARNER, P. 1988. Lipolysis in human adipocytes, effects of cell size, age and 
of regional differences. Horm Metab Res Suppl, 19, 26-9. 
FAROOQUI, A. A., HORROCKS, L. A. & FAROOQUI, T. 2007. Modulation of inflammation 
in brain: a matter of fat. J Neurochem, 101, 577-99. 
FERRONI, P., BASILI, S., FALCO, A. & DAVI, G. 2004. Inflammation, insulin resistance, and 
obesity. Curr Atheroscler Rep, 6, 424-31. 
FLEGAL, K. M., CARROLL, M. D., KUCZMARSKI, R. J. & JOHNSON, C. L. 1998. 
Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J 
Obes Relat Metab Disord, 22, 39-47. 
FOLCH, J., LEES, M. & STANLEY, G. H. S. 1957. A simple method for the isolation and 
purification of total lipids from animal tissues. J. Biol. Chem., 226, 497-509. 
FRAULOB, J. C., OGG-DIAMANTINO, R., FERNANDES-SANTOS, C., AGUILA, M. B. & 
MANDARIM-DE-LACERDA, C. A. 2010. A mouse model of metabolic syndrome: 
191 
 
insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in 
C57BL/6 Mice fed a high fat diet. J Clin Biochem Nutr, 46, 212-23. 
FREDERICH, R. C., HAMANN, A., ANDERSON, S., LOLLMANN, B., LOWELL, B. B. & 
FLIER, J. S. 1995. Leptin levels reflect body lipid content in mice: evidence for diet-
induced resistance to leptin action. Nat Med, 1, 1311-4. 
FRIEDEWALD, W. T., LEVY, R. I. & FREDRICKSON, D. S. 1972. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without use of the 
preparative ultracentrifuge. Clin Chem, 18, 499-502. 
GARNEAU, V., RUDKOWSKA, I., PARADIS, A. M., GODIN, G., JULIEN, P., PERUSSE, L. 
& VOHL, M. C. 2012. Omega-3 fatty acids status in human subjects estimated using a 
food frequency questionnaire and plasma phospholipids levels. Nutr J, 11, 46. 
GOMEZ CANDELA, C., BERMEJO LOPEZ, L. M. & LORIA KOHEN, V. 2011. Importance 
of a balanced omega 6/omega 3 ratio for the maintenance of health: nutritional 
recommendations. Nutr Hosp, 26, 323-9. 
GRAY, S. L. & VIDAL-PUIG, A. J. 2007. Adipose tissue expandability in the maintenance of 
metabolic homeostasis. Nutr Rev, 65, S7-12. 
GRUNDY, S. M. 2004. Obesity, metabolic syndrome, and cardiovascular disease. J Clin 
Endocrinol Metab, 89, 2595-600. 
GUO, K. Y., HALO, P., LEIBEL, R. L. & ZHANG, Y. 2004. Effects of obesity on the 
relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat 
depots in mice. Am J Physiol Regul Integr Comp Physiol, 287, R112-9. 
192 
 
GUO, S. S., CHUMLEA, W. C., ROCHE, A. F. & SIERVOGEL, R. M. 1998. Age- and 
maturity-related changes in body composition during adolescence into adulthood: the 
Fels longitudinal study. Appl Radiat Isot, 49, 581-5. 
HALLER, H., LEONHARDT, W., HANEFELD, M. & JULIUS, U. 1979. Relationship between 
adipocyte hypertrophy and metabolic disturbances. Endokrinologie, 74, 63-72. 
HAUSMAN, D. B., DIGIROLAMO, M., BARTNESS, T. J., HAUSMAN, G. J. & MARTIN, R. 
J. 2001. The biology of white adipocyte proliferation. Obes Rev, 2, 239-54. 
HODSON, L., SKEAFF, C. M. & FIELDING, B. A. 2008. Fatty acid composition of adipose 
tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res, 
47, 348-80. 
HOLM, G., JACOBSSON, B., BJORNTORP, P. & SMITH, U. 1975. Effects of age and cell size 
on rat adipose tissue metabolism. J Lipid Res, 16, 461-4. 
JAMDAR, S. C. 1978. Glycerolipid biosynthesis in rat adipose tissue. Influence of adipose-cell 
size and site of adipose tissue on triacylglycerol formation in lean and obese rats. 
Biochem J, 170, 153-60. 
JULIUS, U. 2003. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic 
dyslipidemia. Exp Clin Endocrinol Diabetes, 111, 246-50. 
KATAN, M. B. & BEYNEN, A. C. 1987. Characteristics of human hypo- and hyperresponders 
to dietary cholesterol. Am J Epidemiol, 125, 387-99. 
KEENAN MHJ, R. A. S. B. 1982. Effect of Plasma-membrane Phospholipid Unsaturation on 
Solute Transport into Saccharomyces cerevisiae NCYC 366. J Gen Microbiol, 128, 2547-
2556. 
193 
 
KERSHAW, E. E. & FLIER, J. S. 2004. Adipose tissue as an endocrine organ. J Clin Endocrinol 
Metab, 89, 2548-56. 
KRALISCH, S. & FASSHAUER, M. 2013. Adipocyte fatty acid binding protein: a novel 
adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia, 
56, 10-21. 
KUBOTA, N., TERAUCHI, Y., MIKI, H., TAMEMOTO, H., YAMAUCHI, T., KOMEDA, K., 
SATOH, S., NAKANO, R., ISHII, C., SUGIYAMA, T., ETO, K., TSUBAMOTO, Y., 
OKUNO, A., MURAKAMI, K., SEKIHARA, H., HASEGAWA, G., NAITO, M., 
TOYOSHIMA, Y., TANAKA, S., SHIOTA, K., KITAMURA, T., FUJITA, T., EZAKI, 
O., AIZAWA, S., KADOWAKI, T. & ET AL. 1999. PPAR gamma mediates high-fat 
diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell, 4, 597-609. 
KUDA, O., JELENIK, T., JILKOVA, Z., FLACHS, P., ROSSMEISL, M., HENSLER, M., 
KAZDOVA, L., OGSTON, N., BARANOWSKI, M., GORSKI, J., JANOVSKA, P., 
KUS, V., POLAK, J., MOHAMED-ALI, V., BURCELIN, R., CINTI, S., BRYHN, M. & 
KOPECKY, J. 2009. n-3 fatty acids and rosiglitazone improve insulin sensitivity through 
additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. 
Diabetologia, 52, 941-51. 
LARDIZABAL, K. D., MAI, J. T., WAGNER, N. W., WYRICK, A., VOELKER, T. & 
HAWKINS, D. J. 2001. DGAT2 is a new diacylglycerol acyltransferase gene family: 
purification, cloning, and expression in insect cells of two polypeptides from Mortierella 
ramanniana with diacylglycerol acyltransferase activity. J Biol Chem, 276, 38862-9. 
194 
 
LOPEZ, I. P., MARTI, A., MILAGRO, F. I., ZULET MD MDE, L., MORENO-ALIAGA, M. J., 
MARTINEZ, J. A. & DE MIGUEL, C. 2003. DNA microarray analysis of genes 
differentially expressed in diet-induced (cafeteria) obese rats. Obes Res, 11, 188-94. 
MANSON, J. E., COLDITZ, G. A., STAMPFER, M. J., WILLETT, W. C., ROSNER, B., 
MONSON, R. R., SPEIZER, F. E. & HENNEKENS, C. H. 1990. A prospective study of 
obesity and risk of coronary heart disease in women. N Engl J Med, 322, 882-9. 
MCNAMARA, R. K., ABLE, J., JANDACEK, R., RIDER, T. & TSO, P. 2009. Gender 
differences in rat erythrocyte and brain docosahexaenoic acid composition: role of 
ovarian hormones and dietary omega-3 fatty acid composition. 
Psychoneuroendocrinology, 34, 532-9. 
MISRA, A., VIKRAM, N. K., GUPTA, R., PANDEY, R. M., WASIR, J. S. & GUPTA, V. P. 
2006. Waist circumference cutoff points and action levels for Asian Indians for 
identification of abdominal obesity. Int J Obes (Lond), 30, 106-11. 
MISRA, A., WASIR, J. S. & VIKRAM, N. K. 2005. Waist circumference criteria for the 
diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic 
groups. Nutrition, 21, 969-76. 
MITCHELL, S. E., REES, W. D., HARDIE, L. J., HOGGARD, N., TADAYYON, M., ARCH, 
J. R. & TRAYHURN, P. 1997. ob gene expression and secretion of leptin following 
differentiation of rat preadipocytes to adipocytes in primary culture. Biochem Biophys 
Res Commun, 230, 360-4. 
ORIO, F., JR., PALOMBA, S., CASCELLA, T., SAVASTANO, S., LOMBARDI, G. & 
COLAO, A. 2007. Cardiovascular complications of obesity in adolescents. J Endocrinol 
Invest, 30, 70-80. 
195 
 
PARRISH, C. C., PATHY, D. A. & ANGEL, A. 1990. Dietary fish oils limit adipose tissue 
hypertrophy in rats. Metabolism, 39, 217-9. 
PAWLOSKY, R. J., HIBBELN, J. R., NOVOTNY, J. A. & SALEM, N., JR. 2001. Physiological 
compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res, 
42, 1257-65. 
PEGORIER, J. P., LE MAY, C. & GIRARD, J. 2004. Control of gene expression by fatty acids. 
J Nutr, 134, 2444S-2449S. 
PELTON, P. D., ZHOU, L., DEMAREST, K. T. & BURRIS, T. P. 1999. PPARgamma 
activation induces the expression of the adipocyte fatty acid binding protein gene in 
human monocytes. Biochem Biophys Res Commun, 261, 456-8. 
PFAFFL, M. W. 2001. A new mathematical model for relative quantification in real-time RT-
PCR. Nucleic Acids Res, 29, e45. 
RASOULI, N., MOLAVI, B., ELBEIN, S. C. & KERN, P. A. 2007. Ectopic fat accumulation 
and metabolic syndrome. Diabetes Obes Metab, 9, 1-10. 
REINEHR, T., STOFFEL-WAGNER, B. & ROTH, C. L. 2007. Adipocyte fatty acid-binding 
protein in obese children before and after weight loss. Metabolism, 56, 1735-41. 
RESELAND, J. E., HAUGEN, F., HOLLUNG, K., SOLVOLL, K., HALVORSEN, B., BRUDE, 
I. R., NENSETER, M. S., CHRISTIANSEN, E. N. & DREVON, C. A. 2001. Reduction 
of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res, 42, 743-50. 
RONCARI, D. A. & VAN, R. L. 1978. Promotion of human adipocyte precursor replication by 
17beta-estradiol in culture. J Clin Invest, 62, 503-8. 
196 
 
ROUSSEAU, V., BECKER, D. J., ONGEMBA, L. N., RAHIER, J., HENQUIN, J. C. & 
BRICHARD, S. M. 1997. Developmental and nutritional changes of ob and PPAR 
gamma 2 gene expression in rat white adipose tissue. Biochem J, 321 ( Pt 2), 451-6. 
RUZICKOVA, J., ROSSMEISL, M., PRAZAK, T., FLACHS, P., SPONAROVA, J., VECK, 
M., TVRZICKA, E., BRYHN, M. & KOPECKY, J. 2004. Omega-3 PUFA of marine 
origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids, 
39, 1177-85. 
SCHACHTRUP, C., EMMLER, T., BLECK, B., SANDQVIST, A. & SPENER, F. 2004. 
Functional analysis of peroxisome-proliferator-responsive element motifs in genes of 
fatty acid-binding proteins. Biochem J, 382, 239-45. 
SHILLABEER, G. & LAU, D. C. 1994. Regulation of new fat cell formation in rats: the role of 
dietary fats. J Lipid Res, 35, 592-600. 
SMITH, J., AL-AMRI, M., DORAIRAJ, P. & SNIDERMAN, A. 2006. The adipocyte life cycle 
hypothesis. Clin Sci (Lond), 110, 1-9. 
SNIDERMAN, A. D., CIANFLONE, K., ARNER, P., SUMMERS, L. K. & FRAYN, K. N. 
1998. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc 
Biol, 18, 147-51. 
STONE, S. J., MYERS, H. M., WATKINS, S. M., BROWN, B. E., FEINGOLD, K. R., ELIAS, 
P. M. & FARESE, R. V., JR. 2004. Lipopenia and skin barrier abnormalities in DGAT2-
deficient mice. J Biol Chem, 279, 11767-76. 
SUZUKI, R., TOBE, K., AOYAMA, M., SAKAMOTO, K., OHSUGI, M., KAMEI, N., 
NEMOTO, S., INOUE, A., ITO, Y., UCHIDA, S., HARA, K., YAMAUCHI, T., 
197 
 
KUBOTA, N., TERAUCHI, Y. & KADOWAKI, T. 2005. Expression of DGAT2 in 
white adipose tissue is regulated by central leptin action. J Biol Chem, 280, 3331-7. 
TAN, N. S., SHAW, N. S., VINCKENBOSCH, N., LIU, P., YASMIN, R., DESVERGNE, B., 
WAHLI, W. & NOY, N. 2002. Selective cooperation between fatty acid binding proteins 
and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol, 
22, 5114-27. 
UYSAL, K. T., SCHEJA, L., WIESBROCK, S. M., BONNER-WEIR, S. & HOTAMISLIGIL, 
G. S. 2000. Improved glucose and lipid metabolism in genetically obese mice lacking 
aP2. Endocrinology, 141, 3388-96. 
VAN HARMELEN, V., SKURK, T., ROHRIG, K., LEE, Y. M., HALBLEIB, M., APRATH-
HUSMANN, I. & HAUNER, H. 2003. Effect of BMI and age on adipose tissue 
cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord, 27, 
889-95. 
WALKER, C. G., BROWNING, L. M., MANDER, A. P., MADDEN, J., WEST, A. L., 
CALDER, P. C. & JEBB, S. A. 2014. Age and sex differences in the incorporation of 
EPA and DHA into plasma fractions, cells and adipose tissue in humans. Br J Nutr, 111, 
679-89. 
WEINBERG, S. L. 2004. The diet-heart hypothesis: a critique. J Am Coll Cardiol, 43, 731-3. 
WILLETT, W. C., MANSON, J. E., STAMPFER, M. J., COLDITZ, G. A., ROSNER, B., 
SPEIZER, F. E. & HENNEKENS, C. H. 1995. Weight, weight change, and coronary 
heart disease in women. Risk within the 'normal' weight range. JAMA, 273, 461-5. 
198 
 
XU, A., WANG, Y., XU, J. Y., STEJSKAL, D., TAM, S., ZHANG, J., WAT, N. M., WONG, 
W. K. & LAM, K. S. 2006. Adipocyte fatty acid-binding protein is a plasma biomarker 
closely associated with obesity and metabolic syndrome. Clin Chem, 52, 405-13. 
YU, X. X., MURRAY, S. F., PANDEY, S. K., BOOTEN, S. L., BAO, D., SONG, X. Z., 
KELLY, S., CHEN, S., MCKAY, R., MONIA, B. P. & BHANOT, S. 2005. Antisense 
oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and 
hyperlipidemia in obese mice. Hepatology, 42, 362-71. 
ZHANG, Y., GUO, K. Y., DIAZ, P. A., HEO, M. & LEIBEL, R. L. 2002. Determinants of leptin 
gene expression in fat depots of lean mice. Am J Physiol Regul Integr Comp Physiol, 282, 
R226-34. 
ZIMMERMAN, A. W. & VEERKAMP, J. H. 2002. New insights into the structure and function 
of fatty acid-binding proteins. Cell Mol Life Sci, 59, 1096-116. 
ZIMMERMANN, R., STRAUSS, J. G., HAEMMERLE, G., SCHOISWOHL, G., BIRNER-
GRUENBERGER, R., RIEDERER, M., LASS, A., NEUBERGER, G., EISENHABER, 
F., HERMETTER, A. & ZECHNER, R. 2004. Fat mobilization in adipose tissue is 
promoted by adipose triglyceride lipase. Science, 306, 1383-6. 
ZOU, C. & SHAO, J. 2008. Role of adipocytokines in obesity-associated insulin resistance. J 
Nutr Biochem, 19, 277-86. 
 
 
 
  
199 
 
 
 
 
 
CHAPTER FIVE 
 
 
The dose and age specific effects of n-3 PUFA on the accretion of 
docosahexaenoic acid in the brain and the expression of neurotrophins 
 
 
 
 
 
 
A version of this chapter is published in the Neurochemistry International 2014. (91): p. 39 
 
 
200 
 
5.1 Abstract 
N-3 PUFA and neurotrophins are pivotal to the proper functioning of the central nervous 
system.  We investigated the effects of perinatal and postweaning n-3 PUFA diets on cerebral 
cortical phospholipid fatty acid composition, and the expression of neurotrophins at weaning and 
16 weeks postweaning of the male offspring of C57BL/6 mice. Female C57BL/6 mice were fed 
semi-purified diets (20% w/w fat) containing 10% (high) and 2% (low) n-3 PUFA before mating, 
during pregnancy, and until weaning.  Offspring were studied at weaning and 16 weeks 
postweaning on their mother’s designated diet.  Cerebral cortical phospholipid fatty acids and 
mRNA expressions of BDNF, NGF, CREB, and TrkB were measured. The protein concentration 
of phosphorylated CREB (pCREB) was determined by ELISA.  DHA and total n-3 PUFA were 
significantly higher in cortical phospholipids of the high n-3 PUFA group compared to the low 
n-3 PUFA group (P<0.0001), and increased significantly from weaning to 16 weeks (P<0.0001).  
There was a significant effect of diet (P<0.05) and age (P<0.05) on the mRNA expression of 
NGF.  The mRNA expression of BDNF increased significantly (P<0.01) in the high n-3 PUFA 
group compared to the low n-3 PUFA group.  The mRNA expression of TrKB was significantly 
higher (P<0.0001) at 16 weeks in the high n-3 PUFA group compared to the low n-3 PUFA 
group; however, no difference was observed at weaning.  PCREB/Total CREB was higher in the 
high n-3 PUFA group compared to the low n-3 PUFA group (P<0.05).  Our findings demonstrate 
that perinatal and postweaning diets high in n-3 PUFA lead to accretion of n-3 PUFA in brain 
cortex.  We further found that n-3 PUFA upregulates the expression of neurotrophins and their 
target receptors in an age-dependent fashion.  
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5.2  Introduction 
There is an alarming rise in the prevalence of mental and neurological disorders, with a 
global burden surpassing cancer and CVD (Collins et al., 2011).  According to a United Nations 
report published in 2007, nearly 1 in 6 people of the global population suffer from neurological 
disorders (UN, 2007).  The causes of most neurological disorders are poorly understood, and are 
defined by numerous factors in which genetics and environment play vital roles.  Nutrition as an 
environmental factor is important in brain development and approximately 60% of the brain’s 
structural component is lipid (Crawford, 1992).  During development, there is accumulation of 
PUFA in the brain, and this represents about 15-30% dry weight of the brain (Hallahan and 
Garland, 2005).  The brain is highly enriched with PUFA of the n-6 class such as AA and n-3 
class such as DHA; 22:6n-3 (Kitajka et al., 2004).  Both n-3 and n-6 PUFA are essential fatty 
acids as the body is unable to synthesize these fatty acids de novo, thus the developing foetus 
depends on the mother’s supply (Crawford et al., 1976).  Over the past generations, there has 
been a decline in the consumption of n-3 PUFA in the Western diet (Bazan et al., 2011), and a 
concurrent increase in the burden of neurological disorders (Collins et al., 2011).  Furthermore, 
there is inadequate consumption of n-3 PUFA by pregnant women in Canada and Europe 
(Loosemore et al., 2004, Denomme et al., 2005), which could partly be responsible for the 
increasing incidence of neurological disorders.  
During development, the human brain is formed in the late period of pregnancy and early 
postnatal periods (Oppenheim, 1991).  This is the period during which DHA accumulates in the 
brain, where it functions as an important component of neuronal membrane (Clandinin et al., 
1980a).  A decrease in neuronal membrane DHA positively correlates with an increased 
predisposition to neurodegenerative disorders (Yehuda et al., 2002).  DHA has been shown to be 
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involved in neurocognition (Fedorova and Salem, 2006); studies have also revealed the 
preventive roles of DHA in diseases such as Alzheimer’s disease and multiple sclerosis 
(Georgieff, 2007).  Furthermore, both rodent and human studies support the roles of DHA in 
brain development and neurocognition (McNamara and Carlson, 2006, Luchtman and Song, 
2013). Fully differentiated neurons are incapable of mitotic division, and the final composition 
and number of neurons are determined early in development (Oppenheim, 1991).  Any alteration 
at this point could be deleterious, and may be carried throughout lifespan.  Altered brain 
development during perinatal period is consequently a high risk factor for the development of 
neurodegenerative disorders (Miller and O'Callaghan, 2008, Barlow et al., 2007, Palubinsky et 
al., 2012).  Some secretory trophic factors are involved in neurogenesis and growth, and the most 
studied of these trophic factors are neurotrophins (Barde, 1990).  Neurotrophins are pivotal to the 
proper functioning of the central nervous system (Chao et al., 2006), and are central to the 
regulation of neuronal survival, function, and synaptic plasticity (Bramham, 2008, Cohen and 
Greenberg, 2008, Reichardt, 2006).  The upregulation of neurotrophin is considered therapeutic 
for the alleviation of the symptoms of neurological disorders (Huang and Reichardt, 2001).  
BDNF and NGF are the best characterised neurotrophins, and are synthesized as their precursor 
proteins (pro-neurotrophins), which are further cleaved to release the mature neurotrophins 
(Chao et al., 2006).  BDNF is abundant in the brain and elicit its biological functions by binding 
to its high affinity receptor, TrKB, which signals the downstream activation of the transcription 
factor CREB (Bhatia et al., 2011).  Activation of CREB turns on the expression of genes 
involved in neuronal survival and plasticity.  Abnormalities in neurotrophin expression in the 
brain underlie the pathology of most neurological disorders (Chao et al., 2006, Dawbarn and 
Allen, 2003).  
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Neurotrophins have been suggested to affect brain functions differently at different stages of 
life.  Studies have shown that the mRNA and protein expressions of BDNF and NGF fluctuate at 
different stages of development, emphasizing the different regulatory roles of BDNF and NGF at 
different developmental stages (Maisonpierre et al., 1990).  BDNF is involved in neuronal 
development and survival during development by preventing the death of key peripheral, 
sensory, cholinergic, dopaminergic, and motor neurons (Ernfors et al., 1994).  In adulthood, 
BDNF plays an important role in modulating synaptic plasticity, thereby enhancing long term 
potentiation (Hu et al., 2011, Korte et al., 1995);  learning and memory (Egan et al., 2003), and 
preventing brain insults (Lindvall et al., 1994).  Studies have shown that the expression of BDNF 
and NGF decreases with age (Maisonpierre et al., 1990, Deogracias et al., 2004).  However, the 
effects of exposure to perinatal and sustained post-weaning diets varying in n-3 PUFA quantity 
on the expression of BDNF, NGF, TrKB, and CREB at different stages of life are not known.   
In the present study, we hypothesized that a perinatal and sustained postweaning diet high in 
n-3 PUFA will cause an accretion of DHA in the brain of the offspring, and consequently 
increase the mRNA expressions of BDNF, NGF, TrKB, and CREB in an age dependent fashion.  
The specific objectives were: 1) to investigate the effects of perinatal and sustained postweaning 
diets high in n-3 PUFA on cerebral cortical phospholipid fatty acid composition of the offspring 
of C57BL/6 mice at different stages of life (weaning and 16 weeks); 2) to investigate the effects 
of perinatal and sustained postweaning diets high in n-3 PUFA on the regulation of mRNA 
expression of BDNF, NGF, TrKB, and CREB at different stages of life; and 3) to investigate the 
effects of perinatal and sustained postweaning diets high in n-3 PUFA on the phosphorylation of 
CREB.  Our findings show for the first time that perinatal and postweaning diets high in n-3 
PUFA cause accretion of n-3 PUFA in the brain cortex, with a concomitant increase in the 
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expression of neurotrophins and their target receptors in an age dependent fashion.  Our data also 
suggest that n-3 PUFA regulates the expression of CREB at the post-translational level by 
phosphorylation at serine-133. 
5.3  Materials and Methods 
5.3.1.  Diets 
The diets were prepared as described in section 2.3.1.The fatty acid composition of the 
experimental diet is given in Table 2.2. 
5.3.2. Animals and experimental design 
The experimental animals were treated as described in section 2.3.2. After the period of 
acclimatization, female mice were randomly divided into two groups.  Each group was fed one 
of the two experimental diets that differed in their n-3 PUFA composition, and designated as 
“High n-3” and “Low n-3” diets, for two weeks before mating.  Female mice were continued on 
the experimental diets throughout gestation, lactation, and until weaning.  Half of the male 
offspring (n=6 per treatment group) were studied at weaning, while the rest of the male offspring 
(n=6 per treatment group) were continued on their mothers’ designated diet for 16 weeks 
postweaning.  Mice were sacrificed after an overnight fast either at weaning or after 16 weeks 
postweaning on the specified diets using isoflurane.  Tissues were collected and weighed at the 
time of sacrifice, snap frozen in liquid nitrogen and stored at -80ºC until further analyses. 
Throughout the experimental period, animals were provided with water and fresh food ad-
libitum, every other day.  All the experimental procedures were done in accordance with the 
principles and guidelines of the Canadian Council on Animal Care and were approved by 
Memorial University’s Animal Care Committee 
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5.3.3.   Fatty acid analyses of cortical phospholipids  
Total lipids were extracted from cerebral cortex using the method of Folch et al. (Folch et 
al., 1957) as per our previous publication (Chechi et al., 2010).  Cortical phospholipids were 
separated on thin layer chromatography (TLC) plates using hexane: ethyl ether: acetic acid 
(70:30:2 v/v) (Keenan MHJ, 1982, Cheema and Clandinin, 2001).  Fatty acid composition of 
total phospholipids was determined using GLC as previously described in section 2.3.4. 
5.3.4   RNA extraction and real-time qPCR    
Total RNA was extracted from cortical tissues using Trizol method (Chomczynski and 
Sacchi, 1987).  Contaminating genomic DNA was removed by treating with DNAse enzyme 
(Promega, USA).  RNA concentration was measured using Nano Drop 2000 (Thermo Scientific, 
USA).  RNA integrity was assessed using the Agilent RNA 6000 kit (Agilent Technologies, 
USA) according to the manufacturer’s instructions.  The chip was run using an Agilent 
bioanalyzer (Agilent Technologies, USA) and samples with RNA integrity number (RIN) of 9.5 
and above were used for real-time qPCR. All primers used for qPCR were designed using NCBI 
primer blast (www.ncbi.nlm.nih.gov/tools/primer-blast/) and obtained from IDT technologies 
(IA, USA); primer sequences are given in Table 5.1.  Amplification was performed using iQ 
SYBER Green Supermix (Biorad, USA).  The reactions were run in a reaction volume of 25 µl 
and 10 ng cDNA per reaction.  The delta Ct was recorded for each of the gene of interest, and 
normalized with -actin as the house keeping gene.  The expression levels between the two 
groups were compared using the Livak method (Livak and Schmittgen, 2001).   
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Table 5.1. Sequences of primers used for qPCR* 
Gene   Primers   
NGF (S) gcagtgaggtgcatagcgta 
NGF (AS) tctccttctgggacattgct 
BDNF (S) tacttcggttgcatgaaggcg 
BDNF (AS) gtcagacctctcgaacctgcc
TrKB (S) cggcacataaatttcacacg 
TrKB (AS) ttacccgtcaggatcaggtc 
CREB (S) acaatggtacggatggggta 
CREB (AS) ctgctgtccatcagtggtc 
        
 
*All primers were designed using NCBI primer blast, and obtained from IDT technologies. 
Abbreviation: S, sense primer; AS, anti-sense primer; NGF, nerve growth factor; BDNF, brain 
derived neurotropic factor; TrKB, tropomyosin receptor kinase; CREB, cAMP response element 
binding protein   
5.3.5. Measurement of CREB protein concentration 
Cortex samples were homogenized in an extraction buffer containing: 10 mM Tris, pH 7.4, 
100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% 
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM PMSF, and protease inhibitor 
cocktail (Sigma, CA).  Total protein concentration of the lysate was measured using the 
bicinchoninic acids BCA protein assay (Bradford, 1976), with bovine serum albumin as 
standards.  Total CREB and pCREB) protein concentrations were measured using ELISA kits 
(Invitrogen, USA) according to the manufacturer’s instructions.  The intensity of the colored 
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product was measured at 450 nm using PowerWave XS microplate reader (Biotek, USA).  One 
unit of standard is equivalent to the amount of pCREB derived from 80 pg of CREB that was 
phosphorylated by protein kinase A.  Values of pCREB (Units/mL) were normalized for total 
CREB (ng/mL) content, and results are presented as ratios of pCREB to total CREB 
(pCREB/Total CREB).  
5.3.6. Statistical Analysis 
Data were analysed using IBM SPSS Statistics (version 20.0).  Means were compared using 
two way analysis of variance (ANOVA) to determine main effects of diet and age. Pairwise 
comparisons were performed using Bonferrroni correction to determine differences among the 
four groups when there was an observed interaction between diet and age.  Results are expressed 
as mean ± standard deviation (SD).  Pearson’s correlation was used to compare the relationship 
between cortical phospholipid DHA composition and gene or protein expression levels.  Cortical 
phospholipid fatty acid compositions were expressed as weight percentage of the total extracted 
fatty acids; fatty acid composition data were then arcsine transformed before subjecting to 
statistical analysis.  Differences were considered to be statistically significant if the associated P 
value was < 0.05.   
5.4  Results 
5.4.1. Effects of a diet high in n-3 PUFA on cortical phospholipid fatty acid composition of the 
offspring at weaning and 16 weeks postweaning 
The cortical phospholipid fatty acid composition of the male offspring at weaning and 16 
weeks are presented in Table 5.2.  Diet had no significant effect on individual and total SFA; 
however, cortical myristic acid (C14:0), palmitic acid (C16:0), and total SFA were significantly 
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reduced from weaning to 16 weeks (P<0.001).  There was no independent effect of diet on total 
MUFA at weaning or 16 weeks between the two diet groups; however there was a significant 
interaction between diet and age (P<0.01), with age causing an increase from weaning to 16 
weeks (P<0.0001).  Oleic acid (C18:1n9) also revealed a significant interaction between diet and 
age similar to total MUFA (P<0.01), and showed an increase from weaning to 16 weeks 
(P<0.0001).  
There was a significant interaction between diet and age for LA (P<0.05).  Furthermore, the 
high n-3 PUFA group showed a significant decrease in cortical phospholipid LA (P<0.01) 
compared to the low n-3 PUFA group at 16 weeks.  There was a significant independent effect of 
diet (P<0.01), and age (P<0.01) on cortical AA, adrenic acid (C22:4n6; ADA), and total n-6 
PUFA. There was also a significant reduction of AA (P<0.001), ADA (P<0.01), and total n-6 
PUFA (P<0.001) from weaning to 16 weeks.  Moreover, the high n-3 PUFA group showed a 
significant decrease in cortical AA (P<0.01), ADA (P<0.0001), and total n-6 PUFA (P<0.0001) 
compared to the low n-3 PUFA group. 
There was a significant independent effect of diet and age on cortical phospholipid 
individual and total n-3 PUFA (P<0.05).  DHA and total n-3 PUFA significantly increased from 
weaning to 16 weeks (P<0.0001).  Exposure to high perinatal and postweaning n-3 PUFA caused 
an accretion of DHA in the offspring cortical phospholipids (P<0.0001).  There was also a 
significant increase in total cortical phospholipid DHA in the high n-3 PUFA group compared to 
the low n-3 PUFA (P<0.0001).  Interestingly, EPA was not detected in the offspring cortex in 
both dietary groups at weaning, however, the offspring in the high n-3 PUFA group had a 
significantly higher concentration of EPA (P<0.01), and docosapentaenoic acid (22:5n3; DPA) 
(P<0.01) at 16 weeks, compared to the low n-3 PUFA group.  
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Table 5.2. Effects of a diet high or low in n-3 PUFA on the cortical phospholipids fatty acid 
composition of male offspring at weaning and 16 weeks postweaning* 
Fatty Acids 
  
Weaning    I6 Weeks Main effect 
   High n-3 Low n-3    High n-3 Low n-3    Diet Age Diet*Age 
C14:0  0.54±0.09 0.44±0.06 0.20±0.023 0.24±0.09 NS P<0.0001 P<0.01 
C16:0 25.49±1.26 24.5±0.82 22.77±1.47 22.77±0.61 NS P<0.0001 NS 
C18:0 23.5±0.76 24.2±0.46 24.05±0.85 24.82±1.27 NS NS NS 
∑ SFA 49.54±0.99 49.05±0.84 47.02±2.09 47.84±1.29 NS P<0.001 NS 
C16:1n7 0.56±0.09 0.51±0.04 0.5±0.03 0.50±0.05 NS NS NS 
C18:1n9 11.82±0.44 12.34±0.57 15.79±1.48a 14.26±0.69b NS P<0.0001 P<0.01 
C18:1n7 2.58±0.15 2.76±0.16 2.91±1.8 3.04±0.16 P<0.01 P<0.0001 NS 
C20:1n9 0.38±0.09 0.47±0.19 1.14±0.48 1.01±0.2 NS P<0.0001 NS 
∑ MUFA 15.34±0.57 16.08±0.86 20.34±1.98 18.81±0.93 NS P<0.0001 P<0.01 
C18:2n6 1.18±0.15 1.18±0.05 0.84±0.23a 1.18±0.2b P<0.05 P<0.05 P<0.05 
C20:4n6 12.69±0.76 13.80±0.76 9.29±1.27 10.58±0.1 P<0.01 P<0.0001 NS 
C22:4n6 2.61±0.17 3.42±0.22 2.28±0.27 3.10±0.38 P<0.0001 P<0.01 NS 
∑ Omega-6 16.48±0.81 18.4±0.95 12.41±1.56 14.86±1.13 P<0.0001 P<0.0001 NS 
C18:4n3 ND  ND  0.08±0.04 0.06±0.04 
C20:5n3 ND ND 0.11±0.07a 0.06±0.05b 
C22:5n3 0.78±0.51 0.54±0.34 0.51±0.11 0.10±0.06 P<0.05 P<0.05 NS 
C22:6n3 17.87±1.1 15.98±0.56 19.52±0.83 18.28±0.1 P<0.0001 P<0.0001 NS 
∑ Omega-3 18.65±0.93 16.51±0.55 20.22±0.91 18.5±1.02 P<0.0001 P<0.0001 NS 
                                
*Data are expressed as weight percentage of the total extracted fatty acids.  Values are 
expressed as mean  SD, n = 6.  Main effects and interactions were determined by two-way 
ANOVA after arcsine transformation.  Within a row, statistically significant values are marked 
with unlike superscripts when a significant interaction was observed (P < 0.05).  Σ SFA= sum of 
saturated fatty acids; Σ MUFA= sum of monounsaturated fatty acids; Σ PUFA= sum of 
polyunsaturated fatty acids; Σ Omega-6= sum of omega-6 polyunsaturated fatty acids; Σ 
Omega-3= sum of omega-3 polyunsaturated fatty acids, ND = Not detected 
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5.4.2 Effects of a diet high or low in n-3 PUFA on cortical mRNA expressions of BDNF, 
TrKB and NGF of the offspring at weaning and 16 weeks postweaning 
The effects of perinatal and sustained postweaning diets high in n-3 PUFA on cortical 
mRNA expressions of NGF, BDNF and TrKB were assessed using real time qPCR analyses.  
There was an independent significant effect of diet (P<0.05) and age (P<0.01) on the mRNA 
expression of NGF.  The mRNA expression of NGF reduced significantly from weaning to 16 
weeks (P<0.01; Figure 5.1A).  On the other hand, a diet high in n-3 PUFA significantly 
increased the mRNA expression of NGF (P<0.05; Figure 5.1A) compared to the low n-3 PUFA 
diet.  Furthermore, there was a significant positive correlation between NGF mRNA expression 
and cortical phospholipid DHA at weaning (r=0.95; P<0.0001; Figure 5.1B); however, no 
significant correlation was observed at 16 weeks (Figure 5.1C).   
BDNF mRNA expression was not altered with age (Figure 5.2A); however there was a 
significant effect of diet (P<0.01; Figure 5.2A).  Diet high in n-3 PUFA significantly increased 
the mRNA expression of BDNF compared to the low n-3 PUFA diet (P<0.01; Figure 5.2A).  
Furthermore, there was a positive correlation between BDNF mRNA expression and cortical 
phospholipids DHA at 16 weeks (r=0.83, P=0.0009; Figure 5.2C) and at weaning (r=0.83, 
P=0.0017; Figure 5.2B).  
A significant interaction was observed between diet and age on the mRNA expression of 
TrKB (P<0.01; Figure 5.3A).  There was a significant increase in the mRNA expression of TrKB 
from weaning to 16 weeks in the high n-3 PUFA group (P<0.01; Figure 5.3A).  However, diet 
had no effect on the mRNA expression of TrKB at weaning (Figure 5.3A), whereas TrKB 
mRNA expression was significantly higher in the high n-3 PUFA group at 16 weeks compared to 
the low n-3 PUFA group (P<0.001; Figure 5.3A).   
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Figure 5.1. Effects of a diet high or low in n-3 PUFA on the mRNA expression of nerve 
growth factor (NGF) in male offspring at weaning and 16 weeks postweaning: The data 
represent male cortical mRNA expression of NGF at weaning and 16 weeks (A) normalized with 
β-actin as the house-keeping gene, and Pearson’s correlation analyses between the mRNA 
expression of NGF and cortical phospholipid DHA at weaning (B) and 16 weeks postweaning 
(C).  Main effects and interactions were determined by two-way ANOVA.  There was an 
independent effect of diet (P < 0.05) and age (P < 0.001).  Data are presented as mean (n=6) ± 
SD. 
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Figure 5.2. Effects of a diet high or low in n-3 PUFA on the mRNA expression of brain 
derived neurotropic factor (BDNF) in male offspring at weaning and 16 weeks postweaning: 
The data represent male cortical mRNA expression of BDNF at weaning and 16 weeks (A) 
normalized with β-actin as the house-keeping gene, and Pearson’s correlation analyses between 
the mRNA expression of BDNF and cortical phospholipid DHA at weaning (B) and 16 weeks 
postweaning (C).  Main effects and interactions were determined by two-way ANOVA.  There 
was an independent effect of diet (P < 0.01).  Data are presented as mean (n=6) ± SD. 
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Figure 5.3. Effects of a diet high or low in n-3 PUFA on the mRNA expression of tropomyosin 
receptor kinase (TrKB) in male offspring at weaning and 16 weeks postweaning: The data 
represent male cortical mRNA expression of TrKB at weaning and 16 weeks postweaning (A) 
normalized with β-actin as the house-keeping gene; and Pearson’s correlation analyses between 
the mRNA expression of TrKB and cortical phospholipid DHA at weaning (B) and 16 weeks (C).  
Main effects and interactions were determined by two-way ANOVA.  Pairwise comparisons were 
performed using Bonferrroni correction to determine differences among the four groups; data 
are presented as mean (n=6) ± SD **P<0.05. 
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There was a positive correlation between TrKB mRNA expression and cortical phospholipids 
DHA at weaning (r=0.58, P=0.049; Figure 5.3B), and 16 weeks (r=0.86, P=0.0004; Figure 
5.3C). 
5.4.3. Effects of a diet high or low in n-3 PUFA on cortical CREB in offspring at weaning and 
16 weeks postweaning 
CREB has been shown to be activated by phosphorylation, thus the protein expressions of total 
CREB and CREB phosphorylated at Ser-133 (pCREB) were measured to investigate the effects 
of n-3 PUFA.  There was a significant effect of diet on the relative expression of pCREB to total 
CREB (pCREB/Total CREB) (P<0.01; Figure 5.4B); however, age had no effect. 
Phosphorylated CREB/Total CREB was significantly higher in the high n-3 PUFA group 
compared to the low n-3 PUFA (P<0.05; Figure 5.4B).  There was also a positive correlation 
between pCREB/Total CREB and cortical phospholipids DHA at weaning (r=0.88, P=0.0001; 
Figure 5.4C) and 16 weeks (r=0.83, P=0.0013; Figure 5.4D).   
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Figure 5.4. Effects of a diet high or low in n-3 PUFA on the expression of cAMP response 
element binding protein (CREB) in male offspring at weaning and 16 weeks postweaning: The 
data represent male cortical mRNA expression of CREB normalized with β-actin as the house-
keeping gene at weaning and 16 weeks (A), male phosphorylated CREB (pCREB) protein 
concentration normalized for total CREB (pCREB/Total CREB) at weaning and 16 weeks (B), 
and Pearson’s correlation analyses between the pCREB/Total CREB and cortical phospholipid 
DHA at weaning (C) and 16 weeks (D). Main effects and interactions were determined by two-
way ANOVA. There was an independent effect of diet (P < 0.01) on pCREB/Total CREB.    Data 
are presented as mean (n=6) ± SD. 
 
W
ean
ing
16
 w
eek
s
0
1
2
3
High n-3
Low n-3
A
CR
EB
 m
RN
A
 ex
pr
es
sio
n
W
ean
ing
16
 w
eek
s
0.00
0.01
0.02
0.03
0.04
High n-3
Low n-3
B
pC
RE
B/
To
ta
l C
RE
B
Diet: P < 0.01
14 16 18 20 22
0.00
0.01
0.02
0.03
C
r =  0.88
P = 0.0001
High n-3
Low n-3
Cortical Phospholipid DHA
pC
RE
B/
To
ta
l C
RE
B
14 16 18 20 22
0.00
0.01
0.02
0.03
0.04
D
r = 0.83
P = 0.0013
High n-3
Low n-3
Cortical Phospholipid DHA
pC
RE
B/
To
ta
l C
RE
B
216 
 
5.5 Discussion 
The effects of n-3 PUFA on the regulation of neurotrophins during early and later stages of 
life are not clear.  During development, there is rapid incorporation of n-3 PUFA into brain 
phospholipids where they play important roles in neurodevelopment and cognition (Clandinin et 
al., 1980b, Hoffman et al., 1993).  We investigated the effects of perinatal and sustained 
postweaning diets high in n-3 PUFA on accretion of DHA in the brain of the offspring, and the 
regulation of mRNA expressions of BDNF, NGF, TrKB, and CREB.  We report for the first time 
an age- and diet-dependent accretion of DHA in the brain.  Our findings also show an age and 
diet dependent regulation of neurotrophins.  The brain’s architecture is built on lipids, and 
approximately 35% of the brain’s structural component is PUFA primarily AA and DHA (Haag, 
2003, Wainwright, 2002). There is high foetal accretion of AA and DHA during the third 
trimester and early postnatal period, which represents the stages of rapid brain development 
(Arbuckle and Innis, 1992, Wainwright, 2002). We observed no effect of diet on total SFA and 
MUFA at weaning and 16 weeks; however there was an age-dependent decrease in SFA, while 
MUFA increased with age from weaning to 16 weeks. This is an interesting finding being 
reported for the first time.  Our observations suggest an increase in desaturation and elongation 
pathways with age to convert SFA into MUFA; however the rationale for this is not clear and 
needs further investigation.   
There was an independent effect of diet and age on cortical phospholipid n-6 PUFA. The 
high n-3 PUFA treatment caused a decrease in total n-6 PUFA compared to the low n-3 PUFA 
group.  Amongst individual n-6 PUFA, cortical phospholipid LA composition was not different 
at weaning between high and low n-3 PUFA dietary groups.  Moreover, there was no change in 
the levels of LA from weaning to 16 weeks in animals fed a low n-3 PUFA diet.  Suganuma et al 
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(Suganuma et al., 2010) also reported similar observations where neonatal rats in the control and 
n-3 PUFA groups showed no statistical significant difference in brain phospholipid LA 
composition.  The high n-3 PUFA diet however caused a decrease in AA and ADA in high n-3 
PUFA diet group compared to the low n-3 PUFA diet group.  Desaturation of LA to AA has 
been shown to be greatly reduced during ageing process in mouse brain (Horrobin, 1981, Bourre 
et al., 1990, Cook, 1991). Studies have also shown that in adult rat, the desaturation and 
elongation of LA to AA is greatly reduced (DeMar et al., 2006).  Reduced incorporation of AA 
into brain phospholipids has also been suggested to be due to an increase in the expression of 
phospholipase A2 (Terracina et al., 1992).  Our findings to show a decrease in AA and no 
changes in LA suggest that there is a decrease in elongation and desaturation process, or an 
increase in the expression of phospholipase A2 with ageing.   
A decrease in brain n-6 PUFA has been shown to be compensated by an increase in brain 
DHA (Wainwright et al., 1991).  DHA is important in brain development and accumulate during 
perinatal period, which is around the last three days of gestation in rodents such as rats, and the 
third trimester in humans (Clandinin et al., 1980a, Clandinin et al., 1980b, Green and Yavin, 
1996).  Accretion of DHA in brain phospholipids plays a vital role in enhancing neuronal 
membrane fluidity, and an abnormal deficiency of neuronal membrane DHA could lead to 
irregularities in cellular signalling (Marteinsdottir et al., 1998, Zimmer et al., 2000).  The high n-
3 PUFA treatment caused an increase in total n-3 PUFA compared to the low n-3 PUFA group.  
Amongst n-3 PUFA, there was a higher accretion of DHA in the high n-3 PUFA group.  Similar 
observations were reported by Bhatia et al (Bhatia et al., 2011) after feeding rat pups for 15 
weeks on high n-3 PUFA diet, and Suganuma et al, in neonatal rat pups (Suganuma et al., 2010).  
Our findings to show an increase in DHA, and a concomitant decrease in AA on a high n-3 
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PUFA diet supports that an increase in brain DHA is compensated by a decrease in brain AA 
(Wainwright et al., 1991).  The concentration of EPA was not detectable at weaning in both 
dietary groups; however, the high-3 PUFA group had a significantly higher cortical EPA 
concentration compared to the low n-3 PUFA group at 16 weeks.  Compared to other PUFA, the 
cortical concentration of EPA was low, which is similar to the findings, reported by others 
(Brenna and Diau, 2007, Diau et al., 2005).  A plausible explanation for lower levels of EPA is 
rapid conversion of EPA to longer chain DHA, or a quick metabolism through β-oxidation in the 
brain (Chen et al., 2013).  
The incorporation of n-3 and n-6 PUFA, such as DHA and AA, are important in neuronal 
growth and function (Yehuda et al., 2002), and play a critical role in neuronal signalling 
pathways (Yehuda et al., 2002) regulated by neurotrophins.  The high n-3 PUFA treatment 
caused an increase in the mRNA expression of NGF compared to the low n-3 PUFA group. 
Interestingly, there was a decrease in the mRNA expression of NGF from weaning to 16 weeks 
in mice.  There is only one other report to date that show a decrease in the protein expression of 
NGF with age (Katoh-Semba et al., 1998).  NGF promotes survival and prevents neuronal 
apoptosis (Chen et al., 1997), and is also important in the functioning of cholinergic neurons vital 
for memory functions (Chen et al., 1997).  Consistent with the health benefits of n-3 PUFA, NGF 
has been shown to alleviate the symptoms of neurodegenerative disorders such as Alzheimer’s 
disease (Chao et al., 2006), and an improvement of the impairment of memory function 
associated with the pathology of  Alzheimer’s diseases.  Our NGF data reaffirm the 
neuroprotective benefits of n-3 PUFA, and offers a platform for further investigative studies on 
the mechanisms involved in the regulation of the expression of NGF by n-3 PUFA at different 
developmental stages.  
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BDNF plays a major role in the regulation of synaptic plasticity, neuronal survival, and 
differentiation in the nervous system (Lewin and Barde, 1996, Huang and Reichardt, 2001).  
Abnormalities in the synthesis and release of BDNF are potential culprits for development of 
neurological disorders (Rehn and Rees, 2005).  Interestingly, the cortical mRNA expression of 
BDNF was higher in the high n-3 PUFA group compared to the low n-3 PUFA; however, age 
had no effect on the mRNA expression of BDNF.  Bhatia et al reported a similar observation 
where a high n-3 PUFA diet caused an increase in the protein expression of BDNF in the 
hypothalamus and hippocampus when male rat offspring of dams fed high n-3 PUFA diet during 
gestation and lactation were weaned on their mother’s diet for 15 weeks postweaning (Bhatia et 
al., 2011).  However, Bhatia et al did not measure BDNF expression of the offspring at weaning; 
thus our findings compared for the first time the effect of age on the mRNA expression of 
BNDF. The expression of BDNF has been shown to be both basal and activity dependent 
(Bramham and Messaoudi, 2005, Poo, 2001, Thoenen, 1995), which control the permissive and 
instructive roles of BDNF respectively.  Furthermore, BDNF functions differently during 
development and adulthood.  During development, BDNF is involved in axonal path-finding (Hu 
et al., 2005), neuronal survival (Ernfors et al., 1994), and the growth of inhibitory synapses 
(Hong et al., 2008).  On the other hand, in adulthood, BDNF plays critical role in synaptic 
plasticity (Hu et al., 2011), memory (Egan et al., 2003), and neuroprotection (Saylor and 
McGinty, 2008).  The exhibition of different functionality by BDNF at different stages of life 
could very much call for a different regulatory control at different stages of life.  There was a 
positive correlation between cortical mRNA expression of BDNF and cortical phospholipid 
DHA composition reinforcing the importance of DHA in regulating BDNF.  
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BDNF exerts its biological function by binding to its high affinity receptor TrKB (Huang 
and Reichardt, 2001).  The interaction between BDNF and TrKB leads to the phosphorylation of 
TrKB, and a consequent stimulation of downstream signalling cascades vital to the activities of 
BDNF (Hashimoto et al., 2005, Numakawa et al., 2010).  We report for the first time an 
interaction between high n-3 PUFA diet and age in the mRNA expression of TrKB.  The mRNA 
expression of TrKB increased significantly with sustained dietary exposure to high n-3 PUFA 
from weaning to 16 weeks.  There was no difference in cortical mRNA expression of TrKB 
between the two dietary groups at weaning; however, there was a significant increase in the 
cortical mRNA expression of TrKB in the high n-3 PUFA group compared to the low n-3 PUFA 
group at 16 weeks.  This is consistent with the mRNA expression of BDNF, indicating a 
regulatory relationship between BDNF and TrKB.  It has been shown that BDNF rapidly 
upregulates the surface expression of TrKB in hippocampal neurons (Haapasalo et al., 2002), 
which supports our observation of a concomitant increase in BDNF and TrKB.  Bhatia et al also 
found that feeding a high n-3 PUFA diet to rats for 15 weeks postweaning increased the protein 
expression of TrKB in the brain (Bhatia et al., 2011).  However, these authors did not measure 
the regulation of TrKB at different stages of life.  We found a positive relationship between the 
mRNA expression of TrKB and cortical phospholipid DHA both at weaning and at 16 weeks, 
reinforcing the role of DHA in regulating TrKB.    
The BDNF/TrKB complex stimulates the activation of downstream transcription factor 
CREB (Bhatia et al., 2011), which is vital to the nervous system (Lonze and Ginty, 2002).  
CREB’s target genes includes BDNF (Nibuya et al., 1996, Finkbeiner et al., 1997), and other key 
genes involved in neuronal survival (Bonni et al., 1999), neuroprotection (Deak et al., 1998), 
addiction (McClung and Nestler, 2003), learning and memory (Alberini, 2009), circadian rhythm 
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(Kornhauser et al., 1996), and many others.  We found no effects of diet and age on the mRNA 
expression of CREB between the two diet groups.  CREB protein is activated by post-
translational modification by phosphorylation at serine-133 (Gonzalez and Montminy, 1989); 
and this activation is needed to activate its downstream targets including BDNF (Finkbeiner et 
al., 1997).  We found a significant effect of diet on the phosphorylation of CREB, with the high 
n-3 PUFA group showing an increase in pCREB/Total CREB compared to the low n-3 PUFA 
group.  However, age had no effect on the phosphorylation of CREB, which is consistent with 
our BDNF data.  This is a novel finding suggesting the possible regulatory effects of CREB by n-
3 PUFA at the post-translational level.  Although we found no effect of diet on the mRNA 
expression of CREB, there was a significant increase in pCREB/Total CREB suggesting that n-3 
PUFA regulates CREB at the post-translational level.  It is possible that n-3 PUFA directly 
regulate one or more of the kinases responsible for the phosphorylation of CREB.  Furthermore, 
the expression of TrkB in neurons has been shown to be regulated by CREB (Deogracias et al., 
2004), and CREB is activated by downstream signalling of TrKB (Kaplan and Miller, 2000).  
The activation of CREB by increased expression of TrKB could be a potential mechanism by 
which n-3 PUFA regulates neurotrophin signalling.  The potential mechanisms by which DHA 
regulates neurotrophin signalling are depicted in Figure 5.     
In conclusion, we report for the first time that the metabolism of n-3 and n-6 PUFA in the 
brain is influenced by age and diets varying in n-3 PUFA quantity.  Furthermore, our findings 
demonstrate an age and dietary n-3 PUFA dependent regulation of BDNF, TrKB, and NGF, and 
suggest that n-3 PUFA regulates the expression of CREB at post-translational level.  Our 
findings also established that longer exposure to n-3 PUFA is important in regulating 
neurotrophin levels. Neurotrophins are important during foetal development and in adulthood 
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(Huang and Reichardt, 2001), and a deficiency in their secretion have been implicated in the 
pathogenesis of most neurological disorders (Chao et al., 2006).  Maintaining the levels of 
neurotrophins throughout life span will be important to prevent neurological disorders, thereby 
highlighting the importance of dietary n-3 PUFA. 
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6.1 Summary and conclusions 
CVD is ranked as the number one cause of death worldwide and accounts for 50% of all 
mortality in North America (Holub, 2009).  The causes of CVD are defined by the interplay 
between genetics and environmental factors; this interplay contributes to the complexity of the 
pathophysiology of CVD. The risk of development of CVD increases with age (Gupta et al., 
2009), and research evidence suggests that sex also play a vital role in the development of CVD.  
It has been reported that men and women differ significantly in their circulating blood lipids 
(Johnson et al., 2004).  In spite of the advancement in medical science and drug discovery, the 
prevalence of CVD is still on the rise. The most important environmental factor in the 
pathogenesis of CVD is nutrition, especially the role of dietary fats. There are numerous reports 
supporting the cardioprotective effects of n-3 PUFA; however, there are also controversial 
reports. Given the complexity and physiological variation of the human population, it is pertinent 
to consider the various factors that could potentially affect the metabolism and hence the health 
benefits of n-3 PUFA before a strong recommendation can be made.  
The main objective of the current thesis was to investigate the effects of n-3 PUFA on the 
risk factors of CVD such as dyslipidaemia and obesity with particular focus on how sex, age and 
dose of n-3 PUFA affect lipid and lipoprotein metabolism. The thesis investigated the 
mechanisms by which n-3 PUFA could potentially prevent obesity by reducing adipocyte 
hypertrophy and how sex influences this process, in addition to how the sex-, age- and dose-
dependent effects of n-3 PUFA affect plasma lipid and lipoprotein concentrations.  Furthermore, 
the effects of n-3 PUFA on the accretion of DHA in the brain and the signalling of neurotrophins 
during development and adult stages were studied. The findings from the current thesis 
demonstrate a sex-specific effect of n-3 PUFA on the risk factors of CVD, and further suggest 
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novel regulatory pathways by which n-3 PUFA could reduce dyslipidaemia and obesity.  
Furthermore, results from this thesis demonstrate the importance of long term exposure to high 
n-3 PUFA on the accretion of DHA levels in the brain, and the regulation of neurotrophins.  
Finally, the findings provide clues for the propensity of n-3 PUFA to be neuroprotective and 
cardioprotective through a common neurotrophin signalling pathway.  
6.1.1 Key observations 
1. Perinatal exposure to high dietary n-3 PUFA had no significant effect on the offspring’s 
plasma NEFA and TG at weaning, however, after sustained exposure of the offspring to 
high n-3 PUFA diet for 16 weeks postweaning, there was a significant reduction in 
plasma NEFA and TG in both male and female offspring. Based on this observation, it 
was concluded that in addition to high amount of n-3 PUFA, a longer exposure to 
postnatal diet high in n-3 PUFA is required to observe a significant lipid lowering effect 
(Chapter 2).       
2. A longer exposure to postnatal diet high in n-3 PUFA increased plasma concentration of 
LDL-c in both male and female offspring. Interestingly, the medium n-3 PUFA diet 
showed the lowest levels of plasma LDL-c concentration in the female offspring, 
demonstrating a sex-dependent effect of n-3 PUFA on LDL-c metabolism. It was also 
observed that high n-3 PUFA diet reduced the circulating concentration of atherogenic 
very small LDL particles in both male and females. As the effect of n-3 PUFA on plasma 
LDL-c remains controversial, our findings show that a longer exposure to high n-3 PUFA 
increased the plasma concentration of LDL-c; however, this increase was towards a less 
atherogenic phenotype of LDL particles (Chapter 2).   
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3. No pronounced effect of high dietary n-3 PUFA was observed on the plasma 
concentration of HDL-c; however, plasma samples from mice fed the high n-3 PUFA diet 
caused a higher cholesterol efflux in the male offspring compared to the low n-3 PUFA 
group.  This effect was not observed in female mice, suggesting an effect of sex in n-3 
PUFA mediated cholesterol efflux. It was thus concluded that n-3 PUFA influences 
reverse cholesterol transport not by increasing HDL concentration, but by enhancing the 
functionality of HDL, and that the effect is sex specific (Chapter 2).    
4. A diet high in n-3 PUFA altered the plasma and liver lipidomic profile.  N-3 PUFA was 
preferentially incorporated into PC and LPC; despite the changes in lipidomic profile, the 
total concentrations of these lipids were not altered.  Additionally, dietary n-3 PUFA was 
capable of remodelling the fatty acyl moieties of PC, LPC, and CE, which may have 
important physiological   implications. It was thus concluded that the health benefits of n-
3 PUFA are due to alterations in the fatty acid composition of bioactive lipids, without 
necessarily changing the total concentration of specific lipid classes (Chapter 3).  
5. A diet high in n-3 PUFA reduced adipocyte area in males, with no effect observed in the 
females. The females had smaller adipocyte area compared to male mice in response to 
high n-3 PUFA, suggestive of an effect of sex. High n-3 PUFA diet caused 
downregulation of the mRNA expression of DGAT2, FABP4, PPARγ and leptin in 
males, however no effect was observed in females, which was similar to the data for the 
adipocyte area. These observations show that feeding high dietary n-3 PUFA could 
prevent obesity by reducing the mRNA expression of critical genes involved in adipocyte 
hypertrophy. (Chapter 4).  
238 
 
6. Perinatal diet high in n-3 PUFA caused an accretion of DHA in the brain cortex of the 
male offspring at weaning, and continuous exposure to high n-3 PUFA further increased 
the accretion of DHA into the brain cortex. Furthermore, it was observed that dietary n-3 
PUFA-dependent regulation of BDNF, TrKB, and NGF was age-dependent, and n-3 
PUFA regulates the expression of CREB at post-translational level.    It was thus 
concluded that n-3 PUFA regulate neurotrophin signalling by increasing the 
phosphorylation of CREB (Chapter 5).  
6.2 Implications and future directions 
The series of studies presented in the current thesis support the protective effects of highly 
unsaturated n-3 PUFA in the prevention of dyslipidaemia, a well-known risk factor of CVD; 
however, the effects are sex-dependent. Judging by the counterintuitive effect of n-3 PUFA on 
plasma TC and LDL-c in female mice presented in chapter 2, it is obvious that the effect of n-3 
PUFA on cholesterol metabolism is counteracted by a sex specific component which is likely 
oestrogen. It is believed that endogenous oestrogen protects females from cardiovascular 
diseases (Mendelsohn and Karas, 1999).  This finding has been corroborated by the fact that 
women are more prone to develop CVD after menopause or surgical removal of the ovaries 
(Colditz et al., 1987). Clinical and laboratory findings have shown that there is a regulatory 
relationship between PPARα and oestrogen receptor (ER), and this relationship is influenced by 
n-3 PUFA and oestrogen (Souidi et al., 1999, Wang and Kilgore, 2002). Before a solid 
conclusion can be made on the effect of n-3 PUFA on circulating concentration of cholesterol, it 
will be important to control for the effect of oestrogen. Future studies could look more closely to 
characterise in detail, the crosstalk between n-3 PUFA and oestrogen with regards to lipid and 
lipoprotein metabolism. Regardless of the sex-specific effect of n-3 PUFA on the plasma 
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concentration of LDL-c, the concentration of atherogenic very small LDL particle was reduced 
in response to high dietary n-3 PUFA in both male and female mice. 
Increasing the concentration of HDL appears to be one of the most attractive 
pharmacotherapeutic options of preventing CVD because of its role in reverse cholesterol 
transport. However, the HDL concentration hypothesis in the alleviation of CVD has been 
greatly challenged with conflicting data, and attempts to increase HDL concentration have not 
always yielded positive cardioprotective effects (Tardif et al., 2014, Degoma and Rader, 2011). It 
is thus imperative to look to new mechanisms to enhance the functionality of HDL. Interestingly, 
high n-3 PUFA diet did not increase the concentration of plasma HDL-c in both male and female 
mice in our study. We however observed an increase in macrophage cholesterol efflux in 
response to plasma samples from the high n-3 PUFA groups in male mice; no effect on 
cholesterol efflux was observed in females. I can thus safely speculate that n-3 PUFA increases 
cholesterol efflux; however, I cannot say unequivocally that this increase in cholesterol efflux 
was due to the improvement of the functionality of the HDL, as I used plasma samples from the 
different dietary groups as our acceptor, which are known to contain other apolipoproteins and 
proteins capable of influencing cholesterol efflux. Future studies could investigate the cholesterol 
efflux capacity of HDL isolated from plasma after n-3 PUFA treatment. This will give direct 
information on the influence of n-3 PUFA on the functionality of HDL. The size of HDL 
particles and concentration of APO-A1 could also influence cholesterol efflux capacity; however 
we found no effect of high dietary n-3 PUFA on the particle size of HDL and plasma 
concentration of APO-A1. Furthermore, proteins such as ABCA-1, LCAT, SR-B1 involved in 
reverse cholesterol transport can influence cholesterol efflux; however, I found no effect of high 
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n-3 PUFA diet on the hepatic mRNA expression of these proteins. It is thus imperative to 
explore other possible mechanisms by which n-3 PUFA could influence cholesterol efflux.  
LPC has been shown to promote cholesterol efflux from macrophages (Hara et al., 1997). 
Although the mechanism involved is unclear, it has been suggested that LPC promote cholesterol 
efflux through its association with HDL-associated paraoxonase 1(PON1) (Rosenblat et al., 
2006). An increase in HDL-LPC production increases the binding of HDL to macrophages 
thereby stimulating cholesterol efflux. My results in chapter 3 show that high n-3 PUFA diet is 
capable of remodelling the fatty acid structure of LPC to contain more n-3 PUFA in plasma and 
liver. I speculate that LPC containing DHA or EPA is atheroprotective by stimulating an increase 
in cholesterol efflux. Figure 6.1 summarizes the potential of n-3 PUFA enriched LPC to act as an 
anti-atherogenic molecule.  Overall, there is plenty of evidence that enrichment of membrane n-3 
PUFA content has the ability to modify metabolic and physiological functions, thereby inducing 
cardioprotective effects. Future studies could explore the effect of n-3 PUFA on the fatty acid 
composition of HDL associated phospholipids and the effect on cholesterol efflux. Furthermore, 
in vitro mechanistic studies could be designed to investigate the effect of LPC with different 
fatty acid moieties on macrophage cholesterol efflux, and LPC fatty acid composition could then 
be used as a potential biomarker of CVD risk. 
Obesity is central to the development of CVD. My study reports a sex-specific effect of n-3 
PUFA on the cellular events that lead to obesity, by preventing adipocyte hypertrophy through 
the downregulation of DGAT2 and FABP4 in male mice. My findings suggest that targeting the 
expression of FABP4 by n-3 PUFA may be a mechanism to prevent adipocyte hypertrophy and 
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Figure 6.1: Potential atheroprotective mechanisms of n-3 PUFA enriched 
lysophosphatidylcholine (LPC) 
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diet-induced obesity.  Although I did not measure markers of T2D, ectopic fat deposition and 
adipose tissue dysfunction are common in obese individuals; I can infer from the plasma lipid 
and liproprotein data in chapter 4, that the dyslipidaemia associated with obesity is reduced by 
the administration of high n-3 PUFA diet. Body composition differs between male and females, 
and fat deposition is driven by testosterone and oestrogen differently in both sexes (Guo et al., 
1998); the female sex hormone oestrogen has been shown to drive adipose tissue proliferation 
(Roncari and Van, 1978). Furthermore, the metabolism of n-3 PUFA is affected by oestrogen 
(Childs et al., 2008); thus, there could be a possible interplay in the metabolism of n-3 PUFA, 
sex hormones, and adipose tissue hypertrophy. Furthermore, the accumulation of fat differs 
between males and females, but I only used visceral fat pad in our study. Future studies could 
compare the effects of dietary n-3 PUFA on the different major adipose tissue depot 
(subcutaneous and visceral) and adipocyte hypertrophy; this will give vital information on the 
depot specific effect of n-3 PUFA on adipose tissue and how it relates to obesity. Furthermore, 
exploring the effect of n-3 PUFA on mouse model of obesity will provide information on 
whether n-3 PUFA can reverse the obesity phenotype and ameliorate the complications 
associated with obesity.  
The neuroprotective effects of n-3 PUFA are well documented; however, it is not known 
whether longer exposure to n-3 PUFA causes accretion of cortical DHA, and regulates the 
expression of neurotrophins.  I investigated the age-dependent effect of n-3 PUFA on the 
expression of proteins involved in neurotrophin signalling in males, acknowledging that the 
effects of n-3 PUFA and neurotrophins change with age. I observed an increase in the cortical 
mRNA expression of BDNF and TrKB in response to a high n-3 PUFA diet as presented in 
chapter 5. My data suggest that the increased expression of BDNF was due to increased 
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phosphorylation of CREB by n-3 PUFA. This finding is novel; however, there are a number of 
pathways that lead to the phosphorylation of CREB.  I have not investigated the effect of n-3 
PUFA on the activation of pathways that subsequently lead to the downstream activation of 
CREB.  
I speculate that the upregulation of neurotrophin signalling by n-3 PUFA might be the central 
mechanism by which n-3 PUFA prevent both cardiovascular and neurological disease given that 
neurotrophins have been identified to possess both cardioprotective and neuroprotective 
potentials. My speculation is based on the correlation analysis between the cortical mRNA 
expression of BDNF and plasma concentration of TG and NEFA in response to dietary n-3 
PUFA; those data shows a negative correlation (Appendix VI) suggesting that the effects of n-3 
PUFA are likely through a common pathway.  To appreciate the biological significance of the 
effect of n-3 PUFA on neurotrophin signalling, it will be important to investigate how the 
changes in neurotrophin signalling in response to high n-3 PUFA influence behavioural analysis 
in mice.  The effect of neurotrophin signalling can also be explored in mouse model of 
neurodegenerative diseases; this will provide an insight into the therapeutic potential of altering 
the expression of neurotrophins in neurodegenerative disease state. Furthermore, my observation 
of the upregulation of neurotrophin signalling by n-3 PUFA was made using male mice; it will 
be interesting to see whether there is a sex-specific effect of n-3 PUFA on neurotrophin 
signalling using female mice. 
Finally, we have made speculations and identified novel targets on the cardioprotective and 
neuroprotective potentials of n-3 PUFA; however, we acknowledge that both cardiovascular and 
neurodegenerative disease are chronic in nature, and age is a significant risk factor for both 
conditions. We studied our animals at 16 weeks postweaning which in human years is relatively 
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young to develop these conditions spontaneously. We however decided to use this age so as to 
eliminate the metabolic disturbances and other confounding factors that come with ageing. 
C57BL/6 mice can develop obesity, atherosclerosis, and hyperglycaemia if fed a high fat diet 
over a long period of time; therefore, to investigate the effect of n-3 PUFA on end-stage disease 
states, longer time period is required.  
In conclusion, the results from the current thesis demonstrate that males are more responsive 
to the cardioprotective effects of high dietary n-3 PUFA compared to females. The results show 
that high n-3 PUFA markedly prevented adipocyte hypertrophy and increased cholesterol efflux 
in males but had no effect in females. Furthermore, the findings from the current thesis show that 
a high dietary dose of n-3 PUFA is required to elicit the cardioprotective effects of n-3 PUFA. 
However, it appears that the medium n-3 PUFA diet is better at reducing LDL-c in females; 
nonetheless, this conclusion cannot be made emphatically without controlling for the effect of 
oestrogen.    
In light of the observed sex, age, and dose differences on the effect of n-3 PUFA on the risk 
factors of CVD, it is pertinent to consider these factors in the recommendation of n-3 PUFA as a 
therapeutic agent. Furthermore, the current thesis presents novel understanding of the mechanism 
of action of n-3 PUFA. Our findings report that n-3 PUFA reduces the concentration of 
atherogenic lipoprotein and that n-3 PUFA sex dependently enhances the functionality of HDL 
by stimulating cholesterol efflux. As the understanding of the  cardioprotective mechanisms of n-
3 PUFA continues to grow, my data also report that n-3 PUFA remodelled the plasma and 
hepatic lipidomic profile to produce bioactive lipids with n-3 PUFA moieties and suspected 
cardioprotective benefits. I am also the first to report that n-3 PUFA could sex specifically 
prevent obesity by downregulating the mRNA expression of DGAT2 and FABP4 thereby 
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preventing adipocyte hypertrophy. A thorough understanding of the mechanism involved will 
provide valuable information on the therapeutic potentials of DGAT2 and FABP4 as principal 
anti-obesity targets. Finally, my findings demonstrate that perinatal and postweaning diets high 
in n-3 PUFA lead to accretion of n-3 PUFA in brain cortex, and I also found that n-3 PUFA 
upregulates the expression of neurotrophins and their target receptors in an age dependent 
fashion. Furthermore, there was a positive correlation between the cortical mRNA expression of 
BDNF and plasma concentrations of triglycerides and non-esterified fatty acids, suggesting a 
relationship between neurotrophins and regulation of lipid metabolism. 
Overall, dietary intervention remains the safest strategy to prevent the development of CVD; 
however, with the physiological variation in human population, it is impossible to make a robust 
general recommendation without considering human variability in response to dietary regimen. 
The cardioprotective properties of n-3 PUFAs have been studied over the years, with more 
supportive than confuting findings. This represents a very promising therapeutic option for the 
prevention and treatment of CVD; however more studies need to be undertaken to understand the 
detailed mechanism of action of n-3 PUFA in light of the aforementioned effects of sex and age. 
Furthermore, it will be important to gain new insights into the neurological origin of CVD and 
the implication of n-3 PUFA in facilitating a central therapeutic option for the prevention and 
treatment of both neuropsychiatric and cardiovascular diseases.  
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Appendix I 
RNA Isolation 
RNA was isolated from tissues using the Trizol method (according to the information 
provided by the manufacturer). Briefly, 50-100 mg of tissue samples were homogenized is 1ml 
volume of Trizol reagent. The homogenate was incubated at room temperature for 5 minutes to 
allow for total dissociation of nucleoprotein complexes. The homogenate was centrifuged at 
12,000 rpm for 10 mins at 4°C to remove all cell debris.  The supernatant was transferred to a 
new tube, and treated with 0.2 ml chloroform per 1 ml of Trizol reagent to facilitate phase 
separation of nucleic acids. The sample was vortexed and centrifuged at 12,000rpm for 15 mins 
at 4°C. The upper aqueous phase containing the RNA was carefully transferred into a new tube; 
and RNA was precipitated by adding 0.5 ml isopropanol per 1 ml of Trizol reagent used at the 
beginning of the homogenization. The sample was incubated at room temperature for 10 
minutes, and then centrifuged at 12,000rpm for 15 mins at 4°C. RNA was washed by the 
addition of 1 ml 75% ethanol and air-dried.  Isolated RNA was dissolved in DEPC-treated water 
and the concentration of RNA was determined using nanodrop.  
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Appendix II 
Body weight at sacrifice and average weekly food intake of male mice fed diets varying 
perinatal and postweaning (16 weeks) concentration of n-3 PUFA (Chapter 2) 
  High n-3  Medium n-3 Low n-3 
Body Weight (g) 29.77± 2.33 29.59±3.06 28.18 ± 3.60 
Food Intake (g/week) 22.94 ± 0.70 21.93±1.18 22.27 ± 0.98 
 
Values are expressed as means ± SD, n=8. Data were analyzed using one-way analysis of 
variance. PUFA= Polyunsaturated fatty acids  
 
Body weight at sacrifice and average weekly food intake of female mice fed diets varying 
perinatal and postweaning (16 weeks) concentration of n-3 PUFA (Chapter 2)  
  High n-3  Medium n-3 Low n-3 
Body Weight (g) 22.94± 2.12 24.76±3.84 23.17 ± 3.70 
Food Intake (g/week) 21.35 ± 0.66 24.41±1.16 22.96 ± 1.13 
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Appendix III 
Correlation analyses between experimental diets and breast milk fatty acid composition 
                       
Breast Milk   Diet   
High n-3  Medium n-3 Low n-3 
    r P r P r P 
High n-3  1 < 0.05 0.96 < 0.05 0.94 < 0.05 
Medium n-3 0.87 < 0.05 0.87 < 0.05 0.87 < 0.05 
Low n-3  0.84 < 0.05 0.87 < 0.05 0.87 < 0.05 
                       
 
Pearson’s correlation coefficients of individual and total fatty acids of maternal diet and breast 
milk. Breast milk fatty acids of each dietary group are significantly correlated with the maternal 
diet. 
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Appendix IV 
Total concentrations of plasma and liver phospholipids of mice fed high and low n-3 PUFA 
diets 
              
  PLASMA  (nmol/µl) 
LIVER  
(nmol/mg) 
  High n-3  Low n-3  High n-3  Low n-3 
PC 1.6 ± 0.51  1.7 ± 0.18 28.9 ± 3.00 29.6 ± 3.82 
LPC 0.3 ± 0.05 0.3 ± 0.06 4.3 ± 0.92 4.3 ± 1.11 
PE 0.3 ± 0.22 0.3 ± 0.08 7. 6 ± 2.19 7.6 ± 2.30 
SM 0.01 ±0 .005 0.01 ± 0.002 0.12 ± 0.01 0.12 ± 0.03 
CER* 2.7 ± 0.90 2.7 ± 1.56 0.6 ± 0.15 0.7 ± 0.15 
 
Total concentrations of phospholipids were quantified using ESI-MS. Values are expressed as 
means ± SD, n=6. Data were analyzed using unpaired t-test. PC (phosphatidylcholine), LPC 
(lysophosphatidylcholine), PE (phosphatidylethanolamine), SM (sphingomyelin), CER 
(ceramide), PUFA (Polyunsaturated fatty acids).* Plasma ceramide concentration is pmol/µl 
 
 
 
252 
 
 
Appendix V 
Body weight at sacrifice and average weekly food intake of male mice fed diets varying 
perinatal and postweaning (16 weeks) concentration of n-3 PUFA (Chapter 4) 
  High n-3  Medium n-3 Low n-3 
Body Weight (g) 30.45± 2.75 35.9.±4.09 31.85 ± 4.78 
Food Intake (g/week) 23.44 ± 0.92 22.73±1.26 23.27 ± 1.12 
Body Fat (g) 2.13±0.87 2.46±0.57 2.02±0.73 
 
Values are expressed as means ± SD, n=8. Data were analyzed using one-way analysis of 
variance. PUFA= Polyunsaturated fatty acids  
 
Body weight at sacrifice and average weekly food intake of female mice fed diets varying 
perinatal and postweaning (16 weeks) concentration of n-3 PUFA  
  High n-3  Medium n-3 Low n-3 
Body Weight (g) 25.51± 3.79 23.47±3.24 25.52 ± 1.34 
Food Intake (g/week) 22.64 ± 0.73 23.21±1.45 22.68 ± 1.14 
Body Fat (g) 1.26±0.82 0.84±0.48 0.66±0.40 
 
Values are expressed as means ± SD, n=8. Data were analyzed using one-way analysis of 
variance. PUFA= Polyunsaturated fatty acids  
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Appendix VI 
 
 
 
 
 
 
 
 
The effect of dietary n-3 PUFA diet on cortical BDNF mRNA expression and plasma lipids 
in male offspring at 16 weeks postweaning. Pearson’s correlation analyses between cortical 
BDNF and plasma triglycerides (A) and plasma NEFA (B). 
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